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Abstract 
 
Systemic lupus erythematosus (SLE) carries a significantly enhanced risk of developing 
cardiovascular disease (CVD) and remains a leading cause of death in these patients, accounting for 
~25% of all causes of  mortality. Although there is clear evidence linking accelerated atherosclerosis 
to SLE (and consequently an increase in cardiovascular events), another factor that may contribute to 
CVD related morbidity and mortality is reperfusion injury that occurs post-ischaemia. This is termed 
ischaemic / reperfusion (I/R) injury and is a known important contributor to the size of the eventual 
infarct in the heart, which in animal studies has been shown to account for up to 40-50% of the final 
infarct size. 
 
Hydroxychloroquine (HCQ), originally an anti-malarial drug, is now used to treat autoimmune 
disorders, including SLE. HCQ has been shown to modulate inflammation in rheumatic diseases 
such as SLE and rheumatoid arthritis as well as have potential cardiovascular benefits in these 
patients. One of the keys aims of this thesis was to explore the potential use of HCQ in reducing 
cardiac I/R injury. HCQ was found to be cardioprotective in an in vitro neonatal cardiomyocytes 
simulated I/R injury model as well as in an in vivo cardiac I/R injury model. This was found to be 
through an ERK-dependent mechanism which was blocked in the presence of the ERK inhibitor 
U0126 both in vitro and in vivo. 
 
Another relevant question addressed in this thesis was if I/R injury is enhanced in lupus. There is 
evidence from an autoimmune prone mouse model that lupus IgG are pathogenic in mesenteric I/R 
injury. However, no study as yet has investigated human lupus IgG in a heart model. IgG was 
purified from the serum of SLE patients (aPL +ve vs aPL –ve), antiphospholipid syndrome (APS) 
patients, juvenile onset SLE (JSLE) patients and healthy volunteers. The pre-treatment of neonatal 
rat cardiomyocytes with IgG from all 3 patient groups enhanced simulated I/R injury. However, the 
most pathogenic were those who were aPL positive. Interestingly, JSLE patients who were all aPL 
negative, enhanced I/R injury to similar levels as those who tested positive in the adult patient 
cohort. An enhanced p38 MAPK phosphorylation was observed in the presence of aPL positive IgG 
and this pathogenic effect was blocked in the presence of the p38 inhibitor SB23580. 
 
The results obtained in this thesis have identified a potential role for HCQ in the cardiovascular field 
as a cardioprotective therapeutic in myocardial I/R injury. Additionally, IgG purified from patients 
with SLE, APS and JSLE have been shown to accelerate myocardial I/R injury. 
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Overview of Chapter I 
 
This chapter aims to give an overview of old and current literature that encompasses the role of 
cardiac injury within lupus. It will be split into two clear sections; the first I/R injury and the second 
SLE. Each section will detail the pathogenesis, clinical features and current treatments available. It 
will then conclude by summarizing the role of I/R injury in SLE and potential overlaps in relation to 
pathogenesis for the two. 
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1.1 Ischaemia/reperfusion Injury 
 
1.1.1 Myocardial Infarction 
 
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in the world and in 2012 
it was reported by the World Health Organisation (WHO) that an estimated 17.5 million people died 
as a result of CVD, primarily through myocardial infarction (MI) and stroke. The latest WHO 
estimates suggest that by 2030 around 23 million people will die annually due to CVD (World 
Health Organisation 2012).  
 
Survivors of MI and indeed stroke often suffer post-infarct morbidity due to irreversible tissue 
damage, which causes major organ dysfunction and consequently significant functional compromise. 
Thus, the size of the resulting infarcted tissue is critical in defining the outcome. Patients who 
present with an acute MI require urgent myocardial reperfusion either via thrombolysis or primary 
cutaneous coronary angioplasty which should be administered as early as possible (Bassand J 2005). 
Despite widespread and timely use of these procedures, morbidity and mortality rates remain high. 
Therefore the development of new strategies for cardioprotection which are able to reduce infarct 
size and hence improve clinical outcomes is still an unmet need (Topol 2003).  
 
1.1.2 Myocardial ischaemia/reperfusion (I/R) Injury  
 
Occlusion of the coronary artery results in myocardial cell death primarily through necrosis during 
the ischeamia phase. Reperfusion of the coronary artery, whilst being an essential requirement in 
order to restore cardiac function, can paradoxically result in further myocardial injury and an 
increase in infarct size (Eefting F 2004). This phenomenon of reperfusion-induced damage was first 
described in 1960 and was termed ischaemia/reperfusion (I/R) injury (Jennings RB 1960). 
Reperfusion-induced injury is due to cell death of cardiac myocytes which were viable until blood 
flow was restored following ischaemia. Animal studies have suggested that I/R injury may account 
for 40-50% of the final infarct size post-MI (Yellon 2007; Simonis G 2012). Although medical 
reperfusion following ischaemia can be successful, cardiac failure after reperfusion stands at 25% 
and mortality due to I/R injury estimated at 10% (Keeley EC 2003). Understanding the molecular 
mechanisms that mediate I/R injury and identification of potential targets to modulate this has led to 
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a number of therapeutic candidates that are currently under development. The publication of the 
AMISTAD (Acute Myocardial Infarction Study of Adenosine) study showed for the first time, in a 
multi-center trial, that a drug targeting I/R injury could reduce infarct size in humans (Mahaffey KW, 
Bolli R et al. 1999). 
 
I/R injury targets oxygen dependent cells within tissue and organs including the heart, liver and 
brain, which can be exposed to either periods of cold or warm ischaemia. Typically cold ischaemia 
occurs during transplantation after organ harvesting, when static cold preservation occurs 
(Salahudeen 2004). In contrast, warm ischaemia results following organ trauma such as stroke and 
MI. The cell populations that are affected will have varying degrees of resistance to the different 
types of ischaemia (Halazun K 2007). An example is cardiac endothelial cells which are relatively 
resistant to warm ischaemia (Pompilio G 1997), whereas hepatocytes in the liver are more sensitive 
(Berthiaume F 2009). Whilst organs can tolerate prolonged cold or warm ischemia, it is during 
reperfusion that significant cellular damage can occur through mechanisms such as apoptosis-
induced cell death.  
 
Sections 1.1.3 and 1.1.4 will outline the main mechanisms that are thought to regulate cell death in 
I/R injury and are summarised in figure 1.1. 
 
1.1.3 Myocardial Ischaemia Injury 
Under normal conditions all cells require energy supplied via mitochondrial oxidative 
phosphorylation and therefore cannot be independently supported by anaerobic glycolysis (Jassem 
2004). Consequently, during ischaemia the absence of oxygen causes oxidative phosphorylation to 
be halted, resulting in mitochondrial membrane depolarization, ATP depletion and inhibition of 
mitochondrial contractile function. The absence of oxygen leads to anaerobic glycolysis being 
switched on, lactate accumulation, and a subsequent lowering of the intracellular pH to less than 7.0 
(Hausenloy 2013). In turn, this leads to an increase in the number of protons causing the Na
+
-H
+
 ion 
exchanger to be activated, preventing protons from entering the cell in exchange for Na
+ 
being 
transferred in. Furthermore, a decrease in ATP during ischaemia inhibits Na
+
-K
+
 ATPase causing 
further intracellular Na
+
 overload. In response to this Na
+ 
influx, the 2Na
+
-Ca
2+
 ion exchanger is 
activated resulting in intracellular Ca
2+
 overload as the cell attempts to remove this excess Na
+ 
(Avkiran and Marber 2002). ATP depletion can lead to morphological changes such as cytoskeleton 
depletion and formation of blebs at the cell surface. If ischaemia persists irreversible damage occurs 
  27 
which is mainly associated with mitochondrial swelling, severe damage to plasma membrane and 
swelling of lysosomes (Buja 1998).  A consequence of dysfunction of the energetic machinery of the 
cell (mitochondrial oxidative powerhouse and glycolytic pathway) is irreversible and therefore even 
if the cellular energetic machinery were to be restored, the irreparable damage to the cell membrane 
and genome leads to cell death usually via necrosis. However, when blood flow is restored to cells 
that have been made ischaemic but have yet to die, this can be beneficial but in contrast injury can 
actually be exacerbated. As a result, reperfusion can actually cause additional cell death and the 
mechanisms through which this can occur will be discussed in the following section.  
1.1.4 Myocardial Reperfusion Injury 
 
1.1.4.1 The Inflammatory Response: Neutrophils and The Complement Pathways 
 
Cardiac I/R injury causes attraction, activation, adhesion and migration of neutrophils to the site of 
injury resulting in local as well as remote organ damage. This damage is via the release of 
inflammatory mediators such as cytokines and ROS as well as the local activation of the complement 
system (Dong, 1999).  
 
There are three main pathways in the complement system, which can be activated through different 
mechanisms. The classical pathway is regulated by antigen-antibody interaction, which activates 
C1q, followed by C2- and C4-dependent cleavage of C3 (by C3 convertase) leading to cleavage of 
C5 (by C5 convertase). In the lectin pathway, serum mannose binding lectin (MBL), which is 
homologous to C1q, recognizes microbial surface mannose and triggers activation of MBL-
associated proteases (MASP1-3). This interaction leads to the same activation of C3 and C5. The 
final pathway is the alternative pathway which is activated by presence of lipopolysaccharide (LPS) 
leading to C3 binding to factor B and forms a complex which is cleaved to form the alternative C3 
convertase. Properdin amplifies this activation and stabilizes the complex allowing cleavage of C3b 
and formation of the alternative C5 convertase. All three pathways lead to C3 and C5 cleavage 
resulting in C5a and C5b-9 being produced. These main components of the complement system are 
believed to be responsible for complement pathway mediated cardiac I/R injury (Padua R 1998).  
 
The classical complement pathway is the most extensively studied in I/R injury, and studies have 
suggested that pre-existing natural IgM may be responsible for activating this complement-mediated 
I/R injury (Zhang M 2004). These self-reactive natural antibodies may participate in the early stages 
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of I/R injury by being recruited to the site of injury when ischaemic antigens become exposed. 
Recruitment of natural IgM antibodies to these neoepitpes could be responsible for subsequent 
activation of complement (Zhang M 2006). The identification of natural IgM antibodies that cause 
I/R injury provides a crucial link between initiation and activation of complement after reperfusion 
of ischaemic tissue. This could subsequently lead to identification of neoantigens formed during I/R 
for IgM antibodies to bind to and therefore identify potential new therapeutic targets.  
 
Although these neoepitopes that natural IgM antibodies bind to are still being identified, there have 
already been some experimental studies which have shown a significant reduction in MI. These 
studies have involved therapeutic strategies designed to inhibit the inflammatory process at the time 
of myocardial reperfusion. This includes using antibodies against cell-adhesion molecules (Ma X 
1991; Hayward R 1999) and inhibiting activation of the complement pathway (Vakeva A 1998). 
However, studies in a clinical setting targeting inflammation pathways have had largely negative 
outcomes (Investigators 2007; Atar D 2009). Whilst inhibiting inflammatory pathways may not be 
able to reduce cardiac I/R injury alone, these mechanisms clearly contribute to injury in combination 
with other factors. 
 
1.1.4.2 Reactive Oxygen Species  
Fatty acids are the major fuel choice of cardiac tissue for the cardiac mitochondria supply of    
acetyl-coenzyme A (acetyl-CoA). Beta oxidation of fatty acids generates acetly-CoA as well as 
nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2). This is then 
fed into the Krebs cycle and used to generate further NADH and FADH2 (Jassem 2004). However, 
when the supply of oxygen is reduced the amount of NADH and FADH2 produced is decreased 
leading to insufficient energy production for regular cardiac function. To try and counteract this, 
NADH and FADH2 are transported to the mitochondria to undergo oxidative phosphorylation, 
therefore allowing generation of ATP. Unfortunately, as oxygen is the terminal electron acceptor in 
complex 4, NADH and FADH2 cannot be metabolised due to the lack of oxygen, therefore 
preventing ATP production and so tissue injury begins (Giordano 2005).  
During oxidative phosphorylation, electrons are usually and sequentially transferred to oxygen, 
which along with protons being pumped across the membrane, produce water molecules. 
Occasionally ‘electron leakage’ occurs, whereby oxygen molecules with odd numbers of electron in 
their outermost electron shell are formed, these are highly reactive and are known as reactive oxygen 
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species (ROS) (Giordano 2005). The oxygen molecules produced include O2
. 
(a superoxide anion) 
which is formed due to the donation of a single electron, a process which is catalysed by xanthine 
oxidase (Li 2002). Additionally, the superoxide anion can accept a further electron to form a 
peroxide anion and can become protonated to form hydrogen peroxide H2O2 (Giordano 2005). This 
process would normally be catalysed by the anti-oxidant enzyme superoxide dismutase (SOD), 
leading to catalysis of H202 to water. There are also other free radical species which the heart 
produces which make up another group called reactive nitrogen species (RNS). This includes 
superoxide anion combining with nitrogen oxide (NO) to produce peroxinitrite ONOO
.- 
(Li 2002; 
Giordano 2005). In I/R injury ROS production becomes excessive and therefore the cellular 
physiological mechanisms for lowering ROS levels are overwhelmed, leading to cell injury. This can 
be severe and is known to lead to extensive cell death (Stowe 2009). There are three pathological 
responses that have been shown to occur as a consequence of the elevated ROS levels; lipid 
peroxidation of membranes, nuclear and mitochondrial DNA fragmentation and sulfhydryl-mediated 
protein cross-linkage. All three processes contribute to cell injury but the severity depends on the 
time and strength of the I/R injury insult (Venardos K 2007).  
The generation of ROS during ischaemia can be inhibited using pharmacological inhibitors of 
mitochondrial electron transport, with studies suggesting complex III being the main site of ROS 
production in ischaemia (Chen Q 2003). However, interestingly it has been shown that these same 
inhibitors have little effect on ROS production during reperfusion suggesting they are produced via 
distinct mechanisms in the individual stages of I/R injury (Becker 2004).  
1.1.4.3 Intracellular Calcium Overload 
Reperfusion allows recovery of the mitochondria, therefore restoring the mitochondrial membrane 
potential that is responsible for calcium (Ca
2+
) entry via the mitochondrial Ca
2+
 uniporter. This influx 
of Ca
2+
 subsequently induces the opening of the mitochondrial permeability transition pore (MPTP, 
see section 1.1.4.5). Studies have shown that pharmacologic antagonists of the sarcolemma Ca
2+
 
channel (Herzog W 1997) or the mitochondrial Ca
2+
 uniporter (Miyamae M and Figueredo 1996), 
administered at the onset of myocardial reperfusion reduces MI size by up to 50%. However, not all 
experimental studies targeting Ca
2+
 influx as a therapeutic strategy have yielded positive results. 
Clinical studies of calcium channel blockers administered at the onset of myocardial reperfusion 
have shown no overall beneficial effects (Bär F 2006). 
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1.1.4.4 Restoration of Physiological pH 
During ischaemia, intracellular pH decreases to below 7.0 due to anaerobic glycolysis producing 
lactic acid (Hausenloy 2013). However, during reperfusion, the washout of lactate and activation of 
the Na
+
-H
+
 exchanger restores physiological pH. This shift in pH causes MPTP opening, therefore 
contributing to cardiomyocyte death (Hausenloy 2013). Potential treatments to target this defect 
include utilizing an acidic buffer which has been shown to reduce the cardiac infarct size (Qian T 
1997), as well as slowing the recovery of physiological pH using Na
+
H
+
 exchanger inhibitors 
(Avkiran and Marber 2002).  
1.1.4.5 Mitochondrial permeability transition pore  
 
The mitochondrial membrane potential is controlled by the MPTP, which is a large, non-specific 
pore, spanning the inner and outer mitochondrial membrane (Clerk A 2003). In ischaemia the MPTP 
remains closed due to the low pH within the cell but during the first few minutes of reperfusion the 
pores open as the pH is restored. This leads to an increase in proton levels and ROS production, as 
well as continued inhibition of ATP synthesis (Griffiths EJ 1995). The transition pores formed within 
the mitochondria mean that cytosolic ATP can gain access to mitochondrial ATPase, contributing to 
further ATP loss (Weiss J 2003). Sustained opening of the pore leads to the proton gradient and 
electrical potential across the inner membrane to collapse causing oxidative phosphorylation 
uncoupling. Additionally, under the force of osmotic pressure the matrix swells, and whilst the inner 
membrane is able to adapt through cristae remodeling the outer membrane is unable to and so 
eventually ruptures (Gustafsson AB 2008). This means that pro-apoptotic mediators such as 
cytochrome c, apoptosis-inducing factor (AIF) and endonuclease G are released into the cytosol, 
which further induces apoptosis pathways (Yang JC 1998). This injury process is enhanced by a 
decrease in DNA synthesis and repair leading to cell death (Eefting F 2004). Potential therapeutic 
strategies include preventing MPTP opening during reperfusion by administering MPTP inhibitors 
such as the immunosuppressant cyclosporine A (CsA). This is known to bind to and inhibit 
cyclophilins, which regulate protein folding in vivo. For immunosuppression CsA binds cyclophilin 
A preventing translocation of calcineurin, thereby inhibiting translocation of transcription factors and 
reducing interleukin-2 (IL-2) production. However, in the setting of the heart CsA been shown to 
bind to cyclophilin D, a regulator in MPTP opening. The first studies in isolated rat hearts with CsA 
showed inhibition of MPTP through outputs such as maintained calcium levels and membrane 
potential (Haunsenloy 2002). Further studies have shown that CsA can reduce MI size by 40-50% in 
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both small and large animal MI models (Hausenloy D 2003; Skyschally A 2010). However, due to 
the adverse side effects and non-specific selectivity of CsA for the MPTP a more specific and novel 
MPTP inhibitor needs to be developed. 
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Figure 1.1 An overview of myocardial ischaemia/reperfusion injury. A schematic diagram showing the principle mechanisms that regulate I/R 
injury in the heart. Abbreviations: ROS, Reactive oxygen species; MPTP, Mitochondrial permeability transition pore; SR, sarcoplasmic reticulum; 
Na, Sodium; Ca, Calcium. Adapted from (Hausenloy 2013). 
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1.2 Cell Death in I/R injury 
 
During I/R injury there are two major types of cell death in cardiomyocytes that are thought to occur 
to varying degrees; apoptosis and necrosis. During ischaemia necrosis plays a prominent role due to 
irreversible damage to cells and tissues. Apoptosis induction is also observed, however it is during 
reperfusion that apoptosis has been shown to play a prominent role. This has been shown in many in 
vivo animal models which have shown that prolonged myocardial ischaemia is predominantly due to 
an increase in necrosis, but reperfusion leads to an enhancement in apoptosis (Gottlieb, Burleson et 
al. 1994; Fliss 1996; Dumont E 2000; Hofstra L 2000; Eefting F 2004). 
 
1.2.1 Necrosis 
 
Necrosis is the premature death of cells in living tissue caused by external factors such as trauma, 
toxins and infection, which leads to unregulated digestion of cell components. It is morphologically 
characterised by a gain in cell volume, swelling of organelles, plasma membrane rupture and 
subsequent loss of intracellular contents (Krysko D 2008). An example of a trauma that can cause 
cells to undergo necrosis is hypoxia or anoxia resulting in ischaemic tissue. Interference with the 
blood supply of an organ results in tissue being deprived of access to substances necessary for 
metabolic nourishment. It has been thought for a long time that necrosis is merely an accidental and 
uncontrolled form of cell death, however there is now evidence suggesting that its execution may be 
finely regulated by signal transduction pathways and catabolic mechanisms (Kung G 2011). This has 
led to the identification of a new type of necrotic cell death, namely necroptosis (Degterev 2005). 
Originally this term was used for any form of active necrosis identified. However, more recently it 
has been suggested that it should refer only to necrotic cell death dependent on receptor-interacting 
protein kinase 3 (RIPK3) (Linkermann 2014). 
 
1.2.2 Apoptosis: Extrinsic and Intrinsic pathways 
 
Whereas the mechanisms through which necrosis occurs in a programmed fashion remain unclear, 
apoptosis (a form of controlled cellular suicide) is a highly regulated process. Kerr, Wyllie and Curie 
first described the term apoptosis in 1972 (Kerr J 1972) as the morphologically distinct form of cell 
death although other characteristics have since been identified. Apoptosis results in the formation of 
apoptotic bodies that contain cellular components, which are phagocytised by other cells (Taylor R 
2008). Chromatin condensation and fragmentation as well as cell shrinkage and plasma membrane 
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budding to release apoptotic bodies are common features seen in apoptotic cells (Daniel R 1995).  
Today it is recognised as the distinctive mode of ‘programmed’ cell death, which eliminates cells 
that have been genetically determined for this fate. It is initiated and controlled through precise 
signalling mechanisms, which contain multiple checkpoints as well as anti-apoptotic programmes 
being induced at the same time. Apoptosis is a complex phenomenon, which requires co-ordinated 
and often energy dependent processes to be activated (Elmore 2007) as summarised in figure 1.2. 
The molecular process of apoptosis encompasses the use of dormant proteases (caspases) which 
cleave many cellular substrates leading the onset of cell death (Adams 2003). Cysteine-dependent, 
aspartyl specific proteases, proteases, or caspases, are proteins which exist in the cell as inactive 
zymogens until they are proteolytically cleaved at which time they become involved in the 
programmed death of a cell (Adams 2003). Caspases  are evolutionarily conserved and are found in 
insects, nematodes, hydra and mammals (Hengartner 2000). They can be divided into two groups; 
those which initiate the cell death and those which execute it. The initiator caspases include caspase 
2, 8, 9 and 10 whilst the executioner caspases consist of caspase 3, 6 and 7 (Boatright 2003). 
 
Two main pathways of caspase activation have been identified. The first involves (intracellular) 
intrinsic damage or inadequate cytokine support and the second (extrinsic) is activated by ‘death 
receptors’ located on the cell surface (Elmore 2007). 
 
1.2.2.1 Extrinsic pathway 
The extrinsic pathway is activated due to ligands binding to death receptors such as FasL and tumour 
necrosis factor alpha (TNF-) (Fulda 2000). Members of the TNF receptor family share a similar 
cysteine rich extracellular domain and have a cytoplasmic domain of approximately 80 amino acids 
called the ‘death domain’. This death domain plays a critical role in transferring death signals from 
the cell surface to intracellular signalling pathways to induce apoptosis (Park H 2007). To date a 
number of ligands and corresponding death receptors have been identified, with the best 
characterised being FasL/FasR and TNF-/TNFR1. These examples have been shown to have 
clusters of receptors, which bind with homologous trimeric ligands. When ligand binding occurs, 
cytoplasmic adaptor proteins are recruited such as the adaptor molecules Fas associated death 
domain (FADD) protein for FasL/FasR and tumour necrosis factor receptor type 1-associated death 
domain (TRADD) protein for TNF-/TNFR1, with subsequent recruitment of FADD and Receptor-
interacting serine/threonine-protein kinase 1 (RIPK1). The FADD adaptor protein is responsible for 
bridging the receptor and caspase-8 by associating with procaspase-8 via dimerization of the death 
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effector domain. At this stage the formation of the death-inducing signalling complex (DISC) occurs 
allowing the auto-catalytic activation of procaspase-8 to occur. This subsequently leads to caspase-8 
activation, which is the beginning of the execution phase that allows apoptosis to be induced. This 
extrinsic or death receptor mediated apoptosis can be inhibited by the protein cellular FLICE 
(FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) which can bind FADD and 
caspase-8, making them inactive (Tait 2010).  
 
1.2.2.2 Intrinsic pathway 
The second apoptotic signalling pathway is the intrinsic pathway which is induced due to a range of 
diverse, non-receptor-mediated stimuli that produce intracellular signals. These signals directly 
target cells and initiate events within the mitochondria (Tait 2010). The induction of the intrinsic 
pathway can produce intracellular signals which can activate pro-apoptotic or anti-apoptotic proteins, 
depending on the stimuli (Elmore 2007).  
 
All stimuli that have been shown to play a role in the intrinsic pathway, cause inner mitochondrial 
membrane changes, which can lead to the opening of the MPTP (Tait 2010). This causes loss of 
mitochondrial trans-membrane potential and the release of two main groups of pro-apoptotic proteins 
from the intermembrane space to the cytosol. Cytochrome c, Smac/DIABLO and the serine protease 
HtrA2/Omi make up the first group and are responsible for activating caspase-dependent 
mitochondrial pathways (Eefting F 2004). Additionally, cytochrome c binds and activates Apaf-1 as 
well as procaspase-9 forming an ‘apoptosome’, causing caspase-9 activation. The other two proteins 
in this group are thought to promote apoptosis by inhibiting inhibitors of apoptosis proteins (IAP) 
however studies suggest that inhibiting Smac/DIABLO and HtrA2/Omi is not sufficient to prevent 
apoptosis being induced and therefore they should not be labelled as pro-apoptotic (Elmore 2007). 
The second group of pro-apoptotic proteins include AIF, endonuclease G and caspase activated 
DNase (CAD), which are released from the mitochondria once apoptosis has been induced, therefore 
they play a role much later within the apoptosis pathway. AIF translocates to the nucleus and causes 
DNA fragmentation as well as condensation of peripheral nuclear chromatin (Cande C 2007). 
Endonuclease G also translocates to the nucleus and cleaves nuclear chromatin to produce 
oligonucleosomal DNA fragments (Li L 2001).  
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1.2.2.3 Interaction and convergence of extrinsic and intrinsic pathways 
The intrinsic and extrinsic pathways are not entirely independent of one another. For instance the 
pro-apoptotic Bcl-2 family member BH3 interacting-domain death agonist (Bid) can be cleaved by 
caspase-8 during death receptor apoptotic signalling, and also by other caspases, granzyme B, 
calpains and cathepsins. Although Bid is primarily cleaved by caspase-8 it can target other Bcl-2 
family members in the intrinsic pathway and alter their activation as highlighted in figure 1.2 (Billen 
L 2009). Both the extrinsic and intrinsic pathways lead into the execution phase which begins with 
activation of execution caspases-3,7 and 9. This causes cytoplasmic endonucleases to be activated 
for degradation of nuclear material as well as activating proteases to degrade nuclear and 
cytoskeletal proteins. Caspase-3 is considered the most important execution caspase and can be 
activated by any initiator caspase (caspase-8,9 or 10). Caspase-3 specifically activates CAD by 
cleaving ICAD to allow its release. CAD is responsible for degrading chromosomal DNA within the 
nuclei as well as chromatin condensation (Mcllroy D 1999). Fragmentation of DNA is a hallmark of 
apoptosis and therefore is defined as one of the main late stage events, making it a good marker of 
apoptosis. Another important role of caspase-3 is to reorganise the cytoskeleton and form apoptotic 
bodies (Daniel R 1995). A key substrate of caspase-3 is gelsolin, an actin binding protein, which acts 
as a nucleus for actin polymerization and can also bind phosphatidylinositol biphosphate, linking 
actin organisation and signal transduction  (Elmore 2007).  
 
The final stage of apoptosis is phagocytic uptake of apoptotic cells with phospholipid asymmetry and 
phosphatidyserine externalization to the surface of apoptotic cells being a hallmark of this phase. It is 
this appearance of apoptotic cells, which facilitates phagocytic recognition for uptake and disposal 
(Erwig L-P 2008).  The figure below (figure 1.2) summarises the two main pathways involved in 
apoptosis. 
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Figure 1.2 An overview of the intrinsic and extrinsic apoptotic pathways. A schematic illustrating the main mechanisms that regulate the 
intrinsic and extrinsic pathways in apoptosis.  Abbreviations: APAF1, Apoptotic protease activating factor 1; BAX, Bcl-2-like protein 4; BID, 
BH3 interacting-domain death agonist; BIM, B cell lymphoma 2 interacting mediator of cell death; Bcl-2, B cell lymphoma 2; TNFR1, tumour 
necrosis factor receptor. Adapted from (Mak 2002) 
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1.2.3 Inhibition of apoptosis 
 
Due to apoptosis playing a critical role in the pathogenesis of many diseases, targeting its inhibition 
constitutes a potential therapeutic target. Inhibitors of apoptosis (IAPs) are a family of proteins 
which contain a caspase recruitment domain (CARD) and a zinc finger binding domain allowing 
them to directly bind to and inactivate caspases (Wei Y 2008). Induction of  the mitochondrial death 
signal, results in release of IAPs such as the proteins SMAC/DIABLO and Omi/HtrA2 from the 
mitochondria so that they can undergo cleavage to form active proteins (Wei Y 2008). Although 
IAPs role is to prevent apoptotic cell death, they themselves are regulated and therefore proteins such 
as Smac when proteolytically cleaved can block their action. XIAP is an example of an apoptosis 
inducing factor (IAP), which is a major constituent of native apoptosome where it binds to and 
inhibits caspase-3, caspase-7 and caspase-9 (Deveraux Q 1997). However, Smac can competitively 
bind to caspase-9 and remove the inhibitory effect of XIAP (Srinivasula S 2001). 
 
Stimulation of other targets has also been shown to block apoptosis from occurring, such as pro-
survival pathways PI3K/Akt and ERK. They elucidate their mechanisms by inhibiting pro-apoptotic 
proteins or up regulating of anti-apoptotic proteins which has been shown to reduce I/R injury and 
therefore is a reversible process. An example of this has been shown in studies where mice lacking 
Fas showed reduced cardiac I/R injury following an MI, as did transgenic mice that over express 
Bcl-2, therefore showing the same protective effect (Lee P 2003). It has also been shown in 
transgenic models that inhibiting the expression of Bax can prevent cytochrome c release from 
mitochondria therefore inhibiting the decrease in the mitochondrial membrane potential leading to 
protection from apoptosis induction (Elmore 2007).  
 
1.2.4 Is apoptosis relevant in the pathogenesis of myocardial I/R Injury? 
 
It is accepted that occlusion of the coronary artery results in ischaemic injury and myocyte cell death 
by necrosis. This underpins the focus of therapeutics on angioplasty and thrombolysis to limit the 
onset of ischaemic injury (Gottlieb, Burleson et al. 1994). However, whilst necrosis contributes 
largely to myocardial infarct size, apoptosis was also shown to play a role in ischaemia and be 
accelerated during reperfusion injury. Gottlieb et al showed using microscopic analysis and DNA 
laddering that apoptosis contributed to infarct area development in I/R injury (Gottlieb, Burleson et 
al. 1994). Studies have conflicting views on the degree to which apoptosis contributes to overall total 
cell death.  Studies in ventricular myocytes of the hearts of patients who died of acute myocardial 
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infarction (AMI) show apoptosis plays a role, most prominent in the border zone of infarcts (Krijnen 
P 2002). In vivo animal models have shown apoptosis in the infarcted myocardium spreads to the 
border zone after 45 minutes of reperfusion injury. Additionally long-term in vivo cardiac I/R injury 
models showed enhanced apoptosis from 24 hours up to 12 weeks after ischaemia in the infarcted 
area and border zone (Palojoki E 2001). It has also been indicated that apoptosis alone can induce 
heart failure, highlighting its importance (Wencker D 2003). Additionally multiple studies, whereby 
apoptosis has been inhibited, have shown large reductions in infarct size. An example of this is 
inhibition of the pro-apoptotic protein Bcl-2, which led to a reduction in the myocardial infarct size 
of mice from 69.9% to 36.6% (± 7.3%) (Chen Z 2001).  Whilst the majority of studies suggest that 
apoptosis plays a significant role in overall cell death there are others which have dismissed its 
importance. This is mainly due to unresolved issues with the contribution of apoptosis to the cell 
death within I/R injury (McCully J 2004). An example is the methodological issues surrounding 
detection of apoptosis which have been questioned by some. Ohno et al  (Ohno M 1998)  showed 
that using immunogold electron microscopy and in situ nick end labelling that coronary artery 
occlusion in the rabbit resulted in detection of necrosis and not apoptosis. Additionally Taimor et al  
(Taimor G 1999) could only identify induction of necrosis in isolated rat myocytes exposed to 
hypoxia-reoxygenation in vitro. 
Inhibition of pro-apoptotic and promotion of anti-apoptotic pathways clearly have a role in I/R 
injury, however whether their contribution to total myocardial cell death is significant enough to be a 
valid therapeutic target remains unknown. Although many drugs have been shown to inhibit 
apoptosis and result in a significant amount of cardioprotection in vitro sand in vivo, results have 
been disappointing in clinic. This will be discussed further in section 1.8. 
 
1.2.5 Alternative mechanisms of cell death in I/R Injury 
 
As with most biological processes it has been shown that multiple pathways exist in cardiac I/R 
injury which lead to cell death, independent of apoptosis and necrosis. Studies have shown that cell 
death can occur in a caspase-independent mediated fashion via apoptosis through granzymes. Studies 
have shown that T cells and natural killer cells destroy virally infected cells by secreting perforin, a 
protein which enables granzymes to enter a cell and trigger apoptosis (Chowdhury 2008). Granzyme 
B has been shown to enter cells and instigate both the extrinsic pathway through caspase-8 cleavage 
as well as cleavage of Bid leading to MPTP opening in the intrinsic pathway (Bolvin W 2009). The 
  40 
process of autophagy has also been implicated in apoptosis, however its role in cardiac I/R injury 
remains unclear as discussed in the next section. 
 
1.3 Autophagy 
 
The word autophagy is derived from the Greek word for ‘self-eating’ and defines the catabolic 
process through which cells turn over their own contents. Autophagy is a recycling pathway which 
refers to pathways which eliminate cytoplasmic components by delivering them to mammalian 
lysosomes or plant and yeast vacuoles. It doesn’t refer to the proteasome and its role in cellular 
degradation (Boya, Reggiori et al. 2013). It has been shown to participate in a range of physiological 
processes including adaptation to starvation, innate and adaptive immunity, lifespan extension and 
cell death (Zhang S 2013). To date, three main types of autophagy have been described; macro 
autophagy, micro autophagy and chaperone-mediated autophagy (Mizushima 2007). Micro-
autophagy involves recruitment of targeted components to the lysosomal membrane, which 
subsequently invaginates and pinches off. In contrast, chaperone-mediated autophagy involves 
proteins carrying the pentapeptide KFEQ-like sequence to be recognized by Hsc70 chaperone. This 
then associates with the integral lysosome membrane protein LAMP-2A and subsequently 
translocation of the bound protein into the lysosome interior (Boya P 2013). This section will focus 
on macroautophagy given that it is the best characterised type of autophagy and thus hereafter the 
term autophagy refers in fact to macroautophagy. A hallmark of autophagy is the formation of a 
double membrane vesicle, called the autophagosome. Upon induction of autophagy, there are five 
key stages, the first being formation of the phagosphore (also known as nucleation). This is followed 
by Atg proteins (specifically Atg5-Atg12) being recruited to the phagosphore. An example is beclin 
1 which is the mammalian homologue of Atg6 and responsible for regulation of autophagy but also 
the crosstalk of apoptosis and autophagy due to its interactions with Bcl-2 family members (Kang R 
2011). Once assembled they interact with other molecules and lipidation of microtubule-associated 
protein 1 light chain 3 (LC3) (mammalian homologue of Atg8) leads to its assembly on the 
extending phagosphore membrane and conversion of it from LC3-I to LC3-II. With the proteins 
successfully assembled, capture of random and/or selective targets for degradation occurs. The 
complete autophagosome subsequently fuses to the lysosome to expose their content to the 
hydrolases in the liposomal interior to allow them to be digested (Boya, Reggiori et al. 2013). The 
resulting metabolites are transported into the cytoplasm where they used either for synthesis of new 
macromolecules or used as a source of energy (Boya P 2013). This process is summarised in figure 
1.3 at the end of this section. 
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In general it has been suggested that autophagy selects random targets for degradation as it appears 
to engulf cytosol indiscriminately. However, it is increasingly being suggested that LC3-II can act as 
a receptor at the phagosphore by interacting with ‘adaptor’ molecules on the target (e.g. protein 
aggregates) to promote selective uptake. An example of this is p62/SQSTM1 which promotes 
turnover of poly-ubiquitinated protein aggregates (Shaid S 2013). 
 
Multiple studies have shown that there is an increase in the number of autophagosomes in the heart 
during I/R injury. Initially it was observed in fetal mouse hearts in organ cultures, which had been 
subjected to a combination of hypoxia and glucose deprivation, followed by reperfusion. Later 
studies showed that brief ischaemia (20 minutes) wasn’t sufficient to induce autophagy in 
Langendorff-perfused rabbit hearts and in this cause autophagy was not induced until reperfusion, 
however during longer periods of ischaemia (i.e. 40 minutes) it can be (Gustafsson 2009). Multiple 
factors are thought to induce autophagy in I/R injury, such as generation of ROS, the opening of the 
MPTP and endoplasmic reticulum (ER) stress. The functional role of autophagy within I/R injury is 
debatable and intense investigations in vivo and in vitro by multiple groups have been done. 
Interestingly, up regulation of autophagy has been reported to both contribute and be the cause of 
cell death in the heart (Ma S). Experiments performed in the lab of my co-supervisor Dr Stephanou 
have suggested that autophagy plays a cardioprotective role in I/R injury, specifically by STAT1 
negatively regulating autophagy. Therefore, when STAT1 deficient mice were exposed to cardiac 
I/R injury in vivo cell death was reduced and autophagy was up regulated (McCormick J 2012). 
Matsui et al also showed that autophagy was protective during ischaemia but that during reperfusion 
it was detrimental and caused cell death. Beclin1 (+/-) heterozygous mice showed reduced levels of 
autophagy in reperfusion compared to wild-type and this correlated with decreased apoptosis during 
reperfusion and reduced infarct size. 
 
However, other groups have shown that enhanced autophagy contributed to cell death in cardiac I/R 
injury. Examples include a study demonstrating that when autophagy was inhibited by using 3-
methyladenine (3-MA), cell death was reduced in the rat cardiomyocyte derived cell line H9c2 in 
simulated I/R injury (Aki T 2003). Additionally, in beclin 1 heterozygous knockout (beclin 1
+/−
) 
mice, a reduction in cardiac I/R injury and therefore myocyte death was observed (Matsui Y 2007). 
Another study has shown that both in vitro and in vivo that calpain, a protease activated in the 
presence of calcium, can cleave Atg5 causing it to translocate to the mitochondria and bind Bcl-2 to 
stimulate apoptosis (Yousefi, 2006). This evidence suggests that increases in calcium would activate 
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autophagy as well as convert some autophagy machinery such as Atg5 to play a role in activating 
apoptosis. Finally, activation of c-Jun NH2-terminal Kinases (JNK) a mitogen activated protein 
kinase (MAPK), which has been shown to induce apoptosis, leads to an increase in Beclin-1. It is 
therefore clear that cross-talk through calpain, calcium flux, Bcl-2 family members and signalling 
kinases allows regulation of autophagy to be linked to other death pathways active in I/R injury 
(Murphy 2008).  
 
Autophagy currently remains a debatable topic in relation to its contribution to cardiac I/R injury. 
This section has presented studies providing evidence for autophagy antagonizing cardiac 
pathogenesis as well as it contributing to further damage. The key could be in suppressing excessive 
autophagy, whilst allowing basal autophagy to still occur.  However, due to the underlying 
mechanism of autophagy remaining unclear, the debate continues.  
 
Mechanisms to induce cell death such as apoptosis, necrosis and perhaps even autophagy have been 
identified as the key players in cardiac I/R injury. However, the regulation of these processes 
involves a vast range of inter-related signalling pathways and proteins, making it a very complex 
task to reduce cell death. The next chapter will discuss the mechanisms that are thought to regulate 
cardiac I/R injury.  
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Figure 1.3 Schematic overview of autophagy. Autophagy begins with the isolation of double-membrane-bound structures inside an intact cell. 
These membrane structures elongate and mature, and LC3 is recruited to the membrane (conversion from LC3-I to LC3-II). The elongated double 
membranes form autophagosomes, which sequester cytoplasmic proteins and organelles such as mitochondria. The autophagosomes mature and fuse 
with the lysosome to become autolysosomes. Abbreviations: Atg, autophagy related gene; Lc3, microtubule-associated protein 1A/1B-light; APAF, 
apoptotic protease activating factor 1; BID, BH3 interacting-domain death agonist; BAX, bcl-2-like protein 4; BIM, Bcl-2-like protein 11; Bcl-2, B-
cell lymphoma 2; Bcl-. Adapted from (Fleming A 2011) 
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1.4 The Regulation of Myocardial I/R Injury 
1.4.1 The Mitogen Activated Protein Kinase Family  
There are some processes, in particular those which require a degree of energy, that appear to only 
occur in the reperfusion stage (Borgers M 1987). An example of this is activation of various 
signalling pathways including the MAPK family. They are a family of serine-threonine kinases, 
which have been implicated in cell differentiation, survival and proliferation (Cobb 1999). MAPK 
have been shown to be heavily involved in I/R injury regulation in both a protective and detrimental 
way (Abe J 2000). Innate immune signals received through toll like receptors (TLRs) results in the 
activation of two main pathways, one being the MAPK pathway. They are activated in response to a 
large variety of signals including inflammatory cytokines, ischaemia, DNA damage and oxidative 
stress. Their function is to transduce signals from the extracellular environment to regulatory 
elements in the cell. Activation of MAPKs occurs through a cascade of upstream kinases including 
MAPKKK (MAPK Kinase Kinase), which phosphorylates a dual specificity protein kinase MAPKK 
(MAPK Kinase) which in turn phosphorylates the MAPK (Figure 1.4). This process allows signal 
amplification but also additional regulation to allow the kinetics, duration and level of activity to be 
precisely managed (Keshet 2010). Mammalian MAPK can be divided into four subgroups based on 
their structure and function; ERKs (Extracellular signal-regulated kinases), p38MAPKs, JNKs and 
ERK5 (Extracellular signal-Regulated Kinase-5) or BMK. Studies have suggested that MAPKs may 
be implicated in apoptosis but their precise role of regulation may be kinase specific. The activation 
of MAPKs in the heart, especially in the cardiomyocytes has been widely demonstrated in vitro and 
in vivo (Yue T 2000) . 
ERK consists of two isoforms; ERK1 (p44) and ERK2 (p42) and is activated in response to primarily 
growth factors and mitogens. These stimuli act through G-protein coupled receptors, which activate 
the small G-protein Ras, which in turn activates Raf leading to phosphorylation of MAP2Ks MEK1 
and MEK2 (Shaul 2007). Activation of ERK promotes many processes including; entry to the cell 
cycle, differentiation, cell migration and inhibition of apoptosis.  ERK 1/2 has many substrates but 
p90 ribosomal S6 kinase (p90RSK) is a key player, mediating the majority of ERK signal 
transductions. Essential functions of p90RSK include regulation of gene expression via 
phosphorylation of various transcription factors such as cAMP-response element-binding (CREB) 
protein. Additionally it has more recently been shown to phosphorylate the serine 112 residue of the 
pro-apoptotic protein Bcl-2 associated death promoter (BAD), which leads to inhibition of BAD-
mediated apoptosis. Therefore, this suggests that ERK promotes cell survival by inhibiting 
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components of the apoptotic pathway (e.g. BAD) but also increasing transcription of pro-survival 
genes (e.g. CREB). 
Yue et al demonstrated that all MAPKs are activated during cardiac I/R injury, for both                
anti-apoptotic and pro-apoptotic functions. Inhibition of ERK 1/2 with the inhibitor PD98059 
enhanced I/R induced apoptosis in cultured cardiomyocytes and perfused isolated rat hearts, 
therefore suggesting a pro-survival role (Yue T 2000). In contrast, studies have shown that inhibition 
of p38 MAPK with the inhibitor SB23580 results in a reduction in myocardial damage (Martin J 
2001) and improved cardiac function (Nagarkatti 1998). Inhibition of p38 MAPK also leads to a 
reduction in inflammatory cytokines such TNF-α, interleukin-1 (IL-1) and interleukin-8 (IL-8), 
therefore reducing the pro-inflammatory response which is known to contribute to cardiac I/R injury 
(Zhang 2008). As a result of this it has been suggested that p38 MAPK inhibitors should be used as a 
therapeutic. However there have also been reports that inhibition leads to a poorer prognosis, due to 
involvement in developmental, differentiation and proliferation and so its use remains a controversial 
view (Kumphune S 2012). 
The findings from these studies suggests that MAPK pathways provide potential therapeutic targets 
to abrogate cell death caused during I/R injury through up-regulation of the protective ERK 1/2 or 
inhibition of pro-death p38 MAPK and JNK. 
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Figure 1.4 The MAPK signalling cascade. MAPK signalling is controlled by a cascade of 
MAP3Ks>MAP2K>MAPK. Stimuli such as cytokines, tyrosine kinases and growth factors all 
activate MAP3Ks causing activation of the main MAPKs; p38, JNK and Akt. Abbreviations: 
MAPK; mitogen-activated protein kinase, p-38; p38 mitogen-activated protein kinases, JNK; c-Jun 
N-terminal kinase, ERK1/2; extracellular signal-regulated kinase, Elk-1; ETS domain containing 
protein, AP-1; Activator protein 1, MKK; Map kinase kinase, Raf; proto-oncogene serine/threonine-
protein kinase. Figure adapted from Cellsignalling.com. 
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1.4.2 PI3K/Akt pathway  
PI3K is a lipid and protein kinase which catalyses the phosphorylation of the inositol ring of 
phosphoinositides at the D3 position as well as phosphorylating non-muscle tropomyosin, which is 
involved in ß-adrenergic receptor endocytosis. Reports have identified PI3K as playing a role in 
cytoprotection and apoptosis reduction (Koyasu 2003). The role of PI3K in cardioprotection is due to 
generation of phosphatidylinositol 3,4,5-triphosphate (PIP3) which facilitates PDK1 phosphorylation 
of substrates such as p70S6K, Akt and Protein Kinase A (PKA). An increase in Akt phosphorylation 
has been observed in pre-conditioning, with this activation inhibited using PI3K inhibitors 
suggesting it is responsible for its activation. Akt is believed to induce cardioprotection by 
phosphorylating target proteins such as GSK-3, endothelial nitric oxide synthetase (eNOS) and pro-
apoptotic Bcl-2 family member BAD (Tong H 2002). Phosphorylation of BAD targets it to 14-3-3 
protein where it is sequestered and therefore its pro-apoptotic actions are blocked. Studies have 
shown that overexpression of Akt leads to blocking of hypoxia-mediated activation of caspase-3 and 
caspase-9. Akt also phosphorylates and activates the ubiquitin ligase mdm2 which is known to 
reduce I/R injury-induced cell death (Davidson S 2006). 
It has been published that Akt can phosphorylate and activate eNOS to produce NO, which has been 
shown to have cardioprotective effects in I/R injury (Roviezzo F 2007). Also, during ischaemia low 
pH and low levels of oxygen allow intracellular nitrite can also be converted into NO by 
deoxymyoglobin or xanthine oxidoreductase. The effects of NO are thought to be on mitochondrial 
K
+
/ATP by production of guanylyl cyclase, which via protein kinase G, can result in the opening of 
the mitochondrial potassium ATP channel leading to an influx of postassium ions and disruptions to 
membrane potential. Conversely, excess NO can lead to post-translational modifications to proteins 
including S-nitrosylation, which is a reversible modification that has the ability to protect thiol 
groups from further oxidation and thus may have a protective role (Dos Santos P 2002). 
1.4.3 The Reperfusion Injury Salvage Kinase Pathway  
Activation of pro-survival kinases during the first stages of ischaemia has been hypothesised to 
attenuate reperfusion-induced cell death. Activation of these pro-survival kinases such as ERK 1/2 
and Akt at reperfusion appears to be sufficient to elucidate protection and therefore these cascade 
pathways have been given the term reperfusion injury salvage kinase (RISK) pathway (figure 1.5) 
(Davidson S 2006). Due to their cardioprotective roles it has been suggested that the ability to 
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manipulate and up-regulate these pathways in reperfusion may provide a potential approach to limit 
reperfusion-induced cell death (Hausenloy 2004).  
A number of growth factors and other agents have been shown to be cardioprotective when 
administered during the early stages of reperfusion, with their mechanism of action linked to 
activation of this RISK pathway. An example of this is insulin, which has been shown to activate the 
PI3K-Akt kinase pathway. Jonassen et al (Jonassen AK 2000) showed that administration of 
glucose-insulin-potassium (GIK) to rats at reperfusion reduced heart infarct size. This 
cardioprotective effect shown with insulin has been linked to phosphorylation of Akt and BAD, with 
increased phosphorylation being seen in comparison to control hearts not treated with insulin 
(Jonassen AK 2000). Another agent which has been identified as having cardioprotective effects is 
the peptide urocortin, which is released by myocytes in response to stress e.g. ischaemia (Brara B 
1999). It has been shown that prolonged hypoxia causes an enhanced presence of urocortin during 
reoxygenation which leads to reduced cell death via increased phosphorylation of ERK 1/2 (Brara B 
1999). Finally, fibroblast growth factor (FGF) has been shown to protect at reperfusion via 
recruitment of the ERK 1/2 signalling cascade (Padua RR and Source 1998). FGF is a polypeptide 
growth factor, which is implicated in cell proliferation, survival and apoptosis. It has been shown 
that when administered during the reperfusion stage in an in vivo rat model of MI that it is 
cardioprotective (Cuevas P 1999) and this is modulated by reduction of apoptotic cell death (Cuevas 
P 1997). The activation of these pro-survival pathways at the time of reperfusion appears to regulate 
downstream effectors such as BAD, BAX, p70S6K and eNOS which are thought to be responsible 
for the protection associated with activation of the RISK pathway. One way in which this may cause 
protection is inhibition of the MPTP opening. It has previously been shown that pharmacological 
inhibitors of MPTP opening leads to cardioprotection (Hausenloy DJ 2002). Inhibition of the       
pro-apoptotic proteins BAD, BAX and p53, which are thought to regulate the MPTP opening, may 
therefore be a mechanism through which the RISK pathway elucidates its protectiveness (Hausenloy 
2004).  
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Figure 1.5 The RISK signalling pathway. RISK signalling involves two main kinases; Akt and ERK which when activated have both and-apoptotic 
effects and anti-autophagic effects, which promote cell survival. Abbreviations: MPTP; mitrochondrial permeability transition pore, GSK3β; glycogen 
synthase kinase 3 beta, eNOS; endothelial nitric oxide synthase, P70SK6; Ribosomal protein S6 kinase beta-1, ERK1/2; extracellular signal-regulated 
kinase, MEK; mitogen extracellular-regulated kinase, Bcl-2; B cell lymphoma-2, BAX; Bcl-2-like protein 4, BAD; Bcl-2-associated death promoter. 
Figure adapted from (Hausenloy 2004). 
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1.4.4 The Bcl-2 family 
 
The Bcl-2 family of proteins have been found to be key players in the apoptotic death programme, 
particularly in mitochondrial regulation and caspase activation. This family of proteins contain both 
pro-apoptotic (Bax and Bak) and pro-survival members (Bcl-XL and Bcl-w) and therefore act as 
critical life-death decision point within the common pathway of apoptosis (Tsujimoto 1998). The 
pro-apoptotic Bcl-2 members can be characterised into either ‘BH (Bcl-2 homology)-multi’ proteins 
with three conserved domains; BH1, BH2 and BH3 and include Bax and Bak. The second group 
contain only the BH3 domain and are therefore known as ‘BH3-only proteins’ and include Bid, Bad 
and Puma  (Burlacu 2003).  
 
Bcl-xl and Bcl-2 are localised in the mitochondrial membrane as well as the endoplasmic reticulum 
and nuclear envelope and prevent the release of factors that contribute to apoptosis being initiated. 
This includes cytochrome c and AIF from the mitochondrial inter-membrane space to the cytoplasm. 
Once here they can activate caspases and induce apoptosis. AIF release is regulated by the opening 
of the MPTP which in turn is regulated by Bcl-2 and Bcl-XL (Tsujimoto 1998). 
 
The pro-apoptotic proteins such as Bax reside in the cytosol prior to apoptosis, but following a pro-
apoptotic signal undergoes a conformational change allowing it to translocate to the mitochondria 
where it participates in disrupting the mitochondrial membrane (Crow M 2004). Bax has been shown 
to integrate into the mitochondrial membrane and form pores to allow cytochrome c release (Cory S 
2003).  
 
Another pro-apoptotic member is BAD which in its inactive state is phosphorylated by survival 
signals and binds to 14-3-3 scaffold proteins in the cytoplasm (Yang E 1995). There are two main 
residues thought to be phosphorylated in the inactive form of BAD; serine 112 and serine 136. They 
have been shown to be regulated by distinct survival kinases, namely serine 112 by ERK and serine 
136 by Akt (Xianjun F 1999). Upon abrogation of survival signals BAD is dephosphorylated, 
dissociates from 14-3-3 and then localises to the mitochondria. The free BAD molecules are then 
able to interact with either Bcl-2 or Bcl-Xl and block their anti-apoptotic functions. Studies have 
shown that the BH3 domain of BAD specifically interacts with Bcl-2 and Bcl-Xl to inhibit them 
(Adachi 2002). 
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This introduction thus far has detailed the mechanisms which define and mediate myocardial I/R 
injury. Given that a key aim of this thesis is to explore these mechanisms in relation to the 
autoimmune disorder systemic lupus erythematosus (SLE), the subsequent sections will therefore 
outline the clinical features, pathogenesis and current treatments for SLE. 
 
1.5 Autoimmune disease 
 
In society we are continually exposed to organisms that are inhaled, swallowed or inhabit our skin 
and mucous membranes (Janeway 2002). The ability of these organisms to cause disease relies on 
the pathogenicity of an organism but also, and perhaps more importantly, how our defense 
mechanisms respond to eliminate the pathogen. The immune system comprises of a complex 
network of cells, humoral factors, cytokines and lymphoid organs. The immune system defense is 
divided into two parts, namely the innate and adaptive immune response, although in practice they 
overlap and have much interaction (Delves 2000).  
 
The innate immune system is the first line of defense against infection and is described as a broad 
response mainly involving phagocytic cells such as neutrophils, monocytes and macrophages, which 
can release pro-inflammatory mediators such as mast cells and natural killer cells. Additionally, there 
is a molecular component of the innate response comprising of complement and cytokines such as 
interferons (IFN) (Medzhitov 2000; Janeway 2002). The second stage of the immune response, the 
adaptive, does not become activated until sometime after exposure to an antigen. However, its 
delayed response allows it to react with high antigenic specificity as well as have the ability to 
generate memory allowing for a more rapid response of subsequent antigenic exposures. Antigen-
specific B and T cells surface receptors bind to antigens and specialised antigen presenting cells 
(APC) display the antigen to the lymphocytes allow them to combine to provide a response to the 
antigen. Ultimately, the adaptive and innate immune responses work collaboratively to eliminate 
pathogens (Delves 2000). This is particularly important in cancer, where studies have suggested that 
the immune system plays a role in surveillance for tumours. The use of both mouse models of cancer 
and humans with cancer have shown strong evidence to suggest that certain immune cell types, 
effector molecules and pathways can function as extrinsic tumour suppressor mechanisms (Swann J 
2007). 
 
The complex nature of the immune system is perhaps best illustrated when it goes wrong. An 
example of this is autoimmunity, whereby failure of an organism to recognise its own constituents as 
Chapter I 
 52 
self, resulting in an immune response which is what drives the pathogenesis of an autoimmune 
disorder. Human autoimmune disorders can be divided into organ specific and systemic diseases. 
Examples of organ specific diseases include Hashimoto’s thyroiditis and insulin-dependent diabetes 
mellitus. These diseases involve an immune response directed primarily against a single organ or 
gland. In contrast, a systemic disease is directed against a broad range of tissues and present 
manifestations in a variety of organs. This pathogenesis results from cell mediated responses and 
cellular damage caused by autoantibodies or immune complexes. Examples include systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA) and the antiphospholipid syndrome (APS) (Goldsby 
R 2003). 
 
1.5.1 Systemic Lupus Erythematosus 
 
SLE is a chronic, multisystem autoimmune disorder, which can be characterised by inflammation of 
many organ systems including skin, blood elements, kidneys, and heart (Rahman 2008). The 
reported prevalence of SLE in the general population is 20-150 cases per 100,000 (Lawrence RC 
1998; Chakravarty EF 2007; Pons-Estel GJ 2010) and in women this rate has been shown to vary 
from 164 (white) to 406 (African American) per 100,000 (Lawrence RC 1998). Improvements in 
detection of the disease, particularly in mild cases has led to incidence rates tripling in the last 40 
years of the 20
th
 century (Uramoto KM 1999). However, it remains that prevalence is notably higher 
in individuals of Afro-Caribbean extraction and in females of childbearing age (Tsokos 2011).  
 
The bi-modal pattern of mortality in SLE was first described by Urowitz who suggested that early 
death results from active lupus and infection followed by death in later life being primarily due to 
cardiovascular disease (Urowitz MB 1976). The life expectancy of lupus patients has improved from 
a 50% 4-year survival rate in the 1950s to a 15 year survival rate of 80% today. However, a patient 
who is diagnosed at 20 years still has a 1 in 6 chance of dying by 35 years of age (Rahman 2008). A 
multi-national study of 9,547 patients with SLE showed 1,255 deaths and approximately 25% (313) 
were as a result of cardiovascular disease (Bernatsky S 2005). Due to the complex nature of SLE, a 
significant amount of research has been carried out to define the causes and identify potential targets 
for treatment. Hence, the pathogenesis of SLE will be detailed in the next section of this thesis. 
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1.5.2 Pathogenesis of SLE 
 
1.5.2.1 Autoantibodies 
The main disturbance to the function of the immune system is production of pathogenic 
autoantibodies. There a growing number of autoantibodies identified in association with SLE. Many 
are thought to be pathogenic but their individual roles remain largely unclear (Ehrenstein 1999).  
 
These autoantibodies are mostly directed against several self-molecules found in the nucleus,  but 
also to antigens found in the cytoplasm and on the cell surface. Antibodies to nuclear cellular 
components are the most frequently observed and those common ones detected included antinuclear 
antibodies (ANA), anti-double stranded DNA (ds-DNA),  anti-nucleosome antibodies and antibodies 
to extractable nuclear antigens such as anti-Ro (SS-a), anti-La (SS-B), anti-ribonucleoprotein (RNP), 
anti-Sm and anti-histone (Morrow W 1999; Franceschini 2005). ANA antibodies are  present in more 
than 95% of patients and therefore remains the most sensitive test for SLE (Mok 2003) but are not 
specific as many other autoimmune conditions are also associated with ANA positivity and up to 
10% of the healthy population harbor these antibodies. Conversely, anti-dsDNA antibodies are less 
sensitive, but more specific. Anti-dsDNA antibodies are detected in approximately 70% of patients 
with SLE, however they are specific to SLE and rarely found in other diseases or healthy individuals 
(Isenberg 1987). Hence the tests ANA (due to its high sensitivity) and anti-dsDNA (due to its high 
specificity) are both included as two of the 11 criteria for the classification of SLE (Hochberg 1997), 
(see table 1.1). There is a strong association of these antibodies with lupus nephritis and they can be 
found enriched in the kidney, as well as patients with active nephritis often having elevated anti-
dsDNA levels (Bootsma H 1995). 
 
More recently it has been proposed the nucleosome is the principal antigen which contributes to the 
pathogenesis of SLE. The nucleosome (chromatin) is the term given to the native complex of DNA 
and histones and has the ability to become immunogenic under certain conditions. Impaired 
clearance of apoptotic cell debris is a  hallmark of SLE and predisposes to the disease through 
accumulation of chromatin breakdown and DNA fragmentation from dying cells (Herrmann M 
1998), exposing nuclear antigenic material normally not exposed to the immune system and thus 
lowering the threshold for loss of tolerance in susceptible individuals.  Auto-antibodies directed 
against nucleosomes were originally described in lupus mouse models and correlation between anti-
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nucleosome antibodies and renal disease has been shown in SLE patients (Cervera R 2003; Duzgun 
N 2007).  
Approximately 30-40% of patients with lupus test positive for another group of auto-antibodies, 
namely the antiphospholipid antibody (aPL) and therefore additionally have the antiphospholipid 
syndrome (APS), which is discussed in section 1.5.10 of this thesis. The aPL are a family of 
autoantibodies that exhibit a broad range of target specificities and affinities, recognising a 
combination of phospholipids and proteins that bind to phospholipids. Initially it was believed that 
aPL bound to phospholipid directly, however it is now known that the most pathogenic aPL actually 
bind not directly to phospholipids but via proteins complexed to anionic phospholipids (Galli M 
1990). In 1990, three groups independently discovered that anticardiolipin (aCL) antibodies did not 
bind cardiolipin directly but instead via a protein ‘co-factor’, the phospholipid-binding plasma 
protein β2GPI (Galli M 1990; Matsuura E 1990; McNeil H 1990). However, binding is also thought 
to occur via other co-factors such as prothrombin, annexin V, protein S and C (M Sorice 2000), 
although their relevance remains uncertain.  Not all aPL are pathogenic and they can be found in 
healthy adults and patients with infectious, malignant or drug-related disorders who do not go on to 
develop APS (Keeling D 2012). This led to the distinction of two populations of aPL; non-
pathogenic aPL, which bind neutral or anionic phospholipid and do not require serum cofactors and 
pathogenic aPL, which occur in the APS and bind negative phospholipid, requiring the presence of 
serum cofactors such as β2GPI to do so (Keeling D 2012). There are a number of proposed 
mechanisms that have been suggested to contribute to autoantibody production, however, the exact 
mechanism for the generation of aPL remains unknown. The current theories as to the causes of SLE 
are described in section 1.5.4 of this thesis. 
 
1.5.2.2 B and T cells 
Functional immune system alterations to B cell, T cell and monocytic lineage cells have been 
characterised in SLE. These alterations result in polyclonal activation of B cells, increased numbers 
of antibody producing cells and subsequent autoantibody production and immune complex formation 
(Mok 2003). B and T cell activation requires stimulation by specific antigens, however it has been 
shown in mice that bacterial DNA, viral antigens and chemicals such as pristine can induce 
production of anti-DNA antibodies (Hahn 1998). Additionally, self-antigens such as DNA-protein 
and RNA-protein complexes have also been shown to induce autoantibody production (James J 
1995). Both these environmental antigens and self-antigens can be taken up by APC or bind to 
antibodies on the surface of B cells. These antigens are then processed and presented to T cells via 
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their human leukocyte antigen (HLA) molecules, which in turn leads to B cell production of 
autoantibodies (Mok 2003). 
 
B cell activation is abnormal in SLE, with increased numbers of activated cells which have increased 
intra-cytoplasmic calcium responses as well as being more sensitive to cytokines such as interleukin 
6 (IL-6) (Linker-Israeli M 1991). Epitope spreading has also been shown in murine and human SLE 
whereby B cells are more prone to polyclonal activation by antigens and cytokines (Monneaux 
2002). The B lymphocyte stimulator (BLyS), also known as BAFF, is a soluble ligand of the TNF 
cytokine family and a prominent regulator of B cell differentiation, homeostasis and selection 
(Moore PA 1999). BLyS levels alters survival signals and, therefore, selective apoptosis of 
autoantibody-producing B cells. High levels of BLyS cause exacerbation of the SLE disease state, 
due to relaxation of B cell selection and, therefore, enhancement of autoantibody production (Cancro 
2009). This important feature of the BLyS ligand has made it an important therapeutic target, which 
will be expanded on in section 1.5.8.6.  
 
T cell function abnormalities include lower peripheral blood levels as well as a skew of their 
function towards B cell activation, hence increase antibody production (Linker-Israeli M 1990). 
Early events in T cell activation have been shown to be defective, therefore causing a reduced 
capacity to proliferate in response to mitogenic stimulation, thereby reducing interleukin-2 (IL-2) 
production (Alcocer-Varela 1982). It previously has been suggested that altered lipid metabolism 
contributes to SLE pathogenesis with their presence altering early steps during T cell receptor (TCR) 
stimulation (Jury E 2007). The identification of a role for lipid raft-associated glycosphingolipids 
(GSLs) identifies a potential new therapeutic target (Leong 1994). Recent work has focused on 
changes due to alterations in the metabolic processing of lipid biosynthesis. CD4+ T cells from SLE 
patients have been shown to display an altered profile GSLs compared with that of healthy controls 
(McDonald G 2014).  
 
1.5.2.3 Cytokines  
Several cytokines are thought to play a role in the pathogenesis of SLE, such as previously 
mentioned IL-2. More recently, interleukin 10 (IL-10) has been identified as being elevated in the 
serum of SLE patients (Houssiau FA 1995). IL-10 is a T helper 2 (Th2) cell cytokine which acts a 
stimulator of B cell proliferation and differentiation and, therefore, a potential mediator of polyclonal 
B cell activation in SLE (Mok 2003). Another cytokine which has been shown to contribute to SLE 
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pathogenesis is IL-6 which is known to induce terminal differentiation of B lymphocytes into 
antibody-forming cells as well as contributing to differentiation of T cells into effector cells (Tackey 
E 2004). Finally, IFN- is thought to be a key cytokines linked to SLE pathogenesis and promote 
activation of dendritic cells (DCs), B and T cells, endothelial cells, neuronal cells, renal resistant 
cells and other tissues (Bertsias G 2012). Activation of the IFN pathway has previously been linked 
to the presence of autoantibodies specific for RNA-associated proteins. RNA-mediated activation of 
TLR is an important mechanism contributing to production of the key cytokine IFN- as well as 
other pro-inflammatory cytokines and hence TLRs are described in more detail in the following 
subsection (Visentini M 2009). 
 
1.5.2.4 Toll like receptors 
Patients with lupus are unique in their ability to activate endosomal sensors such as TLRs by nucleic 
acids (DNA and RNA) (Rahman 2006). Studies have shown that mice carrying deletions of Tlr7 and 
Tlr9 have reduced disease activity. When mice have double deletion of both Tlr7 and Tlr9 the 
reduction in disease activity is even greater than when independent, therefore suggesting that they 
both contribute to disease pathogenesis (Santiago-Raber ML 2010). In a healthy individual there are 
barriers which prevent this kind of sensor activation, however in SLE, molecules called ‘alarmins’ 
are released due to stress and have the ability to facilitate transfer (Wu 2012). Examples include 
neutrophil extracellular traps (NETs) and immune complexes. The activation of TLRs forms part of 
the enhanced innate immune response in SLE. They are receptors found on cell membranes most 
commonly but also in the cytosol and endosomal compartments (Rahman 2006). The TLRs are 
responsible for engaging with antigens expressed on autoreactive B or T lymphocytes leading to 
their activation. They are also responsible for the activation of APCs such as DCs, enhancing their 
ability to present their auto-antigens. It has been shown that chromatin containing immune 
complexes are 100-fold more efficient in stimulating lupus B cells due to the presence of nucleic 
acids as well as the combined B cell receptor activation and TLR stimulation (Bertsias G 2012). 
There are two main types of DCs; plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells 
(mDCs). pDCs have been likened to IFN alpha factories due to the large quantities of the type 1 
interferon upon activation by antigens or auto antigens recognised by the innate immune receptors 
(Niewold T 2010). In contrast, mDCs are involved in antigen presentation with immature 
conventional mDCs promoting tolerance and mature auto reactivity.  
 
1.5.2.5 Immune complexes 
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Immune complexes and complement activation pathways are responsible for mediating effector 
function and tissue injury. In healthy individuals, immune complexes are cleared by Fc and 
complement receptors. Failure to clear these complexes results in tissue deposition and tissue injury 
at sites (Morrow W 1999). The clearance of immune complexes by phagocytic cells is defective in 
patients with SLE (Salmon J 1996). This is partly due to a reduction in CR1 receptors but also to 
allelic polymorphisms of the IgG receptor, therefore reducing clearance of IgG2 and IgG3 containing 
complexes (Kiss E 1996; Morrow W 1999). Tissue damage is also responsible for recruitment of 
inflammatory cells, reactive oxygen intermediates, and production of inflammatory cytokines and 
modulation of the coagulation cascade (Davies, Peters et al. 1992).  
 
As well as defective immune complex clearance it has also been shown that apoptotic cell clearance 
is also impaired in patients with SLE (Herrmann M 1998). This persistent circulation of apoptotic 
waste can serve as an immunogen for autoreactive lymphocyte activation as well as an antigen for 
immune complex formation (M 2001). 
 
1.5.2.6 Apoptosis 
Apoptosis acts as a source of auto antigens and molecules with the ability to induce cytokine activity 
(e.g. IFN-) (Salmon 1999). The increased spontaneous apoptosis as well as UV induced apoptosis 
in skin cells that SLE patients are susceptible to as well as the impaired clearance of apoptotic 
peripheral blood cells all provide cell blebs which are rich in lupus auto antigens (Casciola-Rosen 
LA 1994; Casciola-Rosen L 1996). Under normal circumstances these apoptotic cells would be 
cleared by macrophages, therefore not producing an immune response, however this is impaired in 
patients with SLE (Herrmann M 1998). The reason for this defect is not clear, however it is thought 
that quantitative or qualitative defects in the early part of complement activation, such as C2, C4 or 
C1q  may play a role (Korb 1997). 
 
1.5.2.7 Complement 
Activation of the complement pathways is commonly observed in patients with SLE and has been 
shown to lead to deposition of complement components at sites of tissue injury such as the renal 
glomeruli. This finding strongly suggests that complement activation contributes to tissue damage in 
SLE. Additionally, it has been shown that complement is important in generating an autoimmune 
response (e.g. in SLE) but that deficiencies in the classical complement pathway can infact cause 
SLE. An example is a lack of C4, which causes a decreased elimination of self-reactive B cells. This 
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lack of C4 has been shown in mouse models to reduce ability for negative selection (Tsokos 2011). 
Additionally, decreases in C1q are known to reduce the body’s ability to clear necrotic waste, which 
is a common characteristic of SLE (Manderson AP 2004) and anti-C1q antibodies are associated 
with SLE.  
 
Following on from defining the pathogenesis of SLE, this chapter will now discuss the clinical 
features which result of the disease progression. 
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Figure 1.6 The Pathogenesis of Systemic Lupus Erythematosus 
An overview of the main mechanisms that have been identified as contributing to the pathogenesis of 
the SLE disease. 
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1.5.3 Clinical Features of SLE 
 
SLE disease progression is characterised by periods of remission and relapse. Non-specific 
symptoms are common in SLE and include fatigue, fever and anorexia. A severe and for many  the 
most disabling symptom of SLE is fatigue (Morrow W 1999). The most frequent symptom of the 
musculoskeletal system is arthralgia which affects approximately 90% of patients with SLE (Morrow 
W 1999). Additionally myalgia, muscle weakness and tenderness have been reported in up to 60% of 
patients (Isenberg DA 1981). Other common features include the classic butterfly rash and pleuritic 
chest pain. Table 1.1 summarises the revised classification criteria for SLE (Tan EM 1982; Hochberg 
1997) listing the clinical features commonly associated with SLE. 
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MANIFESTATION DEFINITION/CHARACTERISTICS 
Malar rash Erythematosus rash over malar area, sparing nasolabial folds 
Discoid rash  
Photosensitivity  
Oral Ulcers Usually painless and observed by physician 
Arthritis Non-erosive, involving two or more joints 
Serositis Pleuritis and/or Pericarditis 
Renal disorder Persistent proteinuria (>0.5g/24 hours or >3+ on dipstick if 
quantification unavailable) 
Neurological disorder Seizures or psychosis (unprovoked) 
Haemolytic disorder Haemolytic anaemia or leucopoenia or lymphopenia or 
thrombocytopenia 
Anti-nuclear 
antibodies 
Raised titre at any point 
Immunological 
disorder 
Raised anti-native DNA antibody or 
Presence of anti-Sm antibody or 
Positive aPL (based on abnormal serum level of IgG or IgM aCL or 
positive LA or false positive test result for Syphilis sustained for at 
least six months 
 
Table 1.1 Classification criteria for the diagnosis of SLE. Adapted from Tan et al (Tan EM 1982) 
and Hochberg et al (Hochberg 1997). Out of the 11 criteria four are required, either serially or 
simultaneously, to make a diagnosis of SLE. Abbreviations: Sm, Smith; aPL, antiphospholipid; LA, 
lupus anticoagulant, IgG; immunoglobulin G, IgM; immunoglobulin M. 
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1.5.3.1 Mucocutaneous Features 
It is acknowledged that mucocutaneous involvement in SLE affects the majority of patients. The 
classic lupus ‘butterfly’ rash is elevated, often painful and precipitated by exposure to sunlight. This 
kind of rash can last for a number of days but may also persist for weeks and is commonly associated 
with other inflammatory manifestations of the disease. Other rashes such as discoid lupus 
erythematosus (DLE) develop in as many as 25% of SLE patients. This type of lesion are small and 
discrete, however infiltrate dilated hair follicles (follicular plugging) (Bertsias G 2012).  
 
Alopecia occurs in the majority of SLE patients and therefore the term ‘lupus hair’ has been 
characterised by thin hair that easily fractures. The hair loss normally corresponds to increased 
disease activity and therefore normally grows back as disease activity subsides. Photosensitivity 
occurs in 60-100% of SLE patients who are defined as developing a rash after minimum exposure to 
ultraviolet (UV) lights.  
 
1.5.3.2 Musculoskeletal features 
In approximately 50-95% of patients with SLE there are signs of the musculoskeletal system being 
affected (Bertsias G 2012). Most commonly arthritis is observed with join involvement classically 
being non-erosive, non-deforming arthralgias in a distribution similar to that seen in patients with 
RA. It most commonly affects small joints in the hands, wrists and knees and may be the primary 
symptom observed or accompany other lupus manifestations during a flare. Another less common 
feature is myositis where general myalgia and muscle tenderness with proximal muscle weakness is 
observed during a flare of the disease. Finally avascular bone necrosis (AVN) is seen in typically 5-
15% of patients (Mok 2003; Ghaleb R 2011)and is a form of acute joint pain presented in the latter 
course of SLE, which causes mortality and disability. Factors, which are known to induce AVN, 
include ischaemia and necrosis to the bone via Raynaud’s phenomenon, vasculitis and the APS. 
 
1.5.3.3 Renal Complications 
Renal involvement in SLE is common, with 40-70% of all patients being affected as well as it being 
a major cause of mortality and hospital admissions. Immune complexes form and deposit themselves 
in the kidney causing intra-glomerular inflammation. This inflammation leads to recruitment of 
leucocytes and activation and proliferation of renal cells. This disruption in renal functions leads to 
lupus nephritis (LN) due to proteinuria of various levels being present in the urine. Lupus nephritis 
presents with proteinuria and may lead to nephrotic syndrome (proteinuria, hypoalbuminaemia and 
peripheral oedema), hypertension and deteriorating renal function if not identified early and treated. 
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1.5.3.4 Nervous System 
The central nervous system (CNS) involvement in SLE is thought to be one that is most difficult to 
diagnose and though less common than renal, skin or musculoskeletal involvement, it remains a 
major cause of morbidity and mortality in patients with SLE. Clinical manifestations observed 
include both central and peripheral nervous systems and they must be segregated from infections, 
metabolic complications and drug-induced toxicity. The diagnosis of CNS involvement is a major 
challenge in the clinical setting with milder symptoms such as migraine, cognitive dysfunction (20-
30% patients) and minor psychiatric disorders being the most difficult to link to SLE. However, it 
has been reported that migraines are the most prevalent manifestation in SLE patients but linking this 
directly to disease activity is very difficult therefore the inclusion of migraine among SLE disease 
activity features remains questionable (Sciascia S 2013). 
 
1.5.3.5 Pleura and Lungs 
Most commonly pleuritis is observed in SLE with 45-60% of patients affected and frequently 
presents with pleuritic chest pain, which can occur in the presence or absence of a pleural effusion. 
The effusions are linked to higher glucose and lower lactate dehydrogenase levels, compared with 
pleural effusions seen in patients with RA (Bertsias G 2012). 
 
1.5.3.6 Haematologic features 
Often haematologic abnormalities are the presenting symptom in SLE, with manifestations such as 
anaemia, leucopenia and autoimmune thrombocytopaenia. Anaemia is common in SLE and has been 
shown to correlate with disease activity (Giannouli S 2005). A common cause is suppressed 
erythropoiesis due to chronic inflammation or autoimmune haemolytic anaemia. Leucopenia is also 
common with white blood cell counts of below 4500/mm
3
 (4-11x10
9
 is normal) reported in about 30-
40% of cases, particularly when disease activity is high (Bertsias G 2012). 
 
1.5.3.7 Cardiovascular features 
Patients with lupus have increased and accelerated atherosclerosis with a greater prevalence of 
cardiovascular and cardiac valvular disease. Studies have also shown an increased risk of MI and 
stroke; however this increased risk cannot be explained by traditional CVD risk factors.         
Valvular heart disease has been likened to the presence of aPL, with the most common abnormality 
being diffuse thickening of the mitral and aortic valves (Gabrielli F 1995).  
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The relative risk of suffering a MI in patients with SLE is high, with a 5-10 fold increase in the 
possibility of developing cardiovascular disease when compared to the background age and gender 
matched population (Elliott JR 2007). The relative risk of developing cardiovascular disease is 
particularly high in pre-menopausal women, who have a 50-fold increase of atherosclerotic disease 
for women aged 35-44, in comparison to age and gender matched controls (Manzi, Selzer et al. 
1999). This higher relative risk of early cardiovascular disease in patients with SLE underlines the 
importance for identifying therapeutic targets, that when modulated may improve morbidity and 
mortality outcomes in these patients. Whilst it is important to investigate treatments that are able to 
prevent an MI from occurring, naturally a significant number of patients with SLE due to their 
increased risk, will ultimately suffer from an event. It is, therefore, also important to explore whether 
patients with lupus are more susceptible to I/R cardiac injury, should an MI occur. Addressing this 
question is important, because if I/R cardiac injury is also worse in SLE and pathways are identified 
in lupus that may promote this enhanced I/R injury, then targeted intervention could have 
translational benefits. Previous studies have shown that the SLE-like B6.MRL/lpr mice have 
accelerated and enhanced intestinal I/R injury. Additionally I/R-induced injury resistant Rag-1
−/−
 
mice infused with whole IgG from old B6.MRL/lpr mice showed restored intestinal I/R injury 
(Fleming S 2004). To date there has been little focus on the heart in terms of investigating I/R injury 
and SLE.  
 
Whilst there is a good understanding of the pathogenesis and the clinical manifestations of SLE, the 
causes are less well defined. The next section will discuss some of the current theories as to why 
individuals are more susceptible to this disease.  
 
1.5.4 Causes of SLE 
 
The aetiology of SLE includes both genetic and environmental components with the female sex 
strongly influencing pathogenesis. All these factors are believed to lead to loss of tolerance 
manifested by immune responses against endogenous nuclear antigens. However, it is important to 
remember that SLE is highly multifactorial disease and it is likely that many causes of disease are yet 
to be discovered. 
 
1.5.4.1 Genetic Factors 
Studies have shown that SLE patient’s siblings are 30 times more likely to develop SLE when 
compared to those with no affected sibling (Bertsias G 2012). Genome-wide association studies 
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using hundreds of thousands of single nucleotide morphism (SNP) markers has allowed the 
discovery of SLE related genes to be identified. Additionally, it has allowed identification of specific 
genes related to immune response and inflammation (e.g. HLA-DR), DNA repairs (e.g. TREX1), 
adherence of inflammatory cells to the endothelium (ITGAM) and tissue response to injury (KLK1) 
(Hom G 2008). Nevertheless, monozygotic twin concordance is 25%, which though higher than 
background prevalence in the population, implies that other non-genetic factors play a role in 
conferring risk (Grennan DM 1997). 
 
1.5.4.2 Epigenetic Factors 
More recently the role of epigenetic modifications such as DNA methylation and post-translational 
modifications of histones have been explored in SLE (Ballestar E 2006). This sort of modification 
can be inherited or can be due to environmental influence. Epigenetics refers to changes in gene 
expression, which are caused by mechanisms independent of DNA base sequence alterations. 
Research has suggested that differences in DNA methylation status of certain genes could explain, at 
least in part, differences observed in some identical twins that are discordant for SLE (Jeffries 2011). 
DNA accessibility to transcription factors and, therefore, gene expression is regulated by histone 
modifications e.g. acetylation as well as DNA methylation. An example is the recruitment of histone 
deacetylase 1 to the IL2 promoter suppressing its expression (Mishra N 2003). Many believe that 
epigenetics may be the missing factor, which links genetic and environmental risk factors (Jaenisch 
2003).  
 
1.5.4.3 Environmental Factors 
Environmental factors such as medication, smoking and exposure to UV light are thought to be 
candidate triggers of SLE (Tsokos 2011). Epstein Barr virus (EBV) has also been identified as a 
possible cause of SLE as it is thought to reside and interact with B cells and promote IFN- 
production by pDCs. Therefore, it is suggested that at least in part lupus could be triggered in 
response to viral infection driven by elevated IFN- levels, a central cytokine in SLE (Obermoser 
2010). Certain drugs have been linked to induction of autoantibodies in a significant number of 
patients, most of who do not develop signs of autoantibody-associated diseases. However, over 100 
drugs have been associated with causing drug-induced lupus (DIL). Although the cause of DIL is not 
well understood, it is believed that a genetic predisposition may play a role. For example, when 
patients with slow acetylator enzymes are given drugs that are metabolized by acetylation they are 
more likely to develop disease (Bertsias G 2012). Also, it has been suggested these drugs may alter 
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gene expression in CD4+ T cells by inhibiting DNA methylation and inducing over-expression of 
LFA-1 antigen, therefore promoting auto reactivity (Zhou 2008). 
 
1.5.4.4 Hormonal Factors 
It has been shown in murine models that oestrogen or prolactin can lead to an autoimmune 
phenotype with an increase in mature autoreactive B cells (Bertsias G 2012). The Nurses’ Health 
Study showed that increased risk of developing SLE was associated with oral contraceptive (relative 
risk 1.9 compared to never users). These findings suggest that hormones can contribute to 
autoimmune development in murine models, however interestingly the use of oral contraceptive does 
not increase disease flares in women who have stable disease (Sanchez-Gierrero 2005).  However, 
other studies have shown that as long as disease state is stable then there is no increased risk of 
disease flare, with only 7 out of 91 patients taking oral contraception having a severe disease flare 
(Petri M 2005). Another important factor is pregnancy, however it has been shown that although in 
some cases disease flares are induced by pregnancy, levels of oestradiol and progesterone are 
actually lowered in the second and third trimester when compared to healthy matched controls 
(Doria A 2008) and this may account for the variation in flare rate seen during pregnancy in patients 
with SLE. 
 
1.5.5 Diagnosis 
 
1.5.5.1 Serological Tests 
A number of serological tests, whereby serum is tested for autoantibodies, have been developed to 
diagnose rheumatic diseases. An example is the ANA antibody assay, which is known to be 
extremely sensitive (95% when using human cultured cells as the substrate) and relatively easy to 
carry out (Bertsias G 2012). A limitation of the ANA assay is its specificity for SLE. ANAs are 
present in many other rheumatic diseases as well as observed in infections, as well as some 10% of 
healthy individuals testing positive. Due to this issue other assays have also been develop, namely an 
assay for antibodies to extractable nuclear antigens (ENAs) and antibodies to Sm (Smith) and Ro are 
those most frequently seen in lupus. The first identified lupus antigen was the nucleosome, a 
complex of DNA and histones (Rumore 1990). Autoantibodies to single stranded DNA (ssDNA) and 
individual histones are common in SLE and antibodies to dsDNA are found in up to 70% of SLE 
patients. Antibodies for dsDNA are 95% specific for the disease and, therefore, are very valuable 
disease marker but clearly less sensitive than ANA. Other antibodies, which have been correlated 
with SLE antibodies to some ENAs, namely anti-Sm (Smith) antibodies and these are found in 10-
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20% of SLE patients (Bertsias G 2012). Additionally, anti-ribosomal antibodies are found in 12-16% 
of patients with SLE, but are less sensitive than anti-dsDNA or anti-Sm antibodies (Nagai T 2005). 
 
1.5.5.2 Prognostic markers 
The analysis of large cohorts has identified clusters of autoantibodies associated with distinct SLE 
features as well as serum anti-dsDNA titers being correlated with LN. The aPL antibodies are 
associated with features of APS, CNS involvement, LN and death. The ENA autoantibodies anti-Ro 
and anti-La have been correlated to neonatal lupus and congenital heart block in neonates of 
seropositive mothers (Hausenloy 2013). 
 
1.5.6 Classification criteria and activity indices 
 
A criterion for the SLE was first developed in 1971 but has since been revised several times, with the 
latest in 2007. The criterion allows patients to be distinguished from those without the disease. The 
American College of Rheumatology ACR classification was developed for clinical studies of lupus 
to ensure that cases reported in the literature do in fact have the disease (Bertsias G 2012). However, 
due to the dynamic nature of the disease, diagnosis can often be challenging.  Whilst this criteria is 
recognised as being used in standard practice, several caveats have been identified. Most 
importantly, this set of criteria was developed to identify patients with an established disease profile 
and therefore may exclude those who are early in the disease progression or have limited organ 
involvement.  As well as disease diagnosis, it is important to scale disease activity. This is because 
lupus is such a complex and varying disease from patient to patient and such scale allows appropriate 
treatment plans to be formed. The activity of the disease needs to be distinguished from permanent 
damage as this has an effect on long-term prognosis as well as identifying the appropriate treatment. 
There are a number of validated global as well as organ-specific activity indices used to measure the 
activity of a patients disease. An example is the British Isles Lupus Assessment Group Scale 
(BILAG) which provides individual organ/system assessment (Hay E 1993). This was updated in 
2004 (BILAG 2004) due to concerns over the division of organs and systems for the purpose of 
activity assessment (Isenberg D). Other global score systems exist which provide an overall measure 
of activity. Examples include the European Consensus Lupus Activity Measurements, Systemic 
Lupus Activity Measure (SLAM), and Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI).  All the different assessment scales have been validated against one another and therefore 
all can be recommended for monitoring a patients disease progression (Romero-Diaz J 2011). Whilst 
the majority of SLE patients are diagnosed during their adulthood, up to 20% of cases are diagnosed 
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before the age of 16 and therefore termed childhood-onset or juvenile-onset SLE (JSLE) (Amaral B 
2014).  
 
1.5.7 Juvenile Systemic Lupus Erythematosus 
 
Although the manifestations of JSLE are broadly similar to that of in adult-onset, differences do 
exist. It is accepted that the age at which the disease begins can have a significant impact on the 
severity and outcome of the disease (Descloux E 2009). It has been suggested that JSLE has a more 
aggressive nature, with renal organ involvement being more frequent greater and long-term treatment 
(e.g. immunosuppressant) being required (Amaral B 2014). This leads to poorer prognosis, resulting 
in earlier morbidity and increased mortality rates due to factors such as a higher risk of cumulative 
damage. Studies have shown that a notable percentage of adolescent-onset patients develop 
cardiovascular events and cancer, and whilst this was not higher than in adult-onset, these diseases 
are uncommon in younger patients suggesting an increased susceptibility (Frostegard 2005).  
 
Correct disease management of both adult and childhood onset SLE is crucial, and as part of this it is 
important to have correct treatment plans. The following section outlines current treatments available 
to patients.  
 
1.5.8 Treatments 
 
1.5.8.1 Non-pharmacologic management 
There is little advice for non-pharmacologic treatment of SLE; however EULAR and ACR 
guidelines make some limited recommendations. They offer guidelines on safe sun protection, as 
one-third of patients are known to be photosensitive. This includes avoiding direct exposure and 
using suitable sun protection (e.g. clothing and sunblock to block UVA and UVB rays) (Ioannou 
2002). It is also advised that smoking be prevented as it has been shown smokers have a significantly 
higher SLEDAI score than previous smokers or those that have never smoked (Ghuassey, 2003). 
Diet is also advised on, with vitamin D and calcium intake particularly important, especially in 
patients receiving long-term glucocorticoid therapy.  
 
1.5.8.2 Pharmacological treatments 
Guidelines were developed by the ACR in 1999 and the EULAR taskforce in 2008 and they are the 
most commonly used guidelines but they do have some limitations, particularly the ACR guidelines 
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because of the outdated proposal.  This means that newer medications aren’t included, simply 
because they were not available. Additionally, the treatment of SLE patients is highly personal and 
therefore each case has to be assessed individually (Gladman 1999 and Bertsais 2008). Mild 
symptoms such as arthralgias and cutaneous manifestations are generally treated by antimalarials and 
non-steroidal anti-inflammatory drugs (NSAIDs), whereas oral corticosteroids and cytotoxic agents 
are used for more severe disease.  Depending on organ involvement and severity, other drugs such as 
cyclophosphamide, immunosuppressive agents and tacrolimus may also be used. 
 
Biologics are increasingly used in lupus. The most recent agent on the market is belimumab, which 
is a human monoclonal antibody that inhibits B cell activating factor (BAFF) and is now licensed for 
patients with SLE with no renal nor CNS manifestations for moderate to severe disease. 
 
1.5.8.3 NSAIDs 
NSAIDs are prescribed in the majority of patients with SLE due to 90% developing arthralgias or 
polyarthritis (Cojocaru M 2011). However, NSAIDs can have significant risks associated with long-
term use (Bertsais 2008) such as having an adverse effect on renal function in the setting of lupus 
nephritis. Their mechanism targets inhibition of cyclooxygenase-2 (COX-2), which in turn inhibits 
the production of prostaglandins that protect the lining of the gastrointestinal tract. This makes 
gastrointestinal bleeding a possible side effect and therefore patient blood count and serum creatinine 
are monitored as well as educating patients on possible symptoms of bleeding (e.g. bloody stools and 
urine) (Gladman 1999). For this reason they are often co-prescribed with gastroprotective agents 
such as proton pump inhibitors. Additionally, there is also evidence to suggest that NSAIDS may 
enhance the risk of developing CVD by up to 35% (Capone ML 2010). 
 
1.5.8.4 Glucocorticoids 
Glucocorticoids are a group of immunosuppressive agents used in the majority of patients with some 
cohort studies suggesting up to 80% of patients use the therapy as a ‘maintenance treatment’ (Mosca 
2011). However, high doses are normally reserved for treatment of patients with active major organ 
involvement (Parker 2007). The concern is that long-term complications at high doses are common 
and often severe and can include hypertension, diabetes, weight gain, osteoporosis and infections 
through immunosuppression, therefore those treated for long periods of time are monitored closely. 
Also long-term steroid use is linked with higher levels of damage incidences (Ruiz-Arruza I 2014).   
 
1.5.8.5 Cytotoxic/immunosuppressive agents 
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The main treatment of active lupus with major organ involvement is broad spectrum 
immunosuppression, whilst at the same time aiming to prevent organ damage (Ioannou 2002). 
Patients who fail to respond to less toxic drugs such as antimalarials are next considered for 
immunosuppressive agents including cyclophosphamide, mycophenolate mofetil and azathioprine. 
Cyclophosphamide is normally administered intravenously to decrease the risk of bladder damage 
and often results in lower overall cumulative dose. Mycophenolate mofetil targets an enzyme in the 
body called inosine monophosphate dehydrogenase that is important for the formation of DNA in 
cells. By interfering with DNA, the medication impairs function of immune system cells that become 
overactive in autoimmune diseases such as lupus (Karim M 2002).  
 
1.5.8.6 Belimumab (Benylsta) 
In March 2011 The Food and Drug Administration (FDA) and European Medicines Agency (EMA) 
approved belimumab for treatment of adults with active, autoantibody-positive SLE. This drug has a 
unique mechanism in that it targets B-cell dysfunction by inhibiting BLyS (Stohl 2013). It blocks the 
binding of soluble BLyS, a B cell survival factor, to receptors on B cells. Although belimumab does 
not directly bind to B cells it inhibits their survival due to its interactions with BLyS, this includes 
targeting autoreactive B cells. Additionally, it reduces the differentiation of B cells into antibody 
producing plasma cells (Furie R 2008). 
 
1.5.8.7 Rituximab 
Rituximab is a chimeric monoclonal antibody (mAb) that was originally developed for the treatment 
of B cell lymphomas (Grillo-López AJ 1999). It is directed against the cell surface molecule CD20 
which is present on B cells when in the immature stage and remains until they differentiate into 
plasma cells (Eisenberg 2005). Rituximab has been shown to trigger cell death through complement-
dependent cytoxocity (CDC), antibody-dependent cell mediated cytotoxicity (ADCC) and direct 
induction of apoptosis. Although initial studies were positive, the LUNAR and EXPLOER studies 
are two double-blind phase II/III randomized, placebo-controlled trials (RCTs) with rituximab in 
SLE or lupus nephritis (n = 257 and 144, respectively) which failed to meet their primary or 
secondary end points (Merrill J 2010; Rovin B 2012). There are a number of issues with these trials, 
such as the excessively high use of steroids and choice of outcome measures that may have 
contributed to these negative results. Multiple, large open labelled studies have confirmed clear 
benefit, with greatest indication for efficacy in early disease (Ezeonyeji 2012) and, hence, this has 
now become an established treatment in SLE.  
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1.5.9 Antimalarials 
 
Antimalarials are used in around 80-90% of patients with SLE (Gladman 1999). 
Hydroxychloroquine (HCQ) is the most commonly prescribed antimalarial agent and this is due to its 
decreased likelihood of causing ocular and gastrointestinal adverse conditions as compared to 
chloroquine. It has been used for over 60 years in the treatment of inflammatory disorders and 
despite its numerous clinical applications the molecular mechanisms by which it elucidates it effects 
are poorly understood. It is very similar to chloroquine except for the addition of a hydroxyl group to 
the side chain and beta hydroxylation of the N-ethyl substituent. HCQ is orally administered and is 
absorbed into the gastrointestinal tract rapidly leading to a large volume of distribution. A variety of 
cytochrome P450 enzymes convert it to an active metabolite called desethyl HCQ (Lee S 2011). 
Post-commencement of therapy, it can take between 3-6 months before maximal clinical efficacy is 
achieved. It is recommended that a dose of 200-400 mg is administered daily, resulting in 
physiological concentrations of 1-2 µg/mL in patient blood being achieved (Costedoat-Chalumeau N 
2006).  
 
As previously mentioned, little is known about the mechanisms of action through which HCQ is able 
to reduce symptoms and improve patient conditions. However, there are some mechanisms which 
have been identified to date. An example is its ability to reduce inflammation by blocking pro-
inflammatory pathways (Willis R 2012).  This includes decreasing production of cytokines such as 
interleukins and IFN-, which are known to be up-regulated in SLE (Crow 2010). HCQ is believed 
to be able to interfere with physiological functions of subcellular compartments that rely on an acidic 
environment due to their weak base nature. It is able to enter lysosomes as well as other acidic 
compartments where it disrupts functions which depend on an acidic milieu such as inflammatory 
mediator secretion, autoantibody production and receptor recycling (Fox 1993). Another example of 
the disruption it can induce is in respect to TLRs, which play a pivotal role in the innate immune 
response. It has been shown that HCQ can inhibit TLR-9 pathways as well as TLR-7 and TLR-3. It 
was originally thought that HCQ inhibited endosomal compartment acidification due to its weak base 
nature, therefore inhibiting activation. However, more recent studies suggest it can interact with 
nucleic acids which act as ligands for TLR-9 and TLR-7, therefore preventing ligand binding 
(Kuznik A and Jerala 2011). This may be the reason why pro-inflammatory cytokines such as 
interferon’s and interleukins are reduced, as these TLRs are known to stimulate cytokine production.  
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Retrospective studies have suggested that HCQ acts as a cardioprotective agent in patients as well as 
research studies, identifying improvements in factors which typically cause cardiovascular disease. 
This includes reduced platelet aggregation (thrombosis) and improved lipid profiles. This data is 
summarised in table 1.2 
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Table 1.2 Summary of published research suggesting HCQ is cardioprotective. Adapted from 
Wallace et al (Wallace D 2012). 
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Patients with lupus typically show increased ‘bad cholesterol’ such as low-density lipoproteins 
(LDLs) and reduced ‘good cholesterol’ such as high-density lipoproteins (HDLs). These lipids have 
the ability to build up in plaque, increasing the risk of a cardiovascular event. A study of a cohort of 
264 patients with SLE showed that HCQ mediated lower serum cholesterol independently of steroid 
administration. Patients on HCQ showed lower levels of atherogenic lipids such as cholesterol, 
triglycerides and LDLs, with the effect on HDLs remaining conflicted (Morris S 2011). This 
improved lipid profile is an important mechanism of action for HCQ in patients with lupus and helps 
reduce their risk of complications associated with the disease. 
 
Antimalarials have been shown to significantly reduce the risk of thrombovascular events in lupus 
patients. One study observed 54 SLE patients with thrombovascular events that were matched to 
controls for the calendar year of their first visit, duration of follow up and highest disease activity 
during a 2 year observation period. It was shown that the risk of all thrombovascular events was 
reduced by 68% for patients on HCQ (Hyejung J 2010).  
 
Annexin A5 is a potent anticoagulant protein, which works by crystallizing over phospholipid 
bilayers therefore preventing them from being available for coagulation reactions. Patients with SLE 
are commonly found to be positive for aPL antibodies which have been shown to disrupt annexin A5 
binding. This prevents annexin A5 exerting its anti-coagulant properties leading to increased risk of 
thrombosis. It has been observed that HCQ reverses aPL antibody-mediated disruption of annexin 
A5 binding on phospholipid bilayers (Rand J 2010). This mechanism of action further supports the 
suggestion that HCQ is able to exert anti-thrombotic effects. 
 
The adverse effects of antimalarials are mild and infrequent. However, rare but serious adverse 
effects include cardiomyopathy, arrhythmias and neuromyopathy. Retinal toxicity is also a concern 
from HCQ treatment, and although incidence is low thousands of individuals take the drug and 
therefore this must be monitored. It is therefore suggested that patients eye sight is checked prior to 
taking HCQ to act as a baseline and then checked annually from 5 years after treatment 
commencement (Marmor M 2011). Therefore, based on current evidence of multiple beneficial 
effects of HCQ in SLE, which includes improved disease activity control, reduced regularity and 
severity of flares, reduced risk of cardiovascular events and reduced overall mortality and favourable 
safety profile, it is recommended by many clinicians that patients with SLE be treated with HCQ 
indefinitely (Wallace D 2012).  
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Within SLE 40-50% of patients can also develop a subsequent autoimmune disorder, the APS, this is 
termed secondary APS. However, it has now been established that it can develop independently from 
any other underlying disease and this is therefore called primary APS (Grossman 2004). Its relevance 
to this thesis is that its main pathogenic effect is mediation of thrombosis and therefore it will be 
expanded upon in the next section of this chapter. 
 
1.5.10 The Antiphospholipid Syndrome 
 
APS is a pro-thrombotic disorder which associates aPL with hypercoagulability (Levine J 2002). 
There are two distinct hallmarks of APS; VT (venous and/or arterial thrombosis) and PM (pregnancy 
morbidity). It most commonly targets the deeps veins of the lower limbs and cerebral arterial 
circulation, however any organ can be targeted (Giannakopoulos 2013).  APS is caused by the 
persistence of pathogenic aPL, detectable by the anti-aCL and/or anti-β2GPI and/or lupus 
anticoagulant (LA) assays (Miyakis S 2006). β2GPI is a protein of approximately 53 kDa, composed 
of 5 homologous polypeptide subunits, which are termed domains I through to V, with domain V 
being responsible for binding anionic phospholipid.  
 
A small subgroup of patients develop catastrophic antiphospholipid syndrome (CAPS) and this is 
characterised by multiple thrombi in small vascular beds resulting in multi-organ failure and high 
mortality (Sciascia S 2012). CAPS represents less than 1% of all APS patients, but is severe with a 
30-50% mortality rate even in the setting of optimal treatment (Asherson RA 1998; Asherson RA 
2001).  
 
1.5.10.1 Classification criteria of the APS 
 
The criteria outlined that definite APS is considered to be present in a patient with at least one 
clinical manifestation (as outlined in table 1.3) and a positive test for circulating aPL (including LA, 
aCL and anti-β2GPI) detected twice, at least 12 weeks apart (Miyakis S 2006). 
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Clinical Criteria 
Vascular 
Thrombosis 
One or more clinical episodes of arterial, venous or small vessel 
thrombosis, in any tissue or organ. 
Thrombosis must be confirmed by objective validated criteria 
Pregnancy 
morbidity 
One or more unexplained deaths of a morphologically normal foetus at 
or beyond the 10
th
 week of gestation, with healthy foetal morphology 
documented by ultrasound or examination of foetus. 
One or more premature births of a morphologically normal neonate 
before the 34
th
 week of gestation because of eclampsia or severe pre-
eclampsia defined according to standard definitions or recognised 
features of placental failure. 
Three or more unexplained consecutive spontaneous abortions before 
the 10
th
 week of gestation, with maternal anatomical or hormonal 
abnormalities and paternal and maternal chromosomal causes excluded. 
Laboratory Criteria 
The presence of LA in plasma on two or more occasions which are at least 12 weeks apart, 
detected according to the guidelines of the International Society on Thrombosis and 
Haemostasis 
The presence of aCL of IgG and/or IgM isotype in the serum or plasma of the patient, present 
in medium or high titres (ie. above 40 G/MPLU or greater than the 99
th
 percentile) 
The presence of the anti-β2GPI antibody of IgG and/or IgM isotype in the serum or plasma of 
a patient on two or more occasions at least 12 weeks apart, measured by a standardised 
ELISA. 
 
Table 1.3  Clinical and laboratory criteria for the APS 
This table outlines the clinical and laboratory classification criteria of the APS as defined in the 
‘International consensus statement on an update of the classification criteria for definite APS’ 
(Miyakis S 2006). 
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1.5.10.2 aPL pathogenicity 
 
Both clinical data and experimental evidence have shown a direct link between aPL antibodies and 
the manifestations of recurrent venous and arterial thromboembolic events. A number of clinical 
studies have shown significant association between increased aPL levels and venous (Schulman S 
1998) and arterial (Brey R 2001) thrombosis. In a prospective study Vaarala et al compared 133 
patients who developed a cardiac end point, defined as death or non-fatal MI, to 133 control subjects. 
Patients who developed a cardiac end point had high levels of aCL compared to control patients 
(Vaarala O 1995). Additionally a study by Meroni et al showed a significant association between 
anti-β2-GPI antibodies and MI occurrence when comparing 172 women with a history of MI and 172 
with no history of thrombosis (Meroni P 2007). 
 
A ‘two hit hypothesis’ has been suggested to explain the clinical observations occur only 
occasionally even when there is a persistent presence of aPL. This theory suggests that the antibodies 
act as the primary hit and induce a thrombophilic state, however clotting only takes place in the 
presence of another thrombophilic state (the second hit e.g. MI) (Shoenfeld Y 2006).  
 
The pathogenic effects of aPL have been widely explored, particularly in endothelial cells due to the 
enhanced risk of suffering from thrombosis. Human monoclonal and polyclonal aPL have been 
demonstrated to induce a signalling cascade similar to that observed with LPS. There is evidence to 
suggest TLR2 and TLR4 could be implicated in aPL activation in endothelial cells. Pierangeli et al 
(Pierangeli SS 2007) demonstrated that TLR4 is involved in the pathogenesis of aPL-mediated 
thrombosis and aPL activation of endothelial cells. Two strains of mice (LPS responsive vs 
unresponsive) were injected with the following IgG; IgG purified from 2 patients with primary APS 
(1 with a history of thrombosis and 1 with no history of APS and PM), 1 healthy control IgG and 1 
polyclonal IgG from an aPL-negative patient with SLE. The mice were then subjected to mechanical 
pinch induced thrombi to their right femoral vein. The IgG purified from APS patients produced 
significantly larger thrombi in comparison to the non-APS samples in LPS responsive mice. LPS 
unresponsive mice treated with APS IgG showed a significant reduction in thrombus size suggesting 
that TLR4 is implicated in the pathogenic effects of APS IgG in this animal model. Vega-Ostertg et 
al  (Vega-Ostertag ME 2007) have shown that activation of p38 MAPK  (a downstream target of 
TLR4) leads to aPL mediated thrombosis as well as aPL mediated activation of endothelial cells. 
They demonstrated that IgG from 6 aPL positive patients increased phosphorylation of p38 MAPK 
in endothelial cells compared with IgG from 2 healthy controls. Activation of p38 is known to 
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promote an inflammatory response via the production of cytokines and chemokines, therefore its 
activation is thought to contribute to the pathogenesis of SLE (Iwata Y 2003). 
 
The pathogenic role of SLE derived autoantibodies in cardiac I/R injury has been relatively 
unexplored, although some work that has been published on the role of natural IgM which was 
discussed in section 1.5.2.2 of this chapter. However, there has been some interesting work published 
in relation to pathogenic IgG and its contribution to enhanced mesenteric I/R injury. Previously it has 
been shown that in mesenteric I/R injury an autoimmune prone mouse model is more susceptible to 
I/R injury as compared to a sham control. Furthermore, when IgG from a lupus mouse model is 
injected into a Rag-1 deficient mouse, which has no B or T lymphocytes, cell injury is accelerated in 
comparison to control (Fleming S 2004). Fleming et al (Fleming S 2004) next went on to show that 
aPL antibodies restore mesenteric I/R Injury in Complement Receptor 2/Complement Receptor 1-
Deficient Mice, therefore suggesting a role for them in mediating I/R injury. They identified β2GPI 
as a binding site for aPL antibodies, however proposed that multiple neoantigens are expressed in 
response to I/R injury and therefore these auto-antibodies could be also binding other sites.  
 
To date no one has extensively explored the role of myocardial I/R injury in lupus or indeed APS. It 
would be expected that due to the enhanced risk of cardiovascular complications, that lupus 
contributes to enhanced I/R injury in the heart. The next section will therefore discuss the possible 
mechanisms through which this could occur by speculating on common pathogenic processes which 
are present in both SLE and cardiac I/R injury 
 
1.6 I/R injury in SLE 
 
Accelerated atherosclerosis is widely accepted as a major cause of cardiovascular related morbidity 
and mortality in SLE, and this is currently the research focus of a number of groups around the 
world. However, what remains relatively unexplored is the role that I/R injury may be play in cardiac 
related morbidity and mortality in lupus. Many of the molecular mechanisms that mediate I/R, such 
as oxidative stress and enhanced apoptosis, are mechanisms that may be amplified in lupus and 
therefore one may speculate that I/R may be enhanced in SLE and contribute to patient morbidity 
and mortality. Understanding the relationship between lupus and I/R injury in greater depth, and 
identifying dominant common pathways that may be targeted may provide a novel target for 
ultimately improving outcomes in patients with SLE. This section will briefly describe the main 
pathogenic mechanisms which are both involved in SLE and I/R injury. 
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The presence of apoptotic bodies and enhanced apoptosis induction in SLE may cause accelerated 
apoptosis and, therefore, enhanced myocardial death in I/R injury due to stress pathways already 
being activated (Salmon 1999). Although it is known that apoptosis is a defined factor that 
influences lupus development, how these abnormalities trigger the disease are not well understood. A 
better understanding of the link would give a greater insight in to how this may affect the severity of 
I/R injury cell death via apoptosis induction. 
 
MAPK have also been shown to play a role in SLE by their activation contributing to disease 
activity. For example ERK and JNK have both been shown to have increased activation correlating 
with increased disease activity (Richardson 2010). Specifically the MAPK pathway has been shown 
to have a role in regulation, selection, differentiation and maturation of T cells. Multiple 
abnormalities in T cell pathways have been linked to autoimmunity suggesting there might be a 
common denominator in pathogenesis of autoimmune diseases. Studies in SLE-prone mice with 
active SLE have been shown to have increased JNK activation and that treatment with 
complementary-determining regions peptide hCDR1 led to a decrease in JNK, lympohocyte 
apoptosis and caused amelioration of the SLE manifestations (M Rapoport 2005). In comparison, as 
previously reported for I/R injury, the role of MAPK can be kinase specific. When ERK activation is 
diminished, SLE induction was observed meaning a balance between pro-survival and pro-apoptotic 
MAPK is essential.  Additionally, it is possible that local activation of MAPK family occurs; 
therefore an observation made in one target organ could be different to that seen in another 
 
Multiple studies have suggested that the innate immune system and TLRs are relevant in both I/R 
injury and SLE, however it remains unclear to what extent the precise mechanisms of the innate 
immune system activation which may overlap between the two conditions. Interestingly, it has been 
shown that in a subset of SLE patients (20-40%) aPL target TLR2 and TLR4 activation and therefore 
it is possible that this subset of patients may be more prone to I/R injury (Satta N 2011) 
 
ROS evidently play an important role in both cell death in I/R injury and pathogenicity in SLE. 
Given that ROS are known to promote pro-apoptotic signalling pathways and necrosis in I/R injury, 
one may hypothesize that I/R injury is enhanced in patients with SLE due to the increased baseline 
levels of ROS observed in this disease. 
The role of complement in I/R injury and SLE is conflicting in that activation during I/R injury 
appears to contribute to pathogenicity through induction of various inflammatory pathways. In 
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contrast in SLE it has been suggested there is complement deficiency which is thought to be 
responsible in part for defective clearance of apoptotic cells. It would, therefore, suggest that those 
with SLE should have reduced I/R injury due to complement being relatively deficient, though this 
may be offset through an enhancement of apoptosis and increased baseline ROS levels. Studies have 
shown a role of antibodies in both I/R injury and SLE however patients with SLE typically have low 
complement levels and if complement is a dominant mechanism in I/R injury then it may be 
conceivable that the low complement effect seen in lupus may have a protective effect. Nevertheless, 
it is possible that due to the auto reactive nature of antibodies from patients with SLE that they may 
have a lower threshold for pathogenic IgM and therefore be more susceptible to I/R injury. Another 
feature of the immune response which is important is the enhancement of neutrophils in SLE 
patients. This may be a significant contributing factor to accelerated I/R injury due to enhanced 
neutrophil infiltration causing a larger inflammatory response and impaired degradation of neutrophil 
NETS as a source of ROS and nuclear antigenic material. The activation of complement may 
enhance I/R injury despite the relative deficiency of complement observed in SLE.  
 
All the factors mentioned in this section could be important contributors to accelerated I/R injury in 
SLE. In order to explore the role of SLE on severity of I/R injury it is important to have robust model 
systems and, therefore, the next section will summarise the main animal models currently available 
to study myocardial I/R injury and the mechanisms, which contribute to severity. 
 
1.7 Animal models in I/R injury 
 
Myocardial ischaemia has been extensively studied in cardiovascular research; however its true 
meaning is still being debated (Hearse 1994). The majority of investigators define ischaemia as 
abnormalities between oxygen and substrates supplied to the heart, therefore preventing normal 
function. This is due to the heart depending on oxygen for oxidative phosphorylation, an essential 
metabolic process which has the ability to provide sufficient energy for normal myocardial 
contraction. Myocardial ischaemia is therefore an in balance between oxygen supply and demand, 
which leads to anaerobic respiration and reduced contractile function (Pieter D 1998). 
 
The most common experimental modes in cardiac research are the isolated whole heart and cultured 
cardiac cells. The use of cell cultures is a common approach due to the versatility, economy and 
convenience compared with whole animal experiments (Chlopcíková S 2001). The neonatal rat 
cardiomyocytes model enables researches to study morphological, biochemical and 
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electrophysiological characteristics of the heart. Most importantly, in vitro studies allow multiple 
comparative experiments at once, unlike in vivo where specific conditions have to be kept, therefore 
limiting the number of questions that can be answered. Apoptosis is a pathological phenomenon that 
has been widely studied in neonatal rat cardiomyocytes, with the ability to study cell morphology, 
metabolism and contractile activities easily. Additionally the expression of proteins, regulation of 
their expression and the effect of drugs on their expression has been widely studied in this model 
(Pieter D 1998). 
 
In contrast in vivo models of myocardial I/R injury provide more robust and transnationally relevant 
data. They have the ability to facilitate studies to verify the effectiveness of a therapy as well as 
various routes of time and application. Functional characterisation using echocardiographic 
investigations or magnetic resonance imaging (MRI) during ischaemia and reperfusion provide 
invaluable data. Additionally, histological and molecular biological experiments can be performed to 
objectify success of therapy and to identify specific mechanisms and targets.   
 
Both in vitro and in vivo systems provide individual and combined valuable data. Neonatal rat 
cardiomyocytes are more accessible and allow the testing of multiple components. However, once 
the main targets have been identified the use of in vivo models is much more appropriate. Models of 
cardiac I/R injury are valuable, however given the number of therapeutics which show promise in the 
lab but fail to translate to the clinic, some have questioned the value of experimental I/R injury. 
There are a number of suggestions as to why these models are not as robust as they should be in 
relation to species, age, sex and most importantly duration of ischaemia and reperfusion (Hausenloy 
D 2010). The following section will expand on this further in relation to past and current treatment 
strategies to target I/R injury. 
1.8 Therapeutic Strategies for I/R Injury 
For the majority of patients myocardial ischaemia will have already taken place and therefore the 
opportunity to intervene is significantly reduced. However, although the restoration of blood flow 
(i.e. reperfusion) remains the most effective treatment, it also causes additional cell death therefore 
identifying a new therapeutic target. Nevertheless, there remains no effective treatment for 
preventing lethal myocardial reperfusion injury. This is despite the substantial progress in 
understanding the mechanisms of I/R injury, as well as the associated attempt to translate this to 
patient care. Some believe that this could be due to alternative mechanisms, which are yet to be 
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explored, whilst others believe it is due to the naive approach that a single intervention could be 
successful in treating such a complex process. Despite the lack of positive outcomes so far, 
investigations continue and the following sections will discuss the pharmacological and mechanical 
interventions currently being explored. 
1.8.1 Therapeutic intervention for reperfusion injury 
Targeting individual components of lethal myocardial injury such as oxidative stress, calcium 
overload and pH correction (as discussed in section 1.1.4 previously) remains unsuccessful 
(Hausenloy 2013). The main problem with this targeted approach is that either adverse side effects 
are observed or that although protection is seen in animal models it does not translate to the clinic. 
An example of this is the recently published IMMEDIATE clinical trial, which investigated the 
effect of metabolic modulation using intravenous glucose insulin potassium (GIK) therapy. This was 
administered in the ambulance to patients suspected of suffering acute myocardial ischaemia with 
potential acute coronary syndrome. However, using a primary end point of progression to acute MI 
no difference was observed, although patients administered GIK therapy experienced less cardiac 
arrest and in-hospital mortality compared with those administered placebo (Selker H 2012). Also, as 
previously mentioned CsA was shown to reduce MI size by 40-50% in both small and large animal 
MI models (Hausenloy D 2003; Skyschally A 2010). This pharmacological agent has been perhaps 
one of the most promising with a small study suggestion that inhibition of MPTP may be of benefit. 
This pilot trial of 58 patients showed that administration of CsA at the time of reperfusion was 
associated with a smaller infarct then with placebo (Piot C 2008). This data is now being expanded 
in a larger clinical trial. 
However, there are a number of therapeutic strategies which have shown promise and clinical trials 
are currently in progress to define the clinical outcomes of patients. This includes mechanical 
interventions such as therapeutic hypothermia (Duncker D 1996) and pharmacological therapies such 
as sodium nitrite. The latter has recently been shown in two human models to improve functionality 
of ischaemic myocardium as well as protection against vascular I/R injury when administered prior 
to ischaemia (Ingram T 2013). Additionally the concept of pre- and post-conditioning has been 
vastly explored as a type of intervention and will be discussed in the next section. 
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1.8.2 Pre-conditioning and Post-conditioning 
Ischaemic pre-conditioning (IPC) was originally described by Murray et al in 1986 and consisted of 
four cycles of 5 minutes ischaemia and 5 minutes of reperfusion prior to sustained ischaemia. Since 
then others have used variations of this protocol with similar results. Studies have shown that       
pre-conditioning can reduce infarct size, lactate generation and rate of fall of ATP (Murry C 1986). It 
has also been shown to reduce arrhythmias and reduce contractile dysfunction. It has been reported 
that pre-conditioning leads to activation of signalling pathways, which has consequential effects 
during prolonged ischaemia leading to protection. It has also been shown that pre-conditioned hearts 
have less anaerobic glycolysis during ischaemia and, therefore, have lower lactate levels. Protection 
offered by pre-conditioning is time dependent and it has been suggested this is due to the fact that 
signalling pathways activation decays with time. These pathways are activated due to the release of 
agonists such as adenosine and opioids which bind to G protein coupled receptors subsequently 
activating cardioprotective signalling pathways (Downey J 2007). The RISK pathway has 
particularly been shown to mediate IPC-induced cardioprotection (Tong H 2000; Fryer R 2001). An 
example is the PI3K pathway which, when activated, results in up regulation of targets such as 
p70SK6 and Akt. Also, signalling through endosomal signalling and   B-arresting results in 
activation of ERK and other kinases and phosphatases. Studies have shown that inhibition of PI3K 
and ERK 1/2 abrogated the IPC-induced infarct limiting effect and also abolished the IPC-induced 
phosphorylation of Akt and ERK 1/2 (Hausenloy 2004). The activation of these targets leads to 
subsequent activation of further downstream signalling pathways. There are drugs such as sildenafil 
which have been shown to mimic the action of pre-conditioning. Mechanistic studies have shown 
that it exerts protection through NO generation (from eNOS/iNOS), activation of ERK 1/2 signalling 
and opening of ATP-sensitive potassium channels (Kukreja R 2005).  
In 2003, Zhao et al showed that intermittent reperfusion following ischaemia (post-conditioning) can 
reduce infarct size, this was termed post-conditioning (Zhao Z 2003). The duration and number of 
reperfusion intervals required has been reported to largely depend on the species. This protection is 
thought to involve signalling pathways similar to IPC, which includes molecules such as Akt, and 
ERK. 
There are currently a number of clinical trials underway in the UK to assess the potential of pre-
conditioning as a valid therapeutic to reduce I/R injury. This includes the ERICCA trial, a 16 centre 
1610 patient randomised controlled clinical trial, sponsored by the NIHR/MRC/BHF (£1.5 million 
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research grant), to investigate whether remote ischaemic preconditioning can improve clinical 
outcomes in patients undergoing coronary artery bypass graft surgery (Hausenloy D 2012).   
Ultimately reperfusion injury remains a valuable therapeutic target and, therefore, research is 
required to identify therapies to reduce its severity. Although, thus far, the reduction of reperfusion 
injury has been relatively unsuccessful, further research is required to continue to search for a 
molecule that can fulfil the requirements of this drug-targeted therapy. Additionally, there is 
potential for success using drugs that can mimic or enhance pre-conditioning, such as that previously 
shown with sildenafil. 
1.9 Introduction Summary 
 
This introduction has aimed to give an insight into the complex nature of I/R injury by describing the 
various types of cell death and the mechanisms by which cell death in I/R injury may occur and be 
regulated. Furthermore, due to the role of cardiac injury in SLE being some prominent in relation to 
mortality and morbidity this introduction then went on to highlight features of this disease. This 
includes the pathogenesis, clinical features and causes of SLE as well as outlining the current 
therapeutic treatments. This thesis will now describe the data collected in this project to address the 
aims which follow on from this introduction.  
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1.10 Aims of PhD 
 
 To establish an in vitro model of simulated I/R injury model in the cardiac cell line H9c2 and 
neonatal rat cardiomyocytes 
 
 To characterise the effect of pre-treating neonatal rat cardiomyocytes in this in vitro model 
with 
 
o HCQ – a therapeutic currently used to treat SLE patients to investigate if it has 
cardiovascular benefits in simulated I/R injury 
o purified IgG from patients with SLE, JSLE and APS to assess their contribution to I/R 
injury 
 
 To explore the mechanisms through which HCQ and purified IgG exert their effects in 
simulated I/R injury 
 
 To use an in vivo cardiac I/R injury model to replicate data produced in the in vitro simulated 
I/R injury model 
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Overview of Chapter II 
The first part of this chapter, after listing the general materials used, describes the three models of 
simulated I/R injury that were used in this thesis. This includes two in vitro models; a rat 
cardiomyoblast cell line H9c2 and primary neonatal rat cardiomyocytes, as well as a third in vivo rat 
cardiac I/R injury model. 
The second part of this chapter describes the methodological principles for purifying IgG from the 
whole blood of patients with APS, SLE ± APS and healthy volunteers. This also includes 
purification, concentration and endotoxin removal from serum samples. This is followed by a 
description of the antibody detections assays for cardiolipin and β2GPI. 
The final part focuses on describing the techniques for detecting alterations in levels of proteins in 
signalling pathways which are being targeted. This is followed by a description of the alternative cell 
death assays that were used to study simulated I/R injury. 
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2 Materials, Methodological Principles and Details of Procedures 
2.1 Chemicals, General Materials and Equipment 
2.1.1 Chemicals 
All solid chemicals were dissolved in ddH2O and adjusted to the correct pH with 0.1 M HCl or 0.1 M 
NaOH. They were then autoclaved or filter sterilised with 0.22 µm syringe driven filter units 
(Millipore, Bedford, MA, USA). 
2.1.2 General materials and equipment  
15 mL and 50 mL sterile tubes              91015T, Helena Biosciences, Sunderland, UK     
1.5 mL microfuge tubes                         Eppendorf AC, Hamburg, Germany 
Centrifuges                                             Heraeus Fresco 17 (Thermo Scientific) 
                                                                Megafuge 40R (Thermo Scientific) 
Nanodrop                                                ND-1000 Spectrophotometer (LabTech International) 
2.1.3 Cell culture reagents  
Dulbecco’s modified Eagles medium (DMEM) (D5546, Sigma) supplemented with 1% 
penicillin/streptomycin (10 000 U/ mL) (P43333, Sigma) and varying volumes of foetal calf serum 
(FCS) (F6765, Sigma) as described below:  
H9c2 rat cardiomyoblast cell line supplemented with 10% FCS 
Neonatal rat cardiomyocytes supplemented with: 
Plating medium – 15% FCS 
Maintenance medium – 1% FCS 
2.1.4 General buffers and solutions 
Phosphate buffered saline (PBS) pH 7.4. One PBS tablet (Invitrogen, Paisley, UK) was added per 
500 mL sterile water. To make PBS/0.1% Tween, 1 mL “Tween 20” detergent was added to 1 L 
PBS. 
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2.1.5 Specific buffers and solutions 
Neonatal rat cardiomyocyte preparation 
A stock solution of 500 mLs isolation buffer was prepared by dissolving the following components 
in 500 mL of distilled water and the pH adjusted to pH 7.35 
3.4 g  116 mM NaCl 
2.38g  20 mM HEPES 
0.06g  0.77 mM  NaH2PO 
0.5g  5.5 mM glucose 
0.2g  5.4 mM KCl 
0.05g  0.4 mM MgSO4 
For each preparation the following enzymes were dissolved in 100 mLs of Isolation buffer: 
250 U/mg collagenase type II CLS2 (Worthington, New Jersey, USA) 
25 mg pancreatin from porcine pancreas (P-3292, Sigma) 
 
Simulated I/R Injury 
A stock solution of Esumi buffer was made by dissolving the following components in 1 L of 
distilled water and the pH adjusted to 7.4 
137 mM NaCl 
3.8 mM KCl 
0.9 mM CaCl2 
4 mM HEPES 
10 mM Glucose 
 
A stock solution of ischaemic buffer was made by dissolving the following components in 1L of 
distilled water and the pH adjusted to 6.2: 
137 mM NaCl 
12 mM KCl 
0.49 mM MgCl2 
0.9 mM CaCl2 
4 mM HEPES 
 20 mM sodium lactate 
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10 mM deoxyglucose 
 Aliquots of 50 mL were stored at -20ºC and only thawed once. 
Protein Extraction 
 Cell lysates were extracted using 100 µL of lysis buffer composed of the following: 
50 nM Tris-HCl pH 7.4 
150 mM NaCl 
5 mM EDTA 
1 mM EGTA 
1% NP-40 
0.1% SDS 
0.5% Na-Deoxycholate 
1 mM Na3VO4 
A complete mini protease inhibitor cocktail tablet (Roche) was added and aliquots of 1 mL were 
stored at -20ºC and thawed only once. 
 
Western Blot reagents 
A stock solution of 10x running buffer was made by dissolving the following components in 1 L of 
distilled water: 
30 g Tris base 
144 g glycine 
10 g sodium dodecyl sulphate (SDS) 
The antibodies used and their dilution factors are described in table 2.1.          
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Primary Antibody Dilution with 4% (w/v) 
 non-fat milk 
Company 
Rabbit anti-phospho-p42/p44 
MAPK (ERK 1/2) 
1:1000 Cell Signalling 
Rabbit anti-Erk 1 (C-16) 1:1000 Santa Cruz Biotechnology 
Rabbit anti-phospho 
p38MAPK (Thr
180
/Tyr
182
) 
1:1000 Cell Signalling 
Rabbit anti-p38MAPK 1:1000 Cell Signalling 
Rabbit anti-phospho-
SAPK/JNK (Thr
183
/Tyr
185
) 
1:1000 Cell Signalling 
Rabbit anti-SAPK/JNK 1:1000 Cell Signalling 
Rabbit anti-phospho Akt 
(Ser
473
) 
1:1000 Cell Signalling 
Rabbit anti-Akt 1:1000 Cell Signalling 
Rabbit anti-cleaved caspase-
3 (Asp
175
)(5A1E)) 
1:1000 Cell Signalling 
Rabbit anti-cleaved caspase-
8 (Asp
391
) 
1:1000 Cell Signalling 
Rabbit anti-cleaved caspase-
9 (Asp
315
) 
1:1000 Cell Signalling 
Rabbit anti-BAD 1:1000 Cell Signalling 
Rabbit anti-BAD (Ser
112
) 1:1000 Cell Signalling 
Rabbit anti-BAD (Ser
136
) 1:1000 Cell Signalling 
Rabbit anti-LC3B 1:1000 Abcam 
Mouse anti-SQSTM1/p62 1:1000 Abcam 
Mouse anti-GAPDH 1:500 Abcam 
Table 2.1 Antibodies used for Western blot and the dilution factors used. 
 
 
 
 
 
 
Chapter II 
 92 
2.2 Cell Culture 
2.2.1 H9c2 rat cardiomyoblast cell line 
H9C2 rat cardiomyoblast cells (H9c2 (2-1) (ATCC CRL-1446)) were cultured in Dulbecco’s 
modified Eagle’s media (DMEM) supplemented with 10% foetal calf serum (FCS) and 1% 
penicillin/streptomycin (10 000 U/ml, 10 000 µg/ml)(Gibco). Sub-confluent cells (70-80%) were 
sub-cultured 1:4. The cells were trypsinized and plated in cell culture plates and grown for 24 hours 
before treatments.  
 
2.2.2 Animals 
This study was performed in accordance with the United Kingdom. Home Office Animals (Scientific 
Procedures) Act 1986. In vivo studies were performed by a core facility at The Centre for Biomedical 
Imaging (CABI), performed using their project license.   
2.2.2.1 Neonatal rat cardiomyocyte isolation 
Neonatal rat cardiomyocytes were isolated according to an established protocol (Stephanou A 2000). 
Cardiac myocytes were dissociated from the hearts of 1-2 day old rats using 250 U/mg collagenase 
type II CLS2 (Worthington) and 25 mg of pancreatin from porcine pancreas (Sigma #P-3292) in 100 
mL of oxygenated digestion buffer (116 mM NaCl, 20 mM HEPES, 0.77 mM NaH2PO4, 5.5 mM 
glucose, 5.4 mM KCl, 0.4 mM MgSO4, pH 7.35). Pups were culled and hearts isolated into a Petri 
dish of isolation buffer and finely cut into small pieces. The hearts were pipetted into a 25 cm
3 
TC 
flask and buffer removed. The hearts were rinsed once with 7 mLs of digestion buffer, allowed to 
settle and the buffer discarded. Fresh digestion buffer was added and incubated at 37 
o
C for 15 
minutes. The flask was gently shaken, the hearts allowed to settle and the buffer discarded. This 
digestion process was repeated 8 times but the digestion buffer removed into 2 mL of FCS and 
centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded and re-suspended in 4 mLs 
FCS and stored at 37 
o
C whilst the subsequent digestions were carried out. The cells were then 
collected in a 50 mL falcon and centrifuged for 5 minutes at 1000 rpm. The supernatant was 
discarded and the cells were re-suspended in 15% plating media (DMEM supplemented with 15% 
FCS, 1% p/s) and pre-plated in a 175 cm
3
 flask for 1 hour to allow fibroblasts to stick down. The 
media was then removed (containing the myocytes) and cells were plated out at 2x10
6
 cells/well in a 
cell culture plate pre-coated with 1% gelatin. Cells were allowed to attach and the next day media 
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was replaced with 1% maintenance media (DMEM supplemented with 1% FCS, 1% P/S). Cells were 
confluent and beating synchronously 24-48 hours after isolation. 
2.2.2.2 Determination of cell number 
Cell numbers were determined using a haemocytometer with an aliquot of 10ul cell suspension. The 
following formula was used to estimate cell number 
Number of cells in all quadrants X 10
4
 = number of cells / ml 
2.2.2.3 Simulated in vitro I/R injury model 
 
Control cells were kept in a cell culture incubator (5% CO2 in air) and media was replaced with 
Esumi buffer (137 mM NaCl, 3.8 mM KCl, 0.49 mM MgCl2, 0.9 mM CaCl2, 4mM HEPES and 10 
mM Glucose). Cell culture media was replaced with ischaemic buffer (137 mM NaCl, 12 mM KCl, 
0.49 mM MgCl2, 0.9 mM CaCl2∙H2O, 4 mM HEPES, 20 mM sodium lactate, and 10 mM 
deoxyglucose (pH 6.2)) and cells transferred to an hypoxic chamber pre‐warmed to 37°C. Simulated 
ischaemia was achieved by addition of 5% CO2 in balanced argon to displace oxygen from the 
chamber. Cells were subjected to simulated ischaemic injury for a period of between 4 and 6 hours, 
after which ischaemic buffer was replaced with DMEM containing 1% (v/v) FBS and cultured in 5% 
CO2 in air (reoxygenation to simulate reperfusion) for the indicated times.  
 
2.2.2.4 In vivo rat cardiac I/R injury model 
 
I/R injury in the rat was performed as previously described (Carr C 2011). Male Sprague Dawley rats 
were given a week to acclimatize before commencing the experiment. The surgery was performed as 
a core service by UCL based in the Centre for Advanced Biomedical Imaging (CABI). Rats were 
dosed with HCQ (Sigma) 200 mg/kg daily for 3 days via gavage (or water only as a control) and pre-
treated with 1mg of the ERK 1/2 inhibitor U0126 (Promega) via intraperitoneal (IP) injection (or 
water only as a control) 30 minutes prior to surgery. The technicians administering the reagents, 
undertaking the injury and performing histological analyses were blind to the identity of the regents 
that were given. Briefly, the rat is anaesthetised, intubated and ventilated. The heart is exposed 
through a thoracotomy and blood flow to the left anterior descending (LAD) artery occluded by 
placing a suture around the LAD. After 1 hour the suture is released, the incision closed and the 
animal recovered. Following 24 hours reperfusion the animal is sacrificed using pentobarbitone, the 
heart removed and flushed with 2ml saline solution through the left ventricle. The LAD is re-
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occluded before injecting with Evans Blue dye (1 ml/4%) through the left ventricle. The heart is then 
stored for 24 hr at -20 °C and the following day cut into slices 1mm thick. Staining using tetrazolium 
chloride (TTC) at 37 °C is then performed followed by fixation using formaldehyde. The heart slices 
are then scanned and analysed using Image J (NIH). The dual staining allows measurement of the 
area of infarction and area at risk to be calculated.  
2.3 Whole blood hydroxychloroquine detection assay 
 
HCQ concentrations in rat whole blood were assayed by using high performance liquid 
chromatography (HPLC) coupled with fluorescence detection. This assay was performed by Dr 
Benoit Blanchet, Laboratory of Pharmacology, Hôpitaux de Paris. Chromatographic separation was 
achieved on Xterra
®
 Phenyl (250 mm x 4.6 mm, 5 µm; Waters, Milford, USA) associated with a 
guard column packed with the same bonded phase. The mobile phase consisted of a mixture of 
glycine buffer (pH 9.6, 100 mM,) and methanol (46:54; v/v), and was delivered at a flow rate of 1.2 
mL/min throughout the 16-minute run. Chromatography was performed at 50°C. The excitation and 
emission wavelengths are 320 and 380 nm, respectively. 
 
Regarding sample preparation, 20 µl of quinine (internal standard) at 50 µg/mL was added to 200 µl 
of whole blood (calibration standard, internal quality control or rat sample). After mixing, 400 µl of 
cold methanol and 50 µl of cupric sulphate (3 nM) were added before a 2-minute vortex step with a 
VX-2500 Multi-Tube Vortexer
® 
(VWR, Fontenay Sous Bois, France). Then, the tubes were 
centrifuged 15 minutes (13000 rpm, room temperature). The supernatant was transferred into a 
plastic vial for chromatography, and then 20 µl of each sample was injected into the 
chromatographic system. Calibration curves were linear from 25 to 1560 ng/mL. The intra- and 
inter-assay coefficients of analytical variabilities were both less than 10%. The lower quantification 
limit was 25 ng/mL. 
 
2.4 Organ lysate Hydroxychloroquine detection assay 
Regarding tissue lysates, the extraction protocol was similar to that for whole blood sample 
preparation as described previously (section 2.3). However, 200 µl whole blood sample were 
substituted to 100 µl tissue lysate sample + 100 µl of RIPA 1X for all tissues except liver (RIPA 
0.2X). Finally, tissue lysate instead of whole blood was used to build the standard calibration curve. 
This assay was performed by Dr Benoit Blanchet, Laboratory of Pharmacology, Hôpitaux de Paris. 
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2.5 Purification of IgG from human serum 
 
2.5.1 Patient samples 
Serum samples from 3 individuals (Table 2.2) for the H9c2 preliminary study and 34 individuals for 
the neonatal rat cardiomyocyte study (Table 2.3) were obtained for this study from patients under the 
care of University College London Hospital (UCLH), London, UK. Serum samples were selected on 
the basis that they fulfilled the American College of Rheumatology Classification Criteria (Tan EM 
1982; Hochberg 1997). All subjects donated blood after informed consent and the study was 
approved by the local ethics committee (REC 11/LO/0330). 
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Patient number Cardiovascular Event Date of Event Date of Sample 
113 Ischaemic stroke Sept 2011 June 2011 
345 Myocardial infarction March 2009 July 2009 
522 Ischaemic stroke May 2010 Nov 2010 
Table 2.2 SLE patients whose serum samples were used for H9c2 rat cardiac cell line 
preliminary studies. Samples used with taken either prior (113) or after (345 and 522) the described 
event. 
 
 
 APS 
 (n=6) 
SLE/ 
aPL +ve 
(n=5) 
SLE/ 
aPL –ve 
(n=5) 
JSLE 
(n=8) 
Healthy controls 
(n=10) 
Age (Mean ± 
SEM) 
55 
(±4.5) 
45.2 
(±5.1) 
42.8 
(±6.3) 
16.5 
(±0.5) 
35.2  
(±4.7) 
Sex 3 F/3 M 5 F 5 F 7 F/1 M 8 F/2 M 
Serum aCL 
(Mean GPLU ± 
SEM) 
 
5.84 
(±1.7) 
 
 
91.6 
(±19.7) 
 
3.58 
(±0.3) 
 
49.62 
(±16.1) 
 
5.4 
(±0.7) 
Serum anti-
β2GPI 
(Mean SU ± 
SEM) 
 
5.45 
(±1.15) 
 
50.0 
(±20.65) 
 
3.62 
 (±0.34) 
 
43.26 
(±15.83) 
 
4.12 
(±0.58) 
Table 2.3 Clinical and laboratory features of patients and healthy volunteer controls used in 
the neonatal rat cardiomyocyte study. Abbreviations: aCL, anti-cardiolipin antibodies; anti-β2GPI, 
anti β2-glycoprotein-1 antibodies; SEM, standard error of the mean; SLE, systemic lupus 
erythematosus; JSLE, juvenile onset systemic lupus erythematosus; SU, Standard units; GPLU, IgG 
phospholipid units 
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2.5.2 Purification and concentration of IgG  
IgG was purified from serum by protein G sepharose affinity chromatography (Thermo Scientific) as 
previously described (Lambrianides A 2010). In summary, the column was washed with 5 mL of 
binding buffer (0.1 M sodium phosphate pH 7.2).  Patient or control serum was diluted 1:2 with 
binding buffer; filter sterilised and placed in the column, so that serum IgG binds to the protein G 
within the matrix of the column.  The column was then washed with 10 mL of binding buffer and the 
IgG eluted into 3 mL elution buffer (0.1 M glycine pH 2-3).  Glycine in the elution buffer lowers the 
pH to detach the IgG from the column.  The eluted fraction was then neutralised by adding 300 L 1 
M Tris pH 8-9.  Finally, the columns were washed with 5 mL of elution buffer and 5 mL of PBS and 
then stored in 5 mL of storage solution (0.02% sodium azide in PBS). 
IgG from the collected fraction was concentrated using an Amicon ultra centrifugal filter (Millipore) 
with a molecular weight cut off of 30 KDa.  The eluted fraction from IgG purification was placed in 
the filter, which was spun at 7,500 g for 20 minutes.  This process retains IgG (of molecular weight 
150 KDa), which was then washed twice with 2 mL PBS and centrifuged at 7,500 g for 20 minutes, 
before being transferred to clean microcentrifuge tubes and made up to a total volume of 1 mL with 
PBS.  The concentration of purified and concentrated IgG was determined using the Nanodrop ND-
1000 Spectrophotometer (LabTech International).   
2.5.3 Endotoxin removal 
Patient and control IgG samples were passed through Detoxi-Gel
TM
 Endotoxin removing columns 
(Thermo Scientific) to remove endotoxin.  The column contains immobilised polymixin B that binds 
the lipid A portion of bacterial lipopolysaccharide (LPS) and thus removes it from contaminated 
samples.  Endotoxin removal was performed under sterile conditions as follows: each column was 
sequentially washed with 5 mL sodium deoxycholate, followed by 5 mL water and then 5 mL PBS.  
The purified IgG sample was added to the column and the flow through discarded.  Following which 
the IgG was eluted from the column by the addition of 1 mL of PBS and stored at -20C.  The 
column was then washed with 1% sodium deoxycholate, then water and finally 25% ethanol in 
which it was stored at 4C.   
The IgG samples were confirmed to be endotoxin free (<0.25 endotoxin units (EU)/ml) by the 
Limulus Amoebocyte Lysate assay. Endotoxin standard (Sigma) was reconstituted in endotoxin free 
water to obtain a stock concentration of 4000 EU/mL. This stock was then diluted to make a range of 
standard concentrations, from 400 EU/mL to 0.015 EU/mL in sterile capped polystyrene tubes. Next, 
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E-Toxate (Sigma) was reconstituted in 5 mL endotoxin free water. The E-Toxate will react with 
endotoxin present in a sample, forming a gel.  100 L of purified IgG at 500 g/mL, as well as 100 
L PBS, endotoxin free water and the endotoxin standard serial dilutions (400 EU/mL to 0.015 
EU/mL) were placed in non-siliconised glass tubes. Next, 100 L of E-Toxate was added to each 
tube and the tubes were incubated at 37C for one hour. After incubation the tubes were inverted 
once to determine whether a gel was formed. In the presence of a gel a sample was considered as 
endotoxin positive to a threshold determined by the endotoxin standard, whilst absence of a gel 
confirmed that the IgG sample was free of endotoxin. The assay was able to detect levels of 
endotoxin greater or equal to 0.25 EU/ml, as determined by the endotoxin standard.  Endotoxin 
removal was repeated on those samples where a gel had formed until they were endotoxin negative. 
2.5.4 Detection of aCL antibodies 
The aCL activity of purified IgG and also the aCL activity of patient and control serum before IgG 
purification was confirmed by enzyme-linked immunosorbent assay (ELISA). A 96 well Polysorb 
plate (Nunc, Thermo Scientific) was marked vertically to divide it in to a test half and a control half. 
Wells in the test half were coated with 50 µL of 50 µg / L CL 9Sigma) (diluted in ethanol) and wells 
in the control half of the plate were coated with 50 µL of ethanol alone. Plates were left uncovered 
and incubated overnight at 4 ºC. The following day plates were washed twice with PBS and then 
blocked with 100 μL of 10% FCS/PBS at room temperature for 1 hour to block non-specific binding 
of IgG to the plastic. Plates were then washed twice with PBS. Next, either purified IgG diluted to 
500 µg/mL in 10% FBS/PBS was added to row A and E on both test and control sides of the plate 
and 50 µL of PBS was added to all other wells. Purified IgG was serially diluted (1:2) down 4 wells 
of the plate by transferring 50 µL and mixing. In the case of patient and control serum, serum was 
diluted 1:50 with 10% FBS/PBS and 50 µL of each sample was added in triplicate on both the test 
half and control half of the plate. 50 uµL of a standard containing polyclonal IgG of known CL 
binding activity defined as IgG phospholipid units (GPLU) (Louisville APL Diagnositics, Inc. Texas, 
USA) was added to each plate, on both the test (column 1-row A-H) and control half (column 7-row 
A-H). Plates were incubated for 90 minutes at room temperature before being washed three times 
with PBS. Goat anti-human IgG alkaline phosphatase conjugate (Sigma) was diluted 1:1000 in 10% 
FBS/PBS and 50 µL was added to each well of the plate. Plates were incubated for 1 hour at room 
temperature before being washed three times with PBS. Finally 50 µL of diethanolamine (DEA) 
buffer, diluted as follows: 1 mL buffer in 4 mL water plus 1 p-nitropenylphosphate (p-NPP) tablet 
(KPL), was added to each well of the plate. Plates were incubated for 30 minutes at room 
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temperature before being read on a TECAN GENios Microplate reader at 405 nm. Background 
binding to control wells lacking CL was subtracted from binding to CL in corresponding test wells 
and then expressed relative to the standard as GPLU. 
2.5.5 Detection of anti-β2GPI antibodies 
The anti-β2GPI activity of purified IgG and the anti-β2GPI activity of patient and control serum 
before IgG purification was also confirmed by ELISA. A maxisorb plate (Nunc, Thermo Scientific) 
was marked vertically to divide it in two halves: the test half and the control half. Wells in the test 
half were coated with 50 µL of 4 µg/mL β2GPI (Louisvilled APL Diagnostics, Inc. Texas, USA) 
diluted in PBS and wells in the control half of the plate were coated with 50 µL of PBS alone. Plates 
were incubated overnight at 4ºC before being washed twice with PBS/0.1% Tween. Plates were 
blocked with 150 µL of 0.5% gelatin in PBS and incubated for 1 hour at 37ºC. Following this step 
plates were washed three times with PBS/0.1% tween. Next either purified IgG or patient or control 
serum was added to the plate. Keeping column 1 and 7 empty for the standard, in the case of purified 
IgG 100 µL of purified IgG diluted to 500 µg/mL in 1% bovine serum albumin (BSA) was added to 
row A and E on both the test and control side of the plate and 50 µL PBS was added to all other 
wells. Purified IgG was serially diluted (1:2) down 4 wells of the plate by transferring 50 µL and 
mixing. In the case of patient and control serum, serum was diluted 1:50 with 1% BSA/PBS and 50 
µL of each sample was added in triplicate on both the test half and control half of the plate. 50 µL of 
an in house standard diluted at 1:400 was also used and serially diluted (1:2) down 6 wells on both 
the test half (column 1) and control half (column 7) of the plate. The in house standard is a patient 
with positive aPL but no APS. 100 standard units (SU) of the in house standard is equivalent to 125 
ng/mL HCAL (IgG Sapporo standard- Centre for Diease Control, USA). Plates were incubated for 1 
hour at room temperature and then washed three times with PBS/0.1% Tween. Goat anti-human IgG 
alkaline phosphatase conjugate (Sigma) was diluted 1:1000 in 1% BSA/PBS and 50 µL was added to 
each well of the plate. Plates were incubated for 1 hour at room temperatre before being washed 
three times with PBS/0.1% Tween. Finally 50 µL of DEA buffer, diluted as for aCL ELISA was 
added to each well of the plate and incubated for 30 minutes at room temperature before being read 
on a TECAN GENios Microplate reader at 405 nm. Background binding to control wells lacking 
β2GPI was subtracted from binding to β2GPI in corresponding test wells and then expressed relative 
to the in-house standard as SU.  
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2.6 RNA extraction, quantification, detection and characterisation 
2.6.1 RNA extraction 
Cells were washed with 1 mL diethylpyrocarbonate (DEPC) treated PBS before 1 mL TRIzol 
(Invitrogen) was added to each well and incubated for 5 minutes at room temperature (TRIzol is a 
monophasic solution of phenol and guanidine isothiocyanate, which maintains the integrity of RNA 
whilst disrupting cells and dissolving cell components). Next 200 µl chloroform was added, mixed 
and then incubated for 3 minutes at room temperature before centrifugation at 14,000g for 15 
minutes at 4 °C to separate RNA. The clear upper aqueous phase containing the RNA was removed 
and mixed with 500 µL isopropanol per sample, and left for 5 minutes at room temperature. Samples 
were then centrifuged at 14,000 g for 10 minutes at 4 °C following which the supernatant was 
removed and 1 mL 80% ethanol was added per sample. Samples were mixed before being 
centrifuged at 5,000 g for 5 minutes at 4 °C and supernatant was removed and the pellet air-dried.   
30 µl of DEPC treated water and 1 µl RNase (Promega) was added per sample. RNA concentration 
was measured on the Nanodrop ND-1000 Spectrophotometer and samples were then diluted to 1 
µg/µl using DEPC treated water. 
2.6.2 cDNA synthesis 
1 µl random primers (Promega, 1 µg RNA and 1 µl dNTP (Promega)) were added to sterile 
microcentrifuge tube and made up to a total volume of 12 µL with DEPC treated water. This mixture 
was heated to 65 °C for 5 minutes and then chilled on ice. 4 µL of 5x first strand buffer (250 mM 
Tris-HCL pH 8.3, 375 mM KCL, 15mM MgCl2) and 2 µl 0.1 M Dithiothreitol (DTT) was added to 
the sample and incubated at room temperature for 2 minutes. Finally 1 µl of SuperScript II Reverse 
Transcriptase (Invitrogen) was added to the sample, which was incubated at 42°C for 50 minutes. 
The reaction was then stopped by heating the sample to 70°C for 15 minutes. 
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2.6.3 Real Time Polymerase Chain Reaction (RT-PCR) 
RT-PCR of cDNA products was performed to amplify and semi-quantify Hsp70 and Hif1α to 
establish if simulated I/R injury was successful. cDNA was first diluted 1:5 with DEPC treated 
water. The following mixture was added to a PCR tube: 10 µL SYBR Green master mix 
(Invitrogen), 5 µL DEPC treated water, 2 µL of a 5 µM Forward (Fw) and Reverse (Rv) Primer 
working solution (sequences below) and 1 µL cDNA. 
 
Hsp70 Fw: 5’ CGAAGAGAGCGGCTGAAGGCTC 3’  
Hsp70 Rv: 5’ GGGACGGTTACGGTCGAGAGG 3’ 
Hif1α Fw: 5’ TCAAGAGCTCCTGAGCGTTTCCTAATCTCATTC 3’ 
Hif1α Rv: 5’ AGCTACGCGTCCTGGTCCACAGAAGATGTTT 3’ 
GAPDH Fw: 5’ GAG TCA ACG GAT TTG GTC GT 3’ 
GAPDH Rv: 5’ TTG ATT TTG GAG GGA TCT CG 5’ 
Samples were run on a DNA Engine Opticon continuous fluorescence detector (MJ Research) under 
the following conditions: Initial denaturation: 95°C for 3 minutes, followed by 45 cycles of: 95°C for 
30 seconds, 64°C for 30 seconds and 72°C for 30 seconds. A melt curve was performed from 65°C 
to 95°C, read every 0.3°C and held for 1 second between reads, in order to ensure only one primer 
product was made. Following RT-PCR the presence of a PCR product was confirmed by gel 
electrophoresis through a 1.5% agarose gel. 
The cycle threshold (Ct) of the Hsp70 and Hif1α primer products were normalised to the Ct of the 
housekeeping gene GAPDH primer products (Ct), following this Ct was calculated. These Ct 
values were used to calculate the fold change (Ct
2
) between Hsp70 or Hif1 and the housekeeping 
gene GAPDH. 
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2.7 Protein quantification, detection and characterisation 
2.7.1 Protein Extraction 
Cell lysate extracts were prepared as follows: the 6 well TC plate was placed on ice and each well 
was washed with 1 mL ice cold PBS. Next 100 µL of lysis buffer (50 nM, Tris-HCL pH 7.4, 150 
mM NaCl, 5 mM EDTA, 1 mM EGTA, 1% NP-40, 0.1% SDS, 0.5% Na-Deoxycholate, 1mM 
Na3VO4 and complete mini protease inhibitor cocktail tablets (Roche)) was added to each well and 
incubated on ice for 10 minutes. Cells were then scrapped from the bottom of the wells and 
transferred to ice cold microcentrifuge tubes. Then cells were lysed by passage through a 22 gauge 
needle five times and placed on ice for a further 10 minutes. Next lysates were spun at 16,000g at 
4°C for 5 minutes to pellet cell debris. Following centrifugation lysate supernatants were transferred 
to microcentrifuge tubes and stored at -20 °C for future analysis.  
Organ lysates were prepared as follows: organs were removed, washed in PBS, snap-frozen in liquid 
nitrogen and stored at -80°C until use. Organs were crushed in the presence of liquid nitrogen using a 
mortar and pestle. Organ lysate was then lysed in 1 mL of lysis buffer (50 nM, Tris-HCL pH 7.4, 150 
mM NaCl, 5 mM EDTA, 1 mM EGTA, 1% NP-40, 0.1% SDS, 0.5% Na-Deoxycholate, 1mM 
Na3VO4 and complete mini protease inhibitor cocktail tablets (Roche)) on ice for 10 minutes. The 
cells were then lysed by a dounce homogenizer and spun at 16, 000g at 4°C for 5 minutes to pellet 
cell debris. Following centrifugation lysate supernatants were transferred to microcentrifuge tubes 
and stored at -20 °C for future analysis. 
2.7.2 Determination of protein concentration 
Protein concentration was determined using the BCA protein Assay (Thermo Scientific). First 
protein standards were made by diluting a 2 mg/mL bovine serum albumin standard to eight 
concentrations ranging from 25 µg/ml to 2000 µg/ml. Working reagent was then prepared by mixing 
50 parts of BCA reagent A with 1 part BCA reagent B. 5 µl of either the albumin standard or cell 
lysate were pipetted into wells of a maxisorp plate. Then 195 µl of working reagent was added to 
each well and the plate was incubated at 37 °C for 30 minutes. The maxisorp plate was read on a 
TECAN GENios Microplate reader at 560 nm. Protein concentrations of the cell lysates were 
determined from a standard curve produced by the albumin standards. 
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2.7.3 One dimensional PAGE (1D-PAGE) 
2.7.3.1 Resolving gel 
Proteins were separated according to molecular weight devised by Lamelli (1970) using mini-
protean vertical slab gel apparatus (Bio-Rad, UK). N, N, N’, N’ – tetramethylethylenediamine 
(TEMED) and ammonium persulphate (APS) were added to the polyacrylamide solution (30% 
acrylamide mix) with stirring prior to casting of gels. Gels were over-laid with water-saturated 
butan-2-ol and left to polymerise for 1 hour at room temperature 
2.7.3.2 Stacking gel 
A stacking gel (5 %) was used to concentrate the proteins into tight bands before entering the 
resolving gel. Before casting of the stacking gel the butan-2-ol was removed and the resolving 
surface washed with water to remove excess butan-2-ol. After pouring the stacking gel on top of the 
resolving gel a 10 well comb was placed in the stacking gel to allow polymerisation for 1 hour. The 
composition of the resolving and stacking gels is described in table 2.4.  
 
 Volumes (ml) 
 8% gel 10% gel 12% gel Stacking Gel 
(5%) 
30% (w/v) 
Acrylamide 
mix
1 
2.7 3.3 4.0 1.7 
1.5M Tris HCL 
(pH 8.8) 
2.5 2.5 2.5  
1M Tris HCL 
(pH 6.8) 
   1.25 
10% (w/v) SDS 0.1 0.1 0.1 0.1 
10% (w/v) APS
2 
0.1 0.1 0.1 0.1 
TEMED
3 
0.004 0.004 0.004 0.01 
dH2O 4.6 4.0 3.3 6.8 
Table 2.4 The composition of resolving and stacking gels for SDS-PAGE. 
1
Acrylamide bis = 
N,N’-Methylene-bis-acrylamide. 2APS = ammonium persulfate. 3TEMED = NNNN-
tetramethylethalinediamine. 
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2.7.4 Western Blotting 
Sample buffer (125mM Tris-HCl pH 6.8, 5 % (w/v) SDS, 0.25 % (w/v) bromophenol blue, 25 % 
(w/v) glycerol, 10 mM DTT) was added to bring the protein concentration to 20 µg and boiled for 
three minutes before loading. Samples were loaded on a 1D-PAGE gel and electrophoresed at 150 
volts in protein running buffer (191.8 mM glycine, 25 mM Tris, 1 % (w/v) SDS). Gel was run until 
the dye reached the bottom of the plate. 
2.7.5 Transfer of protein to nitrocellulose 
Proteins which had been separated on SDS-PAGE gels were transferred to Hybond C membranes 
(Amersham, Bucks, UK) using a wet-transfer method described by Towbin, 1979 (Towbin H 1979). 
The stacking gel was removed and the resolving gel placed onto a sponge and two pieces of filter 
paper, which had been pre-soaked in transfer buffer (protein running buffer containing 25 % (w/v) 
ethanol). A piece of Hybond-C membrane was cut to the same size as the gel and pre-soaked in 
transfer buffer. The membrane was places on the surface of the gel and two pieces of pre-soaked 
filter paper and a second sponge were placed on top. Proteins were transferred to the membrane at 
100 volts for 1 hour.  
2.7.6 Immunodetection of proteins on western blots 
The membrane was incubated in 4 % (w/v) non-fat milk for 1 hour at room temperature to block 
non-specific protein binding. Antibodies were dissolved in 4 % (w/v) non-fat milk; the membrane 
added and probed over-night at 4
o
C. Membranes were washed in phosphate buffered saline 
containing 0.1 % Tween 20 (Sigma-Aldrich, UK) three times for 5 minutes each to removed 
unbound primary antibody. The membranes were then added to 4 % (w/v) non-fat milk containing 
horse radish peroxidase (HRP) conjugated secondary antibody (1:1000 dilution, Dako, UK), 
incubated for 1 hour at room temperature and washed three times for 5 minutes each to remove 
unbound secondary antibody. 
Proteins were visualised using enhanced chemiluminescence (ECL, Amersham Biosciences, UK). 
Excess PBS-T was removed by placing the membrane on tissue; the ECL reagent was pipetted on to 
the membrane and incubated at room temperature for 1 minute. Excess ECL reagent was removed 
and the membranes exposed to photosensitive film to visualise the proteins of interest. The intensity 
of protein bands was quantified by densitometric analysis (QuantityOne software, Biorad, USA). 
Results were expressed as a ratio of relative expression of phosphorylated protein to total protein.  
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Phosphorylated and total protein for the same signalling protein was analysed on the same 
membrane. After incubation and detection of the phosphorylated protein membranes were washed 
twice for 5 minutes with 0.2 M sodium hydroxide to remove bound antibodies. Membranes were 
then re-blocked for 1 hour in 4 % (w/v) non-fat milk and re-probed with their respective total 
antibody. 
2.8 Immunofluorescence 
Cells were seeded on UV irradiated coverslips at 1 x10
5
 cells/well in a 24 well plate. Cells were 
washed with cold PBS and fixed with 4 % paraformaldehyde (w/v) for 15 minutes at room 
temperature. PBS containing 0.1% (w/v) Triton-X-100 was used to permeabilise for 5 minutes and 
blocked for 1 hour in 5% bovine serum albumin in PBS. Cells were then incubated in primary mouse 
anti-desmin antibody (Santa Cruz) diluted in PBS containing 2.5% (w/v) BSA at 1/1000 dilution for 
1 hour at room temperature. Cells were washed three times with PBS and then incubated in Alexa-
Fluor secondary antibody (emission wavelengths Alexa488, Alexa456, Molecular Probes, USA) 
diluted in 2.5% BSA for 1 hour at room temperature in the dark. Cell nuclei were stained with DAPI. 
Coverslips were mounted onto glass slides using fluorescence mounting media (DAKO, UK) and 
images acquired using a Zeiss Axioscope inverted fluorescent microscope (Zeiss, JP). 
2.9 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
DNA nick end labelling was performed to demonstrate DNA fragmentation. Cells were seeded at 
1x10
5
 cells/well in a 24 well plate on UV irradiated glass coverslips. Cells were treated as per the 
experiment and then washed with cold PBS and fixed with 4 % paraformaldehyde (w/v) at room 
temperature for 15 minutes. In situ cell death was detected in cultured cardiomyocytes by using 
TUNEL assay kit (Roche Diagnostics, Meylan, France) according to the manufactures instructions. 
Briefly, cells were incubated in permeabilisation solution (0.1 % triton X-100, 0.1 % sodium citrate 
in PBS) for 2 minutes on ice and then washed three times with PBS. Positive control cells were 
incubated with DNase I (1:10 dilution of RQ1 RNase free DNase, Promega in 10x Reaction Buffer 
RQ1 DNase, Promega) for 15 minutes to induce DNA breaks and then washed three times with PBS. 
Cells were then incubated with 50 µl / slide TUNEL reaction mix for 60 minutes in a 37°C 
humidified chamber. Cells were then washed and stained to identify nuclei with DAPI (NucBlue® 
Fixed Cell ReadyProbes™ Reagent, Invitrogen) at room temperature for 5 minutes. Coverslips were 
mounted onto glass slides using fluorescence mounting media (DAKO, UK) and images acquired 
using a Zeiss Axioscope inverted fluorescent microscope (Zeiss, JP). The percentage of TUNEL 
positive cardiomyocytes (with green fluorescent nuclei) was measured at 25X magnification in three 
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randomly chosen fields. The proportion of TUNEL positive cardiomyocytes was expressed as a 
percentage of the total cells counted (DAPI positive).  
2.10 3-(4,5-Dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium assay 
 
To estimate cell viability, neonatal rat cardiomyocytes were seeded into 24 well plates in 500 µL of 
1% FBS/DMEM media and incubated at 37°C, 5% CO2. Cells were exposed to 4 hours simulated 
ischaemia and various time points of reoxygenation. Following simulated I/R injury 100 µL of the 
CellTiter 96 Aqueous One Solution (Promega) was added to each well and cells were incubated for 1 
hour in a 37°C, 5% CO2 incubator. 100 µL aliquots of the supernatant were transferred to a 96-well 
plate and absorbance was read on a TECAN GENios Microplate reader at 492 nm.  
  
2.11 Statistical analysis 
For each outcome the experiments were performed at least three times independently and data are 
expressed as mean ± SEM of these independent experiments.  Data was tested for normality using 
the Kolmogorov-Smirnov test (when >5 data points) or by plotting data on a normality plot. All data 
was identified as being normally distributed therefore statistical analysis was undertaken using one-
way analysis of variance (ANOVA) and assessed for overall statistical significance at  level 
(p<0.05). A post-hoc Tukey analysis was performed to compare each individual mean with all other 
means. The unpaired t test was used to make direct comparisons of two data sets which were age and 
gender matched (i.e. cells treated with aPL +ve IgG vs aPL –ve IgG). Data analysis was performed 
using the GraphPad Prism software program (GraphPad Software, San Diego, CA). 
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Overview of Chapter III 
This chapter focuses on the use of an in vitro simulated cardiac I/R injury model to observe changes 
in the level of cell death in the presence of different potential modulators. This chapter can therefore 
be broadly divided into three parts: 
The first part is the optimisation of this I/R injury model system in the rat cardiac cell line H9c2 and 
in neonatal rat cardiomyocytes. 
The second part looks at the effect of the drug HCQ on cell death in these two in vitro simulated 
cardiac I/R injury models using various output measures of apoptosis and total cell death. 
The final section explores the effect of IgG purified from patients with SLE, APS and JSLE on cell 
death in these two in vitro simulated I/R injury models. This includes optimisation of the dose of IgG 
to be used as well as the sub-division of patients depending on their aPL activity levels. 
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3.1 Simulated I/R injury in H9c2 rat cardiac cell line 
 
3.1.1 Introduction 
In the cardiovascular field it is recognized that inducing 30% apoptotic cell death is optimal for in 
vitro models of cardiac injury (Shen M 2012). To achieve this, the duration of hypoxia (simulated 
ischaemia) and reoxygenation (simulated reperfusion) must be optimised. Preliminary experiments 
were carried out in cardiac myoblast cell line H9c2 obtained from within our research group (original 
source H9C2 (2-1) (ATCC
®
 CRL-1446
™
)). This cell line was used to establish optimal cell culture 
conditions to select the most appropriate time points for simulated I/R injury. This in vitro simulated 
cardiac I/R injury model is induced in two stages; firstly cells are placed in a hypoxic chamber in the 
presence of an ischaemic buffer, containing 2-deoxyglucose to inhibit glycolysis. A mix of 
argon/CO2 is pumped into the chamber to create a hypoxic environment due to the ability of the 
argon to layer over the CO2, displacing molecular oxygen. Reoxygenation is induced by removing 
the cells from the chamber and replacing the ischaemic buffer with 1% FCS, DMEM. The cells are 
returned to a cell incubator (5% CO2 in air, 37°C) for the reoxygenation phase to allow oxygen to be 
reintroduced. 
3.1.2 Hsp70 and Hif1α are up-regulated in simulated I/R injury in H9c2 rat cardiac cell line 
Firstly, an experiment was carried out to ensure that hypoxia was being induced. The mRNA levels 
of two proteins; Hsp70 and Hif1α levels were measured after a period of hypoxia and then 
subsequent reoxygenation. Hsp70 is a heat shock protein and therefore is induced in stress, whereas 
Hif1α is a hypoxic induced protein. 
Hif1α (a) and Hsp70 (b) mRNA levels increased during hypoxia induction as shown in figure 3.1. 
However, in reoxygenation Hsp70 continued to have high mRNA levels due to cells still being in a 
stressed environment. In contrast Hif1α mRNA levels decreased due to cells no longer being in a 
hypoxic setting. This experiment confirmed that a hypoxic environment is created when cells are 
placed in the chamber and upon reoxygenation, oxygen is being reintroduced into the system, 
therefore simulated I/R injury was successfully being induced. 
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Figure 3.1 Confirmation of simulated I/R injury in H9c2 cell line. Cells were placed in a hypoxic 
chamber in ischaemic buffer for 5 hours followed by reoxygenation for 4 or 6 hours in 1% 
FCS/DMEM. mRNA levels of hif1α (a) and hsp70 (b) were then investigated using RT-PCR and 
levels expressed relative to the housekeeper GAPDH. Graph shows mean ±SEM of quantitative 
analysis from 3 independent experiments. Statistical analysis determined by one way ANOVA using 
post-hoc Tukey to compare all columns (* p<0.05, ** p<0.005, *** p<0.0005). 
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3.2 Optimisation of TUNEL to detect apoptotic cells 
3.2.1 Introduction 
To optimise our in vitro model to achieve 30% apoptosis a method to detect apoptosis had to be 
selected and it was decided that TUNEL would be used. This kit identifies late stage apoptosis by the 
enzyme TdT catalysing the addition of fluorescently labelled nucleotides onto the free 3’-hydroxl 
terminal of double and single stranded breaks. These breaks are induced during DNA fragmentation, 
a hallmark of terminal apoptosis. 
3.2.2 Results of TUNEL optimisation in H9c2 cells 
A preliminary experiment was carried out to optimise the use of a positive and negative control for 
the TUNEL assay. The positive control was treated with DNase I, to induce DNA fragmentation in 
all cells. The negative control was treated with the reagent minus the TdT enzyme, to eliminate 
potential fluorescent background. 
When cells were pre-treated with DNase I, DNA fragmentation was induced in all cells therefore 
TUNEL positivity was 100% (figure 3.2.a). The negative control was treated with the TUNEL stain 
containing no enzyme therefore TUNEL positivity was zero (figure 3.2.b). 
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Figure 3.2 Optimisation of controls for TUNEL assay in cardiac H9c2 cell line. For the positive 
control cells were treated for 15 minutes with DNase I followed by DAPI and TUNEL staining (a) 
and for the negative control cells were treated with DAPI and TUNEL (minus TdT enzyme) (b). 
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3.3 Optimisation of simulated I/R injury in H9c2 rat cardiac cell line 
3.3.1 Introduction 
Once optimisation of the TUNEL technique was complete an experiment was performed to optimise 
simulated I/R  injury in the H9c2 cardiac cell line. Cells were seeded at 1 x10
5
 cells per well in a 24 
well plate on glass coverslips and the following day subjected to 5 or 6 hours of hypoxia in 
ischaemic buffer. This was followed by a range of reoxygenation timepoints carried out in normal 
media (1% FCS in DMEM) in a cell incubator (5 % CO2 in air, 37°C). This was done to assess the 
duration required to induce approximately 30 % apoptosis/TUNEL positivity. The percentage of 
apoptosis for each condition was determined by counting the number of TUNEL positive cells and 
calculating its percentage relative to total number of cells (DAPI positive cells). Images were taken 
for DAPI positive and TUNEL positive as shown in figure 3.3.a. 
3.3.2 Results of simulated I/R injury 
Optimisation experiments showed that either 5 hours hypoxia followed by 16 hours reoxygenation 
(figure 3.3.b) or 6h hypoxia followed by 4-6 hours reoxygenation (figure 3.3.c) achieved 
approximately 30% TUNEL positivity. This is the desired amount of apoptosis to be induced, as 
suggested by experiments previously performed in my lab (Scarabelli T 2001; Barry S 2009). 
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Figure 3.3 Optimisation of simulated I/R injury in H9c2 cardiac cell line for TUNEL assay. 
Cells were seeded at 1 x10
5
 cells/well in a 24 well plate on glass coverslips and the next day were 
exposed to 5 hours (b) or 6 hours (c) hypoxia in ischaemic buffer followed by a range of 
reoxygenation time points in 1% FCS in DMEM. DNA nick end labelling was then performed to 
demonstrate DNA fragmentation and identify TUNEL positive cells (a). Graph shows mean ±SEM 
of quantitative analysis from 3 independent fields. Statistical analysis determined by 1 way ANOVA 
using post-hoc Tukey to compare all columns (** p<0.005, *** p<0.0005).  
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3.4 The effect of pre-treatment with IgG from patients with SLE in simulated I/R injury in 
H9c2 rat cardiac cell line 
3.4.1 Introduction 
Preliminary experiments were next carried out to explore the effects of IgG purified from patients 
with SLE on apoptosis in I/R injury. Patients selected had suffered a thrombotic event and the serum 
used was taken as close to the event date as possible. IgG from a healthy control was also tested to 
ensure the effects observed were specific to SLE patient IgG. Cells were incubated with 500 µg/mL 
IgG overnight (for 16 hours) at 37ºC and then exposed to simulated I/R injury. IgG was present in 
culture at 500 µg/mL throughout the experiment. 
3.4.2 Results of pre-treating H9c2 cardiac cell line with IgG from SLE patients in simulated I/R 
injury 
IgG from patients 113 and 522 increased apoptosis in simulated I/R injury suggesting they play a 
pathogenic role whereas healthy and patient 345 IgG have no effect on I/R injury (figure 3.4). This 
preliminary data suggests that IgG from patients 113 and 522 have the ability to be pathogenic in 
both hypoxia and reperfusion, but with the greatest increase in apoptosis being during reoxygenation.  
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Figure 3.4 IgG purified from patients with SLE has differential effects on the number of 
TUNEL positive cells in H9c2 cardiac cell line in simulated I/R injury Cells were incubated with 
500 µg/mL purified IgG from a healthy control and 3 patients overnight prior to simulated I/R injury 
(5h hypoxia + 16h reoxygenation). Cells were fixed in 4% PFA and the percentage of TUNEL 
positive cells was assessed. Graph shows mean ±SEM of quantitative analysis from 3 independent 
fields.  
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3.5 The effect of pre-treatment with Hydroxychloroquine (HCQ) in simulated I/R injury in 
H9c2 rat cardiac cell line 
3.5.1 Introduction 
Additionally as part of this project a preliminary experiment was also carried out to explore the 
effects of HCQ on apoptosis in simulated I/R injury. Cells were pre-treated with 1 µg/mL HCQ and 
the following day cells were exposed to simulated I/R injury, with HCQ present throughout. A dose 
of 1 µg/mL was used due to this correlating with blood concentrations achieved in patients currently 
treated with HCQ. 
3.5.2 Results of pre-treatment with HCQ in simulated I/R injury in H9c2 rat cardiac cell line 
Incubation of cells with HCQ reduces apoptosis in simulated I/R injury after 16h reoxygenation from 
50% (±SD 8) to 35% (±SD 4). It also appeared to reduce apoptosis after hypoxia alone from 27% 
(±SD 2) to 18% (±SD 4), however to a lesser extent than observed after reoxygenation (figure 3.5). 
Therefore this preliminary data suggests that HCQ may be cardioprotective. 
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Figure 3.5 Pre-treatment with HCQ reduces TUNEL positive cells in H9c2 cardiac cell line in 
simulated I/R injury. Cells were pre-incubated with 1 µg/mL HCQ and the following day exposed 
to simulated I/R injury. Cells were fixed in 4% PFA the percentage of TUNEL positive cells were 
assessed. Graph shows mean ±SEM of quantitative analysis from 3 independent fields. Statistical 
analysis determined by 1 way ANOVA using post-hoc Tukey to compare all columns (*** 
p<0.0005). 
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3.6 Isolation of neonatal rat cardiomyocytes 
 
3.6.1 Introduction 
 
Neonatal rat cardiomyocytes are the most translationally relevant in vitro model available in the 
cardiovascular field to mimic in vivo I/R injury. It was decided that upon the completion of 
preliminary experiments in cardiac myoblast H9c2 cell line that subsequent experiments would be 
carried out in these primary cells. Cardiomyocytes are isolated from 1-2 day old pups by extracting 
their hearts and digesting in collagenase type 2 and pancreatin. Isolated cells are pre-plated for 1 
hour to allow contaminating fibroblasts to attach. The enriched myocyte prep is then plated on 1% 
gelatin coated cell culture plates. The following day the cells should have attached and can be seen 
beating under the microscope.  
3.6.2 Isolated neonatal rat cardiomyocytes stain positive for desmin 
Due to the nature of the prep it is important to identify that myocytes are successfully being isolated 
and therefore immunofluorescence was performed to stain for Desmin, a common cardiac muscle 
marker. Immunofluorescences showed isolated cells were positive for desmin, which is a subunit of 
intermediate filaments in skeletal muscle tissue, smooth muscle tissue, and cardiac muscle tissue and 
therefore myocytes are positively stained. Contaminating fibroblasts do not stain positive for desmin 
therefore allowing their contamination to be assessed. It was identified that approximately 90% of 
cell preparations are myocyte positive; therefore fibroblast contamination after pre-plating is 
negligible (figure 3.6). 
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Figure 3.6 Immunofluorescence to confirm isolation of neonatal rat cardiomyocytes Cells were 
seeded on UV irradiated glass coverslips at 1 x10
5
 cells/well in a 24 well plate. Cells were fixed in 
4% PFA and immunofluorescence for desmin (green) was performed and nuclei were stained with 
DAPI (blue).  
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3.7 Optimisation of simulated I/R injury in neonatal rat cardiomyocytes 
 
3.7.1 Introduction 
Primary cells are more susceptible to stress induction such as simulated I/R injury in comparison to 
cells lines and therefore optimisation experiments to determine conditions in the neonatal 
cardiomyocytes were carried out. Previous experiments carried out in our lab using neonatal 
cardiomyocytes suggested 4h hypoxia followed by 16h reoxygenation was optimal and this was 
therefore confirmed. 
3.7.2 Results of optimisation of simulated I/R injury in neonatal rat cardiomyocytes 
It was confirmed that 4 hours hypoxia followed by 16 hours reoxygenation was suitable to induce 
30% apoptosis (figure 3.7), therefore for subsequent TUNEL experiments in the neonatal rat 
cardiomyocytes these conditions were used. 
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Figure 3.7 Optimisation of simulated I/R injury in neonatal rat cardiomyocytes Simulated I/R 
injury was induced (4h hypoxia + indicated times of reoxygenation) and cells were fixed in 4% PFA 
for TUNEL analysis. Graph shows mean ±SEM of quantitative analysis from three independent 
fields. Statistical analysis determined by 1 way ANOVA using post-hoc Tukey to compare all 
columns (* p<0.05, *** p<0.0005). 
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3.8 The effect of pre-treatment with HCQ in simulated I/R injury on cell death in neonatal rat 
cardiomyocytes 
3.8.1 Introduction 
The main focuses of this project has been to identify the role of HCQ in I/R injury. This is due to 
preliminary data collected from the H9c2 cardiac rat cell line suggesting a considerable protective 
effect being observed through the reduction of apoptosis. This has the potential to identify a new 
mechanism of action for HCQ, providing further evidence to suggest its importance as a 
cardioprotective agent in patients with lupus and in the wider cardiovascular field. 
3.8.2 Pre-treatment of neonatal rat cardiomyocytes with HCQ in simulated I/R injury reduces 
apoptotic positive cells in TUNEL 
Cells were seeded on UV irradiated glass coverslips at 1x10
5
 cells/well in a 1% gelatin coated 24 well plate. 
Once cells had attached and were beating they were pre-treated with 2 µg/mL HCQ and the following day 
simulated I/R injury was carried out. HCQ was present throughout the experiment and in all subsequent 
experiments. 
The pre-treatment of neonatal rat cardiomyocytes with HCQ reduced apoptosis when simulated I/R injury is 
induced (figure 3.8). When the cells are only exposed to hypoxia and then stained for TUNEL positivity, 
20.65% (±SD 7.38), stain positive and when exposed to re-oxygenation for 16 hours TUNEL positivity is 
enhanced to 30.13% (±SD 7.047)(p<0.005). However, if the cells are pre-incubated with HCQ, then this 
enhancement of TUNEL positivity during the re-oxygenation stage is completely abrogated back down to that 
observed at hypoxia alone (16.93% (±SD 3.002)(p<0.0005). Low levels of apoptosis are detected in control 
cells in both the absence and presence of HCQ due to natural cell turnover. This demonstrates that HCQ is 
cardioprotective in this in vitro simulated I/R injury model. 
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Figure 3.8 HCQ reduces TUNEL positive cells in neonatal rat cardiomyocytes in simulated I/R 
injury Cells were pre-treated with 2 µg/mL HCQ. The following day cells were exposed to 
simulated I/R injury (4h hypoxia and 16h reoxygenation), fixed in 4% PFA and the  percentage of 
TUNEL positive cells was assessed. Graph shows ±SEM of quantitative analysis from 9 independent 
experiments. Statistical analysis determined by 1 way ANOVA using post-hoc Tukey to compare all 
columns (** p<0.005, *** p<0.0005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
on
tr
ol
C
on
tr
ol
 +
 H
C
Q
H
yp
ox
ia
H
yp
ox
ia
 +
 H
C
Q
R
eo
xy
ge
na
tio
n
R
eo
xy
ge
na
tio
n 
+ 
H
C
Q
0
10
20
30
40 *****
%
 T
U
N
E
L
 p
o
s
it
iv
e
 c
e
ll
s
Chapter III 
 125 
3.8.3 Pre-treatment of neonatal rat cardiomyocytes with HCQ in simulated I/R injury reduces 
caspase-3 cleavage 
This finding was very interesting and therefore it was decided that it should be confirmed using 
another method that allows detection of apoptosis. Apoptosis can be induced via a variety of 
mechanisms which all converge to induce cleavage of the execution caspase, caspase 3. Thus 
cleaved caspase-3 is a prominent marker of apoptosis and so this HCQ experiment was repeated to 
detect cleaved caspase-3. 
Cells were plated at 1.5x10
6
 cells/well in a 6 well plate, they were pre-treated with 2 µg/mL HCQ 
and the following day simulated I/R injury was carried out. A dose of 2 µg/mL was used due to this 
correlating with the blood concentration of HCQ achieved in patients of between 1-2 µg/mL. Cells 
were placed in the hypoxic chamber (argon/CO2) for 4 hours in the presence of ischaemic buffer and 
subsequently media was replenished and cells were reoxygenated in a cell incubator (5% CO2 in air, 
37°C) for 2 and 4 hours. Shorter periods of reoxygenation were used due to caspase-3 cleavage 
occurring at an early stage of apoptosis in comparison to DNA fragmentation, which was previously 
quantified using TUNEL. Cell lysates were collected and separated using Western Blotting to allow 
detection of cleaved caspase-3. 
The pre-treatment of neonatal rat cardiomyocytes with HCQ reduces caspase-3 cleavage, therefore 
suggesting a cardioprotective role in this in vitro model of simulated I/R injury (figure 3.9). Cleaved 
caspase-3 is increased during reoxygenation (0.24 relative to GAPDH (±SD 0.09)(p<0.0005) when 
compared to cells in optimal conditions (0.03 relative to GAPDH (±SD 0.03)). In the presence of 
HCQ this increase in cleaved caspase-3 is significantly reduced by 54.16% (0.11 relative to GAPDH 
(±SD 0.05)(p<0.05).  This further clarifies that HCQ is cardioprotective in simulated I/R injury. 
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Figure 3.9 HCQ reduces cleaved caspase-3 in neonatal rat cardiomyocytes in simulated I/R 
injury Cells were pre-treated with 2 µg/mL HCQ. The following day cells were exposed to 
simulated I/R injury (4h hypoxia + 4h reoxygenation) and the level of cleaved caspase-3 was 
assessed by western blot. Graph shows ±SEM of quantitative analysis from 4 independent 
experiments. Statistical analysis determined by 1 way ANOVA using post-hoc Tukey to compare all 
columns (* p<0.05, *** p<0.0005). 
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3.8.4 Pre-treatment of neonatal rat cardiomyocytes with HCQ reduces total cell death in 
simulated I/R injury 
 
Data produced thus far has focused on apoptotic cell death within I/R injury; however it is important 
to assess the relevance of HCQ and its protective effect when looking at total cell death. This allows 
assessment of it protection in simulated I/R injury to be quantified to determine is significance and 
translational relevance. A cell viability assay was therefore used to assess reduction in overall cell 
viability in simulated I/R injury and the effects of HCQ on this viability. A colorimetric cell 
proliferation assay confirmed that HCQ causes a reduction in total cell death in cells exposed to 
simulated I/R injury of 57.89% (±SD 7.14, p=0.0213) when compared to cells not incubated with 
pathways activated by stress signals inducing apoptosis (figure 3.10). 
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Figure 3.10 HCQ reduces total cell death in neonatal rat cardiomyocytes in simulated I/R 
injury Cells were pre-treated with 2 µg/mL HCQ. The following day cells were exposed to 
simulated I/R injury (4h hypoxia + 4h reoxygenation) and a cell viability assay was performed. 
Graph shows ±SEM of quantitative analysis from 4 independent experiments. Statistical analysis 
determined by unpaired t-test (p=0.0213). 
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3.9 Control experiments to confirm IgG had a direct effect on apoptosis in neonatal rat 
cardiomyocytes 
3.9.1 Introduction 
Preliminary studies in the H9c2 rat cardiac cell line suggested that IgG purified from the serum of 
patients with SLE is pathogenic in simulated I/R injury. This experiment was therefore carried out in 
our primary cell system using neonatal rat cardiomyocytes. More samples were tested and 
categorised depending on their antiphospholipid antibody status as well as testing samples from 
JSLE and APS patients.  
3.9.2 Patient and healthy control IgG selection and characteristics 
Purified IgG from 34 patients were selected for use in experiments in this chapter as outlined in 
section 2.7.2 of Material and Methods. Six samples were selected from patients with primary APS, 
five were selected for SLE/aPL +ve, five were selected for SLE/aPL –ve, eight for JSLE and the 
remaining ten were healthy controls.  
The ability of purified and endotoxin free IgG to bind CL and β2GPI at the experimental 
concentration (500 μg/mL) was then determined (figure 3.11).  
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Figure 3.11 IgG aCL and anti-β2GPI levels 
All purified IgG was tested at 500 µg/mL for binding to aCL (a) and anti-β2GPI (b). IgG samples 
that have activity above the cut-off of these assays are plotted as the upper limit of the assay (96 
GPLU or 100 SU). Positivity is defined as above 17 GPLU (aCL) and 9 GPLU (anti-β2GPI) based on 
the testing of 200 healthy controls (±3 SD). 
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3.9.3 Pre-treatment of neonatal rat cardiomyocytes with LPS has no effect on cleaved caspase-3 
in simulated I/R injury 
Prior to testing patient samples some control experiments were performed. One of the challenges 
when purifying IgG from serum of patients is contamination with endotoxins, which could 
potentially activate signalling pathways in target cells. Therefore cells were incubated with varying 
concentrations (1 ng/ml to 10 µg/ml) of LPS to determine if neonatal rat cardiomyocytes are 
sensitive to endotoxin and if so determine the threshold concentration of endotoxin required to cause 
an effect. It was found that there was no significant difference in levels of cleaved caspase-3 when 
cells were treated with increasing concentrations of LPS overnight and the following day exposed to 
simulated I/R injury (figure 3.12a). However, as it is routine in our lab to run purified samples 
through endotoxin removal columns and this was still carried out to ensure there was minimal 
endotoxin contamination (<0.25 endotoxin units (EU/mL).  
3.9.4 Pre-treatment of neonatal rat cardiomyocytes with BSA has no effect on cleaved caspase-
3 in simulated I/R injury 
It was also important to show that any differences observed with IgG from patients was due to the 
effects of the IgG and not due to another factor such as protein overloading. When cells are 
overwhelmed with high concentrations of protein (e.g. BSA), stress pathways may be activated and 
therefore could contribute to changes in levels of cleaved caspase-3. Varying concentrations        
(100 µg/ml to 500 µg/ml) were incubated with cells overnight prior to simulated I/R injury. No 
difference was observed when compared with control cells (figure 3.12b). 
3.9.5 Pre-treatment of neonatal rat cardiomyocytes with IgG purified from the serum of 
healthy controls has no effect on cleaved caspase-3 in simulated I/R injury 
It was essential to assess whether IgG purified from healthy serum was pathogenic in our simulated 
I/R injury model. A pilot experiment was therefore carried out in which cells were pre-treated 
overnight with varying concentrations of healthy IgG (100 µg/ml to 500 µg/ml) followed by 
simulated I/R injury. No effect was seen in the presence of healthy IgG on cleaved caspase-3 
following simulated I/R cardiac injury suggesting healthy IgG is not pathogenic up to a 
concentration of 500 µg/ml (figure 3.12c). It was thus decided that in subsequent experiments IgG 
would be used at a concentration of 500 µg/ml to maximise the potential signal observed with IgG 
purified from patients. 
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Figure 3.12 Neonatal rat cardiomyocytes are not sensitive to LPS, BSA and healthy IgG. 
Neonatal rat cardiomyocytes were treated with a range of LPS concentrations (1ng/mL to 10 µg/mL) 
or a range of BSA concentrations (100 µg/mL to 500 µg/mL) or a range of healthy patient IgG (100 
µg/mL to 500 µg/mL) overnight and the following day exposed to simulated I/R injury before cell 
lysates were collected and probed for cleaved caspase-3 using western blot (n=1). 
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3.10 IgG from patients with SLE, JSLE and APS increase apoptosis in neonatal rat 
cardiomyocytes in simulated I/R injury 
3.10.1 Introduction 
SLE carries a significantly enhanced risk of developing cardiovascular disease (CVD) and remains a 
leading cause of death in these patients. There is clear evidence linking accelerated atherosclerosis to 
SLE, and as a consequence, an increase in cardiovascular events. Another factor which could 
contribute to increased morbidity and mortality related to CVD is enhanced reperfusion injury post 
MI. The factors that could contribute to this are yet to be explored, however there is some evidence 
using a lupus mouse model that lupus IgG antibodies are pathogenic within a mesenteric I/R injury 
model. No study as yet has investigated human lupus IgG in a heart I/R injury model.  
3.10.2 Pre-treatment of neonatal rat cardiomyocytes with IgG purified from patients with SLE 
increases cleaved caspase-3 in a dose dependent manner in simulated I/R injury 
An initial experiment was carried out to confirm at what concentration IgG from SLE patients was 
pathogenic. Patient 113 from preliminary studies was used due to previously identifying it as being 
pathogenic in H9c2 rat myoblast cell line. The most significant increase in cleaved caspase-3 was at 
a concentration of 500 µg/mL (figure 3.13). As previous experiments demonstrated no toxicity with 
healthy IgG at this concentration, this dose was chosen for all subsequent experiments.  
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Figure 3.13 IgG from a patient with SLE increases cleaved caspase-3 in a dose dependent 
manner in neonatal rat cardiomyocytes exposed to simulated I/R injury. Neonatal rat 
cardiomyocytes were pre-treated with a range of IgG concentrations (50 µg/mL to 500 µg/mL) 
purified from patient 113 (SLE/aPL +ve). The following day cells were exposed to simulated I/R 
injury and the cell lysates collected and probed for cleaved caspase-3 using western blot. Graph 
shows ±SEM of quantitative analysis from 4 independent experiments. Statistical analysis 
determined by 1 way ANOVA using post-hoc Tukey to compare all columns (* p<0.05). 
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3.10.3 Pre-treatment of neonatal rat cardiomyocytes with IgG purified from patients with SLE 
enhanced cleavage of caspase-3 in simulated I/R injury 
Cells were incubated with IgG purified from healthy controls and SLE patients overnight and the 
following day exposed to simulated I/R injury. IgG purified from the blood of patients with SLE 
significantly increased cleaved caspase-3 when compared to healthy age and gender matched 
controls in simulated I/R injury. Healthy IgG had no significant effect on cleaved caspase-3 levels, 
however SLE IgG increased levels by a mean of 49.7% (±SD 16.31) when compared with control 
cells (figure 3.14). 
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Figure 3.14 IgG from patients with SLE enhances cleaved caspase-3 in neonatal rat 
cardiomyocytes in simulated I/R injury. Cells were pre-treated with healthy or SLE IgG. The 
following day cells were exposed to simulated I/R injury (4h hypoxia + 4h reoxygenation) and the 
level of cleaved caspase-3 was assessed by western blot. Graph shows ±SEM of quantitative analysis 
from 10 SLE patients and 10 healthy controls. Statistical analysis determined by unpaired t-test (*** 
p<0.0005). 
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3.10.4 Pre-treatment of neonatal rat cardiomyocytes with IgG purified from patients with SLE 
enhances TUNEL positivity in simulated I/R injury 
TUNEL was used as an additional method to assess if IgG from patients with SLE is pathogenic. IgG 
purified from patients with SLE or healthy age and gender matched controls was incubated with cells 
overnight and the following day cells were exposed to simulated I/R injury. Data showed that IgG 
from SLE patients caused a significant increase in TUNEL positivity of a mean of 54.17% (±SD 
8.13), when compared to control cells (figure 3.15) whereas healthy IgG had no significant affect.  
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Figure 3.15 IgG from patients with SLE enhances the number of TUNEL positive cells in 
neonatal rat cardiomyocytes exposed to simulated I/R injury. Neonatal rat cardiomyocytes were 
pre-treated with 500 µg/mL IgG from either healthy or SLE patients and the following day cells were 
exposed to simulated I/R injury (4h hypoxia + 16h reoxygenation). Cells were fixed in 4% PFA and 
the percentage of TUNEL positive cells was assessed. Graph shows mean ± SEM of quantitative 
analysis from 6 SLE patients and 5 healthy controls. Statistical analysis determined by unpaired t test 
(p<0.0001) 
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3.10.5 Pre-treatment of neonatal rat cardiomyocytes with IgG purified from patients with 
JSLE and primary/secondary APS enhances cleaved caspase-3 in simulated I/R injury 
The SLE group was next split into those who tested antiphospholipid antibody (aPL) positive and 
those who were negative. Those who are positive are diagnosed as having ‘secondary’ APS, 
additionally a group titled ‘primary’ APS, which occurs in patients who have APS alone and no other 
autoimmune disease was also included. It was observed that within the SLE group, the aPL positive 
patients had a mean of 68.15% (±SD 13.53) increase in caspase-3 cleavage compared to control cells 
(figure 3.16). This was significantly higher than that seen in the SLE patients who were aPL negative 
and had a mean of 40.66% (±SD 8.7). Additionally, IgG from patients with primary APS caused a 
significant increase in cleaved caspase-3 with a mean of 67.94 (±SD 12.41), similar to that seen in 
patients with secondary APS (figure 3.16). All aPL-IgG samples harboured anti-ß2GPI (ß2GPI) 
antibodies (figure 3.16). This finding suggests a potential aPL dependent mechanism through which 
IgG from patients is pathogenic in this simulated I/R injury model. 
Due to the availability of samples from an adolescent rheumatology clinic samples were also tested 
from patients with juvenile onset SLE (JSLE) to observe if their IgG also resulted in accelerated I/R 
injury. It was observed that JSLE IgG caused a mean increase of 63.98% (±SD 17.99) in cleaved 
caspase-3 compared with control cells (figure 3.16). Interestingly, these JSLE patients are all aPL 
negative, however appear to follow the levels of pathogenicity observed in adult onset SLE patients 
who are aPL positive. 
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Figure 3.16 IgG from patients with JSLE, SLE/aPL +ve, SLE/aPL –ve and APS enhance 
cleaved caspase-3 in neonatal rat cardiomyocytes in simulated I/R injury . Cells were pre-treated 
with healthy, JSLE, SLE/aPL –ve, SLE/aPL +ve or APS IgG. The following day cells were exposed 
to simulated I/R injury (4h hypoxia + 4h reoxygenation) and the level of cleaved caspase-3 was 
assessed by western blot. Graph shows ± SEM of quantitative analysis from 8 JSLE, 5 SLE/aPL +ve 
patients, 5 SLE/aPL –ve patients, 6 APS patients and 10 healthy controls. Statistical analysis 
determined by 1 way ANOVA using post-hoc Tukey to compare all columns (* p<0.5,*** p<0.0005). 
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3.11 Discussion 
The data in this chapter indicates that the drug HCQ is cardioprotective in I/R injury. Additionaly 
IgG purified from the serum of SLE, APS and JSLE patients were found to be pathogenic in 
simulated I/R injury. 
The experiments described in this chapter begin by establishing the optimal conditions for simulated 
I/R injury in cardiac derived cells with the aim to establish approximately 30% enahncement of 
apoptosis during reoxygeneation post hypoxia. This apoptosis induction is the accepted percentage of 
apoptosis for in vitro simulated I/R injury, that mimcs what is observed in vivo (Fujio Y 2000; Shen 
M 2012). In the in vitro model of simulated I/R injury the terminology used to describe the two 
stages of I/R injury is different. The ischaemic phase induced during a MI refers to occlussion of 
blood flow and therefore restriction of oxygen supply to tissue. In this in vitro model a hypoxic 
environment is created, which is the state in which tissue in an in vivo setting is maintained. This is 
achieved by a mix of CO2/argon gas being pumped into a chamber where the argon forms a layer 
over the CO2 causing displacement of molecular oxygen. The reperfusion phase which occurs in vivo 
refers to resotration of blood flow and therefore in the in vitro setting this is instead referred to as 
reoxygenation, due to oxygen being re-introduced into the system. To confirm that successful 
simulated I/R injury was being , the mRNA levels of two proteins; Hif1α and Hsp70 were assessed. 
Hif1α is a hypoxic induced protein and therefore as expected levels of mRNA were increased only in 
the hypoxic stage. Hsp70 is a heat shock protein induced in the presence of stress and therefore 
mRNA levels increased for both hypoxia and reoxygenation (chapter 3, figure 3.1). This experiment 
confirmed that hypoxia was being introduced and that upon reoxygenation, cells were no longer in a 
hypoxic environment, but were still in a stressed state, consistent with the setting of I/R injury. 
Opimisation experiments were completed using TUNEL, which stains cells positive that have DNA 
fragmentation, a late-stage marker of apoptosis. In the H9c2 cardiacmyoblast cell line 5 hours 
hypoxia followed by 16 hours reoxygenation or 6 hours hypoxia followed by 6 hours reoxygenation 
was optimal (chapter 3, figure 3.3). In the neonatal rat cardiomyocytes 4h hypoxia followed by 16 
hours reoxygenation satisified the criteria for in vitro simulated I/R injury (chapter 3, figure 3.7). 
A novel aspect of this study is the investigation of the role of HCQ  in myocardial I/R injury. These 
experiments were peformed due to patients with SLE, prescribed HCQ, have less cardiovascular 
events (Venuturupalli S 2012) due to the drugs lipid lowering effects and ability to reduce platelet 
aggregation (Hyejung J 2010; Rand J 2010; Morris S 2011). No investigation into the effects of HCQ 
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on cardiac I/R injury has been performed and given its effects on the lysosome and autphagy the 
hypothesis was that it may affect I/R injury also. Recent studies in the heart by Zhou et al (Zhou 
2013) have shown that HCQ can significantly increase phosphorylation of the pro-survival kinase 
Akt, without significantly impacting expression of phosphorylated p53 protein in the peri-infarct 
myocardium. Consequently, HCQ can inhibit cardiomyocyte apoptosis in the peri-infarct 
myocardium. Another recently published study has shown that HCQ can protect in an in vivo model 
of renal I/R injury (Todorovic Z 2014). Interestingly, a study looking at the role of HCQ in liver I/R 
injury showed protection in early stage injury, however, HCQ was shown to actually cause damage 
in late stage I/R injury (Fang H 2013). Exploring the effects of HCQ in cardiac I/R injury will 
provide further evidence for its use in patients with SLE, due to their increased risk of cardiovascular 
disease. Additionaly, it may provide evidence for the use of HCQ in the wider cardiovascular field 
i.e for patients who are at risk of developing CVD. 
It was observed that the percentage of TUNEL positive cells in cells pre-treated with HCQ in 
simulated I/R injury was enhanced upon induction of hypoxia and further increased during 
reoxygenation. Interestingly, upon reoxygenation the percentage of TUNEL positive cells was 
signifcantly decreased in the presence of HCQ. This was observed in both a cardiac H9c2 rat 
myoblast cell line (chapter 3, figure 3.5) and primary neonatal rat cardiomyocytes (chapter, figure 
3.8). In neonatal rat cardiomyocytes, HCQ abborgated levels of TUNEL positivty down to levels 
observed in hypoxia alone. This observation was confirmed using another method to detect 
apoptosis, caspase-3 cleavage via western blot. This was done to strengthen the finding that HCQ 
reduced apoptosis. Apoptosis occurs via two main pathways; the extrinsic and intrinsic, however 
these pathways converge to induce cleavage of the execution caspase, caspase-3 (Taylor R 2008). 
This therefore makes it a good indicator of total apoptosis occuring within a cell population. This set 
of experiments showed significantly increased levels of caspase-3 cleavage after 2 hours of 
reoxygenation compared with control cells. Furthermore, after 2 hours of reoxygenation there was a 
statistically significant decrease in cleaved caspase-3 in the presence of HCQ, which was also 
observed at 4 hours (chapter 3, figure 3.9). This experiment required earlier timepoints of simulated 
I/R injury to be explored due to caspase-3 cleavage being an earlier marker of apoptosis in 
comparison to TUNEL. These findings further validated our hypothesis that HCQ is cardioprotective 
in simulated I/R injury.  
I/R injury leads to extensive cell injury and death through apoptosis but also through another 
mechanism of cell death, necrosis. The effects of HCQ on total cell viability were therefore explored 
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in the neonatal rat cardiomyocytes. It was observed that the same protective mechanism could be 
demonstrated when looking at total cell death (chapter 3, figure 3.10). Data was presented as a 
percentage reduction in cell viability relative to control cells. It was observed that there was a 
significant decrease in cell viability following reoxygenation. However, in the presence of HCQ 
there was a significant increase in cell viability. The role of apoptosis in I/R injury is subject to 
conflicting evidence in the cardiovascular field (Eefting F 2004; McCully J 2004), however my data 
suggests that it plays a prominent role, due to the observation that total cell death is reduced 
significantly. However, it should also be noted that HCQ’s protective effect may not just be reducing 
apoptosis and therefore its role in inhibiting necrosis should not be ruled out. Whilst it is well 
established that necrosis induction is mainly due to irreversible damage to cells there is now the 
suggestion that necrosis may also be able to occur through a program-dependent manner (Elmore 
2007). Therefore, exploring the effects of HCQ in relation to necrosis in simulated I/R injury may be 
an important area to explore in the future. The observation that HCQ has a protective effect on total 
cell death increases evidence to suggest this drugs translational relevance. Nevertheless, it should be 
acknowledged that this is preliminary in vitro data, however these initial findings underpinned 
subsequent experiments to investigate the protective effects of HCQ in vivo in a rat cardiac I/R injury 
model and the results are presented in Chapter 5 of this thesis. It is also of interest to explore how 
HCQ is exerting its protective mechanism. It has previously been shown to inhibit autophagy by 
altering the pH of the lysosome therefore causing accumulation of autophagosomes. The role of 
autophagy in cardiac I/R injury is controversial; some believe its activation enhances cell death (Noh 
HS 2010), whilst others believe that its activation leads to protection (Hamacher-Brady A 2006; 
McCormick J 2012). There are other potential targets of HCQ including the pro-survival kinases 
ERK 1/2 and Akt which have been shown to have increased phosphorylation in I/R injury to promote 
cell survival (Haunsenloy 2007). Other drugs such as sildenafil have previously been shown to 
enhance phosphorylation of ERK 1/2 to induce protection in cardiac I/R injury (Das A 2009). 
Subsequent experiments presented in chapter 4 of this thesis aim to dissect out the mechanism 
through which HCQ is cardioprotective. 
The second aim of this project was to explore the pathogenicity of IgG purified from patients with 
lupus in this simulated I/R injury model. Preliminary experiments in the H9c2 cardiomyoblast cell 
line showed promising results. Previously published data has suggested that IgG is pathogenic in a 
murine mesenteric I/R injury model due to accelerated I/R injury in the presence of IgG from a lupus 
prone mouse (Fleming S 2004). However, there is no literature to suggest the effect of IgG in the 
cardiac I/R injury setting has been explored. Three patients were selected for an initial experiment, 
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and it should be noted that they had all had a form of cardiovascular event as detailed in chapter 2, 
table 2.2. TUNEL data suggested that increased apoptosis was observed in cells that were pre-treated 
with two out of the three patient samples (113 and 552) in both hypoxia and reoxygenation (chapter 
3, figure 3.4). Interestingly these patients are positive for aPL antibodies, whereas patient 345 is not. 
aPL have been heavily implicated in an increased risk of thrombosis and enhanced inflammatory 
response due to binding to and altering endothelial cell responses and other cells in thrombosis and 
inflammation such as monocytes (de Laat, Derksen et al. 2004; Giannakopoulos B 2007; Rand J 
2010), however their role in I/R injury to date has not been explored. This preliminary experiment 
therefore suggests that IgG from patients with SLE may be pathogenic in simulated I/R injury, and 
this is further enhanced in patients who are positive for aPL. However, this is a preliminary 
experiment in a cell line.  Following on from this observation this experiment was repeated in 
neonatal rat cardiomyocytes and the cohort of patients was expanded, with the effect confirmed.  
Control experiments were primarily carried out to establish the sensitivity of these neonatal rat 
cardiomycoyte cells to human IgG. Firstly, a range of doses (1 ng/mL to 10 µg/mL) of LPS were 
pre-incubated with cells overnight before exposure to simulated I/R injury. This was done to observe 
whether LPS altered levels of cleaved caspase-3 in cells. IgG purified from serum of patients (and 
healthy controls) is contaminated with endotoxin. Our lab regularly purifies samples to remove 
endotoxin to below <0.25 endotoxin units (EU)/ml, however it is important to establish how 
sensitive cells are to endoxtoin to ensure effects observed are in fact due to a direct effect of the IgG 
and not due to LPS contamination. It was found that none of the doses of LPS administered to cells 
altered levels of cleaved caspase 3 (chapter 3, figure 3.12a). Additionally, cells were pre-treated with 
a range of concentrations of BSA (100 µg/mL to 500 µg/mL) to ensure that high levels of protein did 
not alter cell function and induce cell death. Again, at a range of concentrations there was no effect 
on levels of cleaved caspase-3 (chapter 3, figure 3.12b). Finally, cells were pre-treated with a range 
of healthy IgG concentrations to see at what dose healthy IgG enhanced pathogenicity in simulated 
I/R injury. In this model, up to a concentration of 500 µg/mL, there was no change in cleaved 
caspase-3 observed (chapter 3, figure 3.12c). This experiment was repeated with IgG purified from a 
patient with SLE to see at what doses cleaved caspase-3 was enhanced. From as little as 50 µg/mL 
IgG an increase in cleaved caspase-3 was observed, however maximal increase was observed with            
500 µg/mL (chapter 3, figure 3.13). Due to healthy IgG having no effect on cells at this 
concentration it was decided that subsequent experiments would use a dose of 500 µg/mL. 
IgG was subsequently purified from 10 SLE patients and 10 healthy age and gender matched 
controls. Neonatal rat cardiomyocytes were pre-treated with 500 µg/mL IgG from SLE patients and 
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the following day exposed to simulated I/R injury. In the presence of IgG from patients with SLE 
cleaved caspase 3 was significantly increased (chapter 3, figure 3.14). This was further confirmed 
using the TUNEL assay, where a significant increase in TUNEL positive cells was also observed in 
the presence of IgG from patients with SLE in comparison to healthy age and gender matched 
controls (chapter 3, figure 3.15). Due to the initial observation that only aPL positive patient IgG 
was pathogenic, the patient cohort was split into those who were aPL positive (5 patient samples) vs 
aPL negative (5 patient samples) and an additional group of patients who had APS (i.e.aPL positive 
but didn’t have SLE) (6 patient samples) were included. IgG purified from the blood of patients with 
SLE with aPL positivity and IgG from patients with the APS but without SLE significantly enhanced 
apoptosis in cardiomyocytes post-reoxygenation as compared to IgG from patients with SLE without 
aPL (chapter 3, figure 3.16). All groups enhanced caspase-3 cleavage to a greater extent than that 
observed with IgG from healthy volunteers. It should be noted that all aPL-IgG samples harboured 
ß2GPI and aCL antibodies (chapter 3, figure 3.11). These results were of great interest as previously 
published work has shown that autoimmune prone mice with high titers of autoantibodies have 
accelerated mesenteric I/R injury (Fleming S 2004). Further studies by this group showed that aPL 
antibodies were specifically responsible for accelerated mesenteric I/R injury, in complement 
receptor 2/complement receptor 1 deficient mice (Fleming S 2004). Previous work by my lab and 
others has shown that aPL positive IgG activates p38 MAPK leading to enhanced thrombosis (Vega-
Ostertag ME 2007; Lambrianides A 2010). This signalling pathway is therefore of interest and data 
regarding this work is presented in chapter 4 of this thesis.  
Lastly, a fourth group of patients were included in this set of experiments, those with JSLE (8 patient 
samples). Patients with childhood onset SLE compared to those with adult-onset disease have greater 
prevalence of renal disease, more haematological disease and generally have a worse prognosis with 
significantly greater standardised mortality ratios as compared to adult onset SLE (Amaral B 2014). 
Hence, it was felt relevant to test this group separately. All JSLE patients were aPL negative, 
however interestingly they caused a significant increase in cleaved caspase 3, to the same extent as 
observed with adult aPL positive patients (chapter 3, figure 3.17). IgG purification yields a 
polyclonal population and therefore it is possible that an unidentified subset of IgG is present in both 
aPL positive adult onset SLE and JSLE patients, that is not present in the aPL negative group. 
However, it is also possible that another IgG population, yet to be identified in the purified JSLE 
IgG, targets the same antigen as aPL antibodies. Further experiments are required to explore these 
possibilities. 
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Limitations of these experiments include that this simulated I/R injury model gives a restricted view 
into the kinetics of the protective effect of HCQ and the pathogenic role if IgG from patients. It 
would be of interest to look at longer time points to see if the effects observed and preserved long 
term. Additionally, we were unable to access healthy controls which were age matched to our JSLE 
cohort. 
In summary, an in vitro simulated I/R injury model has been optimized in H9c2 rat cardiomyoblast 
cell line and neonatal rat cardiomyocytes. Pre-treatment with the drug HCQ has been shown to offer 
cardioprotective in these in vitro cardiac I/R injury models. Subsequently, experiments have 
explored the effects of IgG purified from serum of patients with SLE (aPL positive and negative), 
APS and JSLE. It was observed that all IgG enhanced cleaved caspase-3 when compared to healthy 
age and gender matched controls. However, IgG from adults who were aPL positive and JSLE 
patients (who are aPL negative) caused a significantly greater increase in cleaved caspase-3 
compared to adults who were aPL negative. The next chapter of this thesis aims to explore potential 
mechanisms of action for the observations presented in this chapter. 
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The mechanisms through which HCQ is cardioprotective and 
IgG purified from SLE, APS and JSLE patients are pathogenic 
in an in vitro simulated cardiac I/R injury model 
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Overview of Chapter IV 
This chapter aims to expand on observations observed when both the rat cardiac H9c2 cell line and 
neonatal rat cardiomyocytes are exposed to simulated in vitro I/R injury after pre-treatment with 
various the drug HCQ and IgG purified from patients with SLE, APS and JSLE. It focuses on 
potential mechanisms of action that cause these modulators to have an effect. 
The first part will focus on HCQ and how it is cardioprotective in these models of cardiac I/R injury. 
Specifically, the role of signalling pathways and how inhibition of specific pathways alters the ability 
of HCQ to be protective. 
The second part of this chapter will define specific signalling pathways, which appear to be targeted 
by pathogenic IgG from SLE, APS and JSLE patients. Inhibitors of target molecules show that the 
pathogenic effect of these antibodies can be blocked. 
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4.1 The regulation of kinases in neonatal rat cardiomyocytes when pre-treated with HCQ in 
simulated I/R injury 
4.1.1 Introduction 
Confirmation of a cardioprotective role for HCQ via two methods led to subsequent experiments to 
identify how this effect was being produced. I/R injury consists of multiple pathways and 
mechanisms, which account for the myocardial injury and cell death observed. It was decided that 
western blotting would be used to assess the levels of kinases, which have been previously 
implicated in I/R injury. This included the MAPK family, which consists of a series of serine-
threonine kinases that are involved in cell proliferation, differentiation and survival. These kinases 
have been shown to be heavily implicated in I/R injury in both a pro and anti-apoptotic fashion. 
Furthermore PI3K-Akt pathway, also implicated in I/R injury in a pro-survival role, was also 
explored. 
4.1.2 ERK phosphorylation is up regulated in neonatal rat cardiomyocytes in simulated I/R 
injury when pre-treated with HCQ 
The ERK 1/2 signalling pathway is a part of the MAPK family and has been shown to play a 
cardioprotective role in I/R injury by contributing to the RISK pathway, which promotes survival 
mechanisms to protect against cell death. The levels of this protein were detected using western 
blotting to evaluate whether HCQ mediates its protective effects through enhancing phosphorylation 
of the pro-survival kinase ERK 1/2. 
ERK 1/2 phosphorylation occurs at low levels in control cells, however is significantly up regulated 
in reoxygenation due to pro-survival mechanisms being activated. This observed phosphorylation is 
significantly increased in the presence of HCQ during reoxygenation (figure 4.1). In reoxygenation 
cells p-p44 ERK has a mean of 0.55 (±SD0.12 (n=6)) versus an increase in HCQ treated cells to 0.8 
(±SD0.04 (n=6)) relative to total p44 ERK.  For p-p42 ERK reoxygenation cells had a level of 0.37 
(±SD0.23 (n=6)) versus 0.93 (±SD0.12 (n=6)) relative to total p42 ERK. This suggests that HCQ 
could be mediating its protective effect via ERK phosphorylation. 
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Figure 4.1 HCQ increases the pro-survival kinase ERK 1/2 phosphorylation in neonatal rat 
cardiomyocytes in simulated I/R injury Cells were pre-treated with 2 µg/mL HCQ  and the 
following day cells were exposed to simulated I/R injury (4h hypoxia + 4h reoxygenation) and the 
levels of p42/p44 ERK phosphorylation assessed using western blot. Graph shows ±SEM of 
quantitative analysis from 5 independent experiments. Statistical analysis determined by 1 way 
ANOVA using post-hoc Tukey to compare all columns (** p<0.005, *** p<0.0005). 
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4.1.3 Increasing HCQ concentration increases ERK phosphorylation in neonatal rat 
cardiomyocytes in simulated I/R injury 
 
The effect of increasing HCQ concentration was also explored to see the effects on ERK 1/2 
phosphorylation. Cells were pre-treated with HCQ concentrations ranging from 250 ng/mL to 2 
µg/mL prior to simulated I/R injury to identify whether ERK phosphorylation can be increased in a 
dose-dependent manner. 
 
Western blot analysis showed that with increasing concentration of HCQ there was an increase in 
ERK 1/2 phosphorylation, further supporting the evidence to suggest HCQ enhances activation 
(figure 4.2). 
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Figure 4.2 HCQ increases the pro-survival kinase ERK 1/2 phosphorylation in a dose-
dependent manner in neonatal rat cardiomyocytes in simulated I/R injury Cells were pre-
treated with varying concentrations (250 ng/ mL to 2 µg/ mL) HCQ . The following day cells were 
exposed to simulated I/R injury (4h hypoxia + 4h reoxygenation) and the levels of ERK 
phosphorylation assessed using western blot. Graph shows ±SEM of quantitative analysis from 3 
independent experiments.  
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4.1.4 Pre-treatment of neonatal rat cardiomyocytes with HCQ does not affect the regulation of 
Akt, p38 MAPK nor JNK in simulated I/R injury 
Other MAPK family members, as well as Akt, a member of the PI3K signaling cascade were 
assessed by western blot to see if HCQ mediated an effect on their activation also. The MAP kinases 
p38 MAPK and JNK have been implicated in promoting apoptosis in I/R injury whereas Akt is a 
pro-survival kinase and therefore prevents it. It was observed that HCQ had no significant effect on 
levels of other kinases detected by western blotting in simulated I/R injury (figure 4.3). 
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Figure 4.3 HCQ does not significantly alter the phosphorylation levels of other kinases in 
neonatal rat cardiomyocytes exposed to simulated I/R injury Cells were pre-treated with 2 
µg/mL HCQ. The following day cells were exposed to simulated I/R injury (4h hypoxia + 1, 2 or 4h 
reperfusion) and the levels p-38, JNK and Akt phosphorylation were assessed using western blot 
(n=1).  
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4.2 Inhibiting ERK phosphorylation blocks HCQ cardioprotection in neonatal rat 
cardiomyocytes in simulated I/R injury  
4.2.1 Introduction 
Due to ERK 1/2 phosphorylation being identified as a potential mechanism through which HCQ 
could be reducing apoptosis it was decided that subsequent experiments would be performed to 
inhibit this phosphorylation. This was to see if this protective effect could be reversed and was 
explored using a commercially available inhibitor (U0126 (Cell Signalling)) which inhibits        
MEK 1/2, directly upstream of ERK 1/2. An optimisation experiment was done to confirm 
successful inhibition using two concentrations of the inhibitor; 10 µM and 1 µM. Cells were treated 
with U0126 for 2 hours prior to simulated I/R injury and the inhibitor was present in media and 
buffer throughout the experiment. 
 
4.2.2 U0126 inhibits ERK 1/2 phosphorylation in neonatal rat cardiomyocytes 
 
The ERK 1/2 inhibitor U0126 successfully inhibited ERK phosphorylation in simulated I/R injury at 
a concentration of 10 µM (figure 4.4). The inhibitor also enhanced caspase-3 cleavage due to pro-
survival mechanisms being blocked, causing further apoptosis to occur. Immunoblots were also 
probed for other kinases to confirm specificity. The phosphorylation levels of JNK and Akt were 
unchanged in the presence of the inhibitor. 
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Figure 4.4 U0126 selectively inhibits ERK phosphorylation in neonatal rat cardiomyocytes. 
Cells were pre-treated for 2h with 1uM or 10uM of the ERK inhibitor U0126 and then exposed to 
4hr of hypoxia followed by 2h or 4h reoxygenation in simulated I/R injury. Levels of ERK, JNK and 
Akt phosphorylation as well as cleaved caspase-3 were assessed using western blot.  
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4.2.3 Inhibiting ERK phosphorylation reverses the protective effect of HCQ in neonatal 
cardiomyocytes in simulated I/R injury 
Following optimisation an experiment was carried out to see if the presence of U0126 prevented 
HCQ from having a cardioprotective effect in simulated I/R injury. 
Inhibition of ERK 1/2 phosphorylation reverses the cardioprotective effect observed in cells pre-
treated with HCQ (figure 4.5). The reduction in caspase-3 cleavage observed in the presence of HCQ 
during reoxygenation (0.53 (±SD0.25 (n=3))) is increased to 1.06 (±SD0.21 (n=3)) when U0126 and 
HCQ are present. This increase in cleaved caspase-3 restores levels to that seen in reoxygenation 
alone (0.98 (±SD0.21 (n=3)). This finding further validates the hypothesis that HCQ is 
cardioprotective in simulated I/R injury and that this mechanism is mediated through upregulation of 
the pro-survival kinase ERK. 
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Figure 4.5 The ERK inhibitor U0126 blocks the cardioprotective effect of HCQ in neonatal rat 
cardiomyocytes in simulated I/R injury Cells were pre-treated with 2 µg/ mL HCQ and the 
following day incubated with 10 µM U0126 for 2h followed by simulated I/R injury (4h hypoxia + 
4h reoxygenation). Graph shows ±SEM of quantitative analysis from 3 independent experiments. 
Statistical analysis determined by 1 way ANOVA using post-hoc Tukey to compare all columns (* 
p<0.05, *** p<0.0005)  
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4.2.4 The ERK inhibitor U0126 does not inhibit phosphorylation of ERK5 
Studies have suggested that the ERK inhibitor U0126 can also inhibit phosphorylation of another 
kinase, ERK5 which has also been shown to have protective effects in I/R injury (Nishimoto 2006). 
Levels of ERK 5 phosphorylation were therefore also explored to rule out its involvement in the 
protective effects mediated by HCQ. Results showed no difference in phosphorylation of ERK5 in 
the presence of the U0126 inhibitor and HCQ suggesting that it plays no role in the protective effects 
observed (figure 4.6).  
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Figure 4.6 ERK5 phosphorylation is not altered in neonatal rat cardiomyocytes in 
simulated I/R injury Cells were pre-treated with 2 µg/ mL HCQ and the following day incubated 
with 10 µM U0126 for 2h followed by simulated I/R injury (4h hypoxia + 4h reoxygenation) (n=2).  
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4.3 Pre-treatment of neonatal rat cardiomyocytes with HCQ targets intrinsic pathways in 
simulated I/R injury 
4.3.1 Introduction 
Upon identifying that HCQ protects in this in vitro model of cardiac I/R simulated injury through 
inhibiting cleavage of caspase-3 and identifying a role or ERK phosphorylation, potential molecular 
pathways through which this may occur were explored. There are two main pathways that lead to 
cleavage of caspase-3, the extrinsic and intrinsic. Key proteins in these pathways were therefore 
identified and differences were explored to identify a specific signaling pathway through which 
protection is occurring.  
4.3.2 Pre-treatment of neonatal rat cardiomyocytes with HCQ inhibits cleaved caspase-9 in 
simulated I/R injury 
The two main pathways of apoptosis are regulated by different execution caspases, the extrinsic by 
caspase-8 cleavage and the intrinsic by caspase-9 cleavage. It would be expected that if HCQ is 
targeting an ERK 1/2 dependent mechanism that this would result in reductions in the intrinsic 
pathway (i.e. caspase-9) due to the RISK pathway targeting Bcl-2 family members (Hausenloy 
2004).  Cells pre-treated overnight with HCQ and then exposed to simulated I/R injury showed 
reduced cleavage of caspase-9 when compared with control cells (figure 4.7a). Levels of caspase-9 
in cells exposed to reoxygenation had a mean of 0.79 (±SD0.23) (n=3)), which was reduced to 0.44 
(±SD0.27 (n=3)) in HCQ treated cells. However, there was no difference in levels of cleaved 
caspase-8 (figure 4.7b), suggesting that protection is via an intrinsic signaling pathway. 
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Figure 4.7 HCQ reduces cleaved caspase 9 in neonatal rat cardiomyocytes in simulated I/R 
injury Cells were pre-treated with 2 µg/ mL HCQ and the following day exposed simulated I/R 
injury (4h hypoxia + 4h reoxygenation). Cleaved caspase-9 (a) and cleaved caspase-8 (b) were 
assessed by western blot. Graph shows ±SEM of quantitative analysis from 3 independent 
experiments. Statistical analysis determined by 1 way ANOVA using post-hoc Tukey to compare all 
columns (* p<0.05, ** p<0.005)  
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4.3.3 Pre-treatment of neonatal rat cardiomyocytes with HCQ blocks dephosphorylation of 
BAD at serine 112 
Upon identifying changes in caspase-9 cleavage proteins which could connect enhancement of ERK 
phosphorylation to inhibition of caspase-9 cleavage were explored. The pro-apoptotic protein BAD, 
which is a key regulator of apoptotic proteins such as the Bcl family, was identified. BAD is 
activated upon dephosphorylation at two main serine residues; 112 and 136. They are regulated 
independently of each other, by ERK and Akt respectively. It was therefore hypothesized that if 
HCQ truly acted through an ERK dependent manner then serine 112 de-phosphorylation would be 
blocked in the presence of HCQ. In cells pre-treated with HCQ de-phosphorylation of BAD was 
prevented at serine-112 but not serine-136 (figure 4.8). This suggests that HCQ is cardioprotective 
through increased ERK phosphorylation, which in turn blocks dephosphorylation of the pro-
apoptotic protein BAD at serine-112 making it inactive. This subsequently prevents BAD from 
interacting with and inactivating pro-survival proteins such as Bcl-2/Bcl-2XL. This allows these 
survival proteins to prevent Bax/Bak triggered apoptosis, therefore reducing cleaved caspase-9 
(Gross A 1999). 
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Figure 4.8 HCQ blocks de-phosphorylation of serine 112 but not serine 136 of BAD in neonatal 
rat cardiomyocytes in simulated I/R injury Cells were pre-treated with 2 µg/ mL HCQ and the 
following day exposed to simulated I/R injury (4h hypoxia + 4h reoxygenation). Levels of 
phosphorylation at serine 112 (a) and serine 136 (b) were assessed by western blot. Graph shows 
±SEM of quantitative analysis from 3 independent experiments. Statistical analysis determined by 1 
way ANOVA using post-hoc Tukey to compare all columns (*** p<0.0005)  
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4.4 HCQ is most protective when cells are pre-treated and incubated with HCQ throughout 
simulated I/R injury  
4.4.1 Introduction 
It is of translational importance to explore whether it is necessary for HCQ to be present throughout 
the experiment in order to be protective or whether administering it during the simulated ischaemic 
stage or during simulated reperfusion is just as beneficial.  
4.4.2 HCQ abrogates cleavage of caspase-3 in neonatal rat cardiomyocytes only when cells are 
pre-treated with the drug and it is present throughout simulated I/R injury 
Cells were incubated with HCQ at different stages of the experimental protocol and exposed to 
simulated I/R injury as shown in figure 4.9a. Maximal inhibition of cleaved caspase-3 with HCQ 
was observed when HCQ was present throughout the experiment. 
4.4.3 Maximal enhancement of ERK phosphorylation in neonatal rat cardiomyocytes occurs 
when cells are pre-treated with HCQ and it is present throughout simulated I/R injury 
Additionally when cells were pre-treated with HCQ at different stages and exposed to simulated I/R 
injury, maximal enhancement of ERK phosphorylation was observed when the drug was present 
throughout the experiment (figure 4.9b). 
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Figure 4.9 HCQ inhibits cleavage of caspase-3 and increases ERK phosphorylation in neonatal 
rat cardiomyocytes most effectively when cells are pre-treated with the drug and it is present 
throughout I/R injury Cells exposed to simulated I/R injury (4h hypoxia + 4h reoxygenation) were 
treated with 2 µg/mL HCQ at various times; 1-pre-treatment overnight, 2-treatment during simulated 
ischaemia, 3-treatment during simulated reperfusion. Western blotting was used to assess levels of 
cleaved caspase-3 and ERK phosphorylation. Graph shows ±SEM of quantitative analysis from 4 
independent experiments. Statistical analysis determined by 1 way ANOVA using post-hoc Tukey to 
compare all columns (** p<0.005). 
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4.5 HCQ increases Lc3b-II accumulation in neonatal rat cardiomyocytes in simulated I/R 
injury 
4.5.1 Introduction 
There is little evidence in the literature as to the mechanism of action of HCQ, however it is known 
to inhibit autophagy through alteration of the lysosome pH, thus inhibiting lysozomal function (Fox 
1993). This causes a build-up of autophagosomes with scaffold proteins such as Lc3b-II remaining 
attached to their membrane. Recent studies have shown that Lc3b-II accumulation is linked to 
enhanced ERK 1/2 phosphorylation (Martinez-Lopez N. Athonvarangkul D 2013).  
4.5.2 HCQ increases Lc3b-II in neonatal rat cardiomyocytes in simulated I/R injury 
When cells are pre-treated with HCQ overnight and subsequently exposed to simulated I/R injury 
levels of Lc3b-II accumulation are significantly increased (figure 4.10). This suggests that HCQ 
could be inducing cardioprotection via its ability to inhibit lysozomal uptake of atuophagosomes 
leading to their accumulation (as demonstrated through Lc3b-II accumulation in the presence of 
HCQ) thus providing a scaffold for ERK phosphorylation. 
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Figure 4.10 HCQ increases Lc3b-II in neonatal rat cardiomyocytes in simulated I/R injury 
Cells were pre-treated with 2 µg/ mL HCQ and the following day exposed to simulated I/R injury 
(4h hypoxia + 4h reoxygenation). Graph shows ±SEM of quantitative analysis from 6 independent 
experiments. Statistical analysis determined by 1 way ANOVA using post-hoc Tukey to compare all 
columns (* p<0.05, ** p<0.0005)  
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4.6. IgG purified from patients who are aPL positive increases p38 MAPK phosphorylation in 
neonatal rat cardiomyocytes exposed to simulated I/R injury 
4.6.1 Introduction 
Confirmation of a pathogenic role for IgG purified from SLE patients via two methods led to 
subsequent experiments to identify how this effect was being mediated. I/R injury consists of 
multiple pathways and mechanisms, which account for the myocardial injury and cell death 
observed. It was decided that western blotting would be used to assess the levels of kinases 
previously implicated in I/R injury, such as the MAPK family. This family is made of a series of 
serine-threonine kinases, which are involved in cell proliferation, differentiation and survival. These 
kinases have been shown to be heavily implicated in I/R injury in both a pro and anti-apoptotic 
fashion. Furthermore the PI3K-Akt pathway, also has a pro-survival role in I/R injury and therefore 
was also explored. 
4.6.2 Pre-treatment of neonatal rat cardiomyocytes with IgG purified from patients who are 
aPL positive causes increased p38 MAPK phosphorylation compared with aPL negative 
patient samples in simulated I/R injury 
When cells are pre-treated with IgG from SLE patients, different responses to levels in p38 MAPK 
phosphorylation are observed depending on the aPL state of the patient. IgG from patients with aPL 
caused enhanced phosphorylation of p38 MAPK mitogen activated protein kinases (p38 MAPK-
MAPK), whereas IgG without aPL had no such effect (figure 4.11). Levels of p-p38 MAPK in aPL 
positive treated cells had a mean of 0.15 (±SD0.03 (n=3)), which is decreased to 0.005 (±SD0.002 
(n=3)) in cells treated with IgG from aPL negative patients. 
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Figure 4.11 IgG purified from aPL positive patients increases the pro-apoptotic kinase p-38 
MAPK phosphorylation in neonatal rat cardiomyocytes in simulated I/R injury Cells were pre-
treated with 2 µg/mL HCQ. The following day cells were exposed to simulated I/R injury (4h 
hypoxia + 4h reoxygenation) and the levels of p38 MAPK phosphorylation assessed using western 
blot. Graph shows ± SEM of quantitative analysis from 4 aPL +ve and 4 aPL -ve patients. Statistical 
analysis determined by unpaired t-test (** p=0.0010). 
 
 
 
 
 
 
 
 
 
aP
L 
+v
e
aP
L 
-v
e
0.00
0.05
0.10
0.15
0.20
**
p
-p
3
8
/p
3
8
p-p38 
MAPK 
p38  
aPL +ve aPL -ve 
Chapter IV 
 171 
4.6.3 Pre-treatment of neonatal rat cardiomyocytes with IgG purified from patients that are 
aPL positive show no difference in ERK or Akt phosphorylation compared with aPL negative 
patients when exposed to simulated I/R injury  
No differences were seen with other pathways known to be involved in the regulation of I/R injury 
such as ERK 1/2 and Akt (figure 4.12). 
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Figure 4.12 IgG purified from aPL positive patients doesn’t alter other kinase phosphorylation 
levels in neonatal rat cardiomyocytes in simulated I/R injury Cells were pre-treated with 2 
µg/mL HCQ. The following day cells were exposed to simulated I/R injury (4h hypoxia + 4h 
reoxygenation) and the levels of ERK 1/2 (a) and Akt (b) phosphorylation assessed using western 
blot. Graph shows ± SEM of quantitative analysis from 4 aPL +ve and 4 aPL negative patients. 
Statistical analysis determined by unpaired t-test. 
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4.7 Inhibiting p38 MAPK phosphorylation abrogates cleavage of caspase-3 in neonatal rat 
cardiomyocytes pre-treated incubated with aPL positive patient samples and exposed to 
simulated I/R injury 
4.7.1 Introduction 
Due to p38 MAPK phosphorylation being identified as a potential mechanism through which IgG 
from aPL positive patients could be enhancing apoptosis it was decided that subsequent experiments 
would be performed to inhibit this phosphorylation. This was to see if the pathogenic effect of aPL 
positive IgG could be reversed and was explored using a commercially available inhibitor 
(SB203580 (Cell Signalling)) which specifically inhibits p38 MAPK phosphorylation. An 
optimisation experiment was performed to confirm successful inhibition using 10 µM of the 
inhibitor. Cells were treated with SB208350 for 2 hours prior to simulated I/R injury and the 
inhibitor was present in media and buffer throughout the experiment. 
 
4.7.2 p38 MAPK inhibitor optimisation 
The p38 MAPK inhibitor SB203580 successfully inhibited p38 MAPK phosphorylation in simulated 
I/R injury at a concentration of 10 µM (figure 4.13). Successful inhibition is detected through a 
decrease in phosphorylation of MAPKAP-2, downstream of p-38 activation. This is due to the 
inhibitor blocking p38 activation by binding the ATP-binding pocket of p38 MAPK, but it does not 
block other kinases from phosphorylating p38. The inhibitor decreased caspase-3 cleavage due to 
pro-death pathways being blocked. Immunoblots were also probed for other kinases to confirm 
specificity. The phosphorylation levels of ERK and Akt were unchanged in the presence of the 
inhibitor. 
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Figure 4.13 Optimisation of the p38 MAPK inhibitor SB203580 Cells were pre-treated with       
10 µM SB203580 and the following day exposed to simulated I/R injury (4h hypoxia + 2h 
reoxygenation) and the levels of MAPKAP, ERK and Akt phosphorylation as well as cleaved 
caspase-3 were assessed using western blot (n=1).  
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4.7.3 Pre-treatment of neonatal rat cardiomyocytes with IgG from aPL positive patients in the 
presence of the p38 MAPK inhibitor SB203580 inhibits cleavage of caspase-3 when exposed to 
simulated I/R injury 
Following optimization, an experiment was carried out to see if the presence of SB203580 prevented 
aPL positive IgG from having a pathogenic effect in simulated I/R injury. 
Inhibition of p38 MAPK phosphorylation blocked the pathogenic effect observed in cells pre-treated 
with aPL +ve IgG (figure 4.14). The enhancement in caspase-3 cleavage observed in the presence of 
aPL positive IgG during reoxygenation was decreased by 52.81% (±SD14.46 (n=4)) when 
SB208350 and aPL positive IgG were present. In the presence of IgG from aPL negative patients the 
decrease in caspase-3 cleavage observed was significantly lower at 5.68% (±SD11.36 
(n=4))(p=0.0022). This finding further validates the hypothesis that aPL poistive IgG is more 
pathogenic in simulated I/R injury that aPL negative IgG. Furthermore, enhanced pathogenicity in 
aPL poistive IgG is mediated through upregulation of the pro-apoptotic kinase p38 MAPK. 
 
 
 
 
 
 
 
 
 
 
 
Chapter IV 
 176 
H
 Ig
G
H
 Ig
G
 +
 p
38
 in
hi
b
aP
L 
-v
e
aP
L 
-v
e 
+ 
p3
8
aP
L 
+v
e
aP
L 
+v
e 
+ 
p3
8
0.0
0.2
0.4
0.6
0.8
1.0 ** *
c
le
a
v
e
d
 c
a
s
p
a
s
e
 3
 /
 G
A
P
D
H
 
 
 
 
Figure 4.14 In the presence of the p38 MAPK inhibitor SB203580 IgG purified from aPL 
positive SLE patients cannot enhance cleaved caspase-3 in neonatal rat cardiomyocytes in 
simulated I/R injury Cells were pre-treated with 10 µM SB203580 and 2h later 500 µg/mL IgG. 
The following day cells were exposed to simulated I/R injury (4h hypoxia + 2h reoxygenation) and 
the levels of cleaved caspase-3 were assessed using western blot. Graph shows ±SEM of quantitative 
analysis from 3 healthy volunteers, 4 aPL +ve and 4 aPL –ve patients. Statistical analysis determined 
by unpaired t-test (* p=0.0256, ** p=0.0038). 
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4.8 IgG purified from patients with JSLE enhances p38 MAPK phosphorylation in neonatal 
rat cardiomyocytes exposed to simulated I/R injury 
4.8.1 Introduction 
Confirmation of a pathogenic role for IgG purified from JSLE patients, due to an increase in cleaved 
caspase-3, led to subsequent experiments to identify how this effect was being mediated. I/R injury 
consists of multiple pathways and mechanisms, which account for the myocardial injury and cell 
death observed. It was decided that western blotting would be used to assess the levels of the MAPK 
family, which have been previously implicated in I/R injury. 
4.8.2 Pre-treatment of neonatal rat cardiomyocytes with IgG purified from patients with JSLE 
(aPL negative) have increased p38 MAPK and decreased Akt phosphorylation compared to 
adult aPL negative patients when exposed to simulated I/R injury 
When cells are pre-treated with IgG from JSLE patients, there is enhanced p38 MAPK 
phosphorylation and decreased Akt phosphorylation. IgG from JSLE patients had a similar response 
to that of adult onset SLE who are aPL positive for phosphorylation of p38 MAPK (figure 4.15). 
However, JSLE IgG also appeared to decrease phosphorylation of Akt, a pro-survival kinase, albeit 
not as significantly as the alteration in p38 MAPK phosphorylation. 
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Figure 4.15 IgG purified from JSLE patients increases p38 MAPK phosphorylation and 
decreases Akt kinase phosphorylation in neonatal rat cardiomyocytes in simulated I/R injury 
Cells were pre-treated with 500 µg/mL IgG. The following day cells were exposed to simulated I/R 
injury (4h hypoxia + 4h reoxygenation) and the levels of p38 MAPK (a), Akt (b) and ERK 1/2 (c) 
phosphorylation assessed using western blot. Graph shows ±SEM of quantitative analysis from 4 
aPL +ve, 4 aPL –ve and 3 JSLE patients. Statistical analysis determined by 1 way ANOVA using 
post-hoc Tukey to compare all columns (* p<0.05, *** p<0.0005) 
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4.9 Pathogenic IgG prevents HCQ from being cardioprotective in neonatal rat cardiomyocytes 
in simulated I/R injury 
4.9.1 Introduction 
Whilst SLE patients treated with HCQ have been shown to be less susceptible to suffering a MI, 
many still do and mortality and morbidity remains high in these patients. Experiments were therefore 
performed to explore whether the protection shown by HCQ is altered in the presence of IgG 
purified from SLE patients.  
4.9.2 Pre-treatment of neonatal rat cardiomyocytes with IgG from SLE patients blocks HCQ 
from reducing cleaved caspase-3 in simulated I/R injury 
The five most pathogenic IgG (from aPL positive) SLE patients from previous experiments (i.e. 
increased cleaved caspase-3 the most) were selected and pooled. Neonatal rat cardiomyocytes were 
pre-treated overnight with HCQ and IgG and the following day exposed to simulated I/R injury. Five 
healthy control samples were also pooled and incubated with and without HCQ. In the presence of 
IgG purified from SLE patients HCQ was unable to inhibit cleaved caspase-3, however in the 
presence of IgG from healthy age and gender matched controls it was shown to still be 
cardioprotective (figure 4.16). 
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Figure 4.16 IgG purified from aPL positive SLE patients increases HCQ protective effects in 
neonatal rat cardiomyocytes in simulated I/R injury Cells were pre-treated with 2 µg/mL HCQ 
and 500 µg/mL IgG pooled from 5 healthy or aPL positive SLE patients. The following day cells 
were exposed to simulated I/R injury (4h hypoxia + 4h reoxygenation) and the levels of cleaved 
caspase-3 were assessed using western blot. Graph shows ±SEM of quantitative analysis from 3 
independent experiments. Statistical analysis determined by 1 way ANOVA using post-hoc Tukey to 
compare all columns (* p<0.05, ** p<0.005, *** p<0.0005) 
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4.10 Discussion 
Due to evidence suggesting that HCQ has a protective effect in simulated I/R injury, the next step 
was to identify potential mechanisms through which this may be occurring. It was decided that 
different signalling pathways would be explored that are known to play a prominent role in I/R 
injury. The MAPK family are a group of serine-threonine kinases involved in cell proliferation, 
survival and differentiation (Cobb 1999). Within I/R injury it is thought that they play both a pro- 
and anti-apoptotic role in a kinase specific manner. For example, p38 MAPK and JNK have been 
implicated in enhancing apoptosis-induced cell death in I/R injury. In contrast ERK 1/2, another 
MAPK, has been shown to induce pro-survival mechanisms when activated in I/R injury (Yue T 
2000). ERK 1/2 has also be shown to play a prominent role in the RISK pathway, which consists of 
pro-survival mechanisms that are activated in the early stages of reperfusion to try and counteract the 
damaging effects of I/R injury (Davidson S 2006). Another member of this RISK pathway is the 
PI3K-Akt pathway which has been shown to have protective effects by phosphorylating target 
proteins such as GSK-3β, endothelial nitric oxide and pro-apoptotic Bcl-2 family member BAD 
(Tong H 2002). Western blotting was used to determine whether HCQ elucidated its cardioprotection 
through altered regulation of these various kinases. It was identified that ERK 1/2 phosphorylation 
was significantly enhanced in the presence of HCQ in simulated I/R injury (chapter 4, figure 4.1). 
This was interesting due to it previously being published that ERK 1/2 is activated in response to 
ischaemia in the early stages of reperfusion to counteract apoptotic pathways which have been 
induced (Yue T 2000). This finding was confirmed when levels of ERK 1/2 phosphorylation were 
investigated in the presence of increasing concentrations of HCQ. It was detected that as the 
concentration of HCQ was increased, ERK 1/2 phosphorylation was up regulated to a maximum 
concentration of 2 µg/ml of HCQ                 (chapter 4, figure 4.2). Phosphorylation levels of other 
kinases were detected, but no significant differences were observed in the presence of HCQ in 
simulated I/R injury (chapter 4, figure 4.3). 
Following the finding that HCQ enhanced ERK 1/2 phosphorylation a commercially available    
ERK 1/2 inhibitor (U0126) was purchased. Optimisation experiments were carried out to ensure 
successful inhibition of ERK 1/2 could be achieved. As shown by previous studies, 10 µM U0126 
induced complete inhibition of ERK 1/2 (Frias MA 2007) when cells were incubated 1 hour prior to 
simulated I/R injury (chapter 4, figure 4.4).  
Optimisation experiments with the U0126 inhibitor showed that enhanced caspase-3 cleavage was 
seen in the presence of the inhibitor alone suggesting that ERK 1/2 activation occurs in simulated 
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reperfusion to act as a regulator of apoptosis. Protein lysates from this experiment were also used to 
confirm that the inhibitor was specific to ERK 1/2 inhibition. Other MAPK family members 
including JNK and p38 MAPK as well as the pro-survival kinase Akt detected no changes in 
phosphorylated levels in the presence of HCQ (chapter 4, figure 4.4). 
Following optimisation, an experiment was performed to identify if in the presence of an ERK 1/2 
inhibitor (U0126) HCQ’s cardioprotective effects were reversed. It was observed that in simulated 
I/R injury caspase-3 cleavage was induced and as shown previously in chapter 4, figure 4.1 this was 
reduced in cells pre-treated with HCQ. However, when cells were incubated with both HCQ and the 
ERK inhibitor the inhibition of caspase-3 cleavage with HCQ was no longer observed (chapter 4, 
figure 4.5). This experiment therefore suggests that HCQ is mediating its cardioprotective effect at 
least in part through up-regulation of the anti-apoptotic kinase ERK 1/2. 
An additional control experiment was performed due to a recent publication suggesting that HCQ 
enhances another kinase, ERK5 and this has been shown to have a vasoprotective effect in 
endothelial cells (Le N 2014). Additionally, previous studies have suggested that U0126 may also 
inhibit the MEK5/ERK5 pathway (Nishimoto 2006) and therefore it was possible that HCQ could be 
exerting its protective effect instead via ERK5. It was found that in simulated I/R injury there was no 
difference in levels of ERK5 phosphorylation in the presence of HCQ and furthermore no alteration 
in ERK5 phosphorylation in the presence of the inhibitor U0126 (chapter 4, figure 4.6). This 
therefore excluded the possibility of an MEK5/ERK5 mediated protective mechanism, although it 
should be noted that this experiment is n=2 and further validation should be done. 
ERK 1/2 protects against apoptosis through a number of target molecules downstream, including the 
pro-apoptotic Bcl-2 family member BAD. The pro-apoptotic activity of BAD is regulated through its 
phosphorylation at serine-112 and serine-136. Studies have shown that ERK phosphorylation 
specifically regulates serine-112 and Akt is responsible for phosphorylation of serine-136 (Xianjun F 
1999). Results showed that in untreated cells, simulated I/R injury causes dephosphorylation of BAD 
at both serine-112 and serine-136, in order to activate BAD. However, in the presence of HCQ, 
dephosphorylation of serine-112 is blocked (chapter 4, figure 4.7) due to the increased ERK 
phosphorylation previously shown. No difference was observed in the                     de-
phosphorylation of serine 136 in the presence of HCQ, therefore further supporting the concept that 
HCQ protection is mediated through ERK. 
Following on from this observation one would expect that HCQ is protective through regulation of 
cleaved caspase-9. As previously described, there are two main pathways through which apoptosis 
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occurs; the extrinsic and intrinsic. The extrinsic pathway leads to cleavage of caspase-8 and the 
intrinsic cleavage of caspase-9, with subsequent merger into combined cleavage of caspase-3. BAD 
dephosphorylation has been shown to directly activate the opening of the mitochondrial permeability 
transition pore (MPTP), a hallmark of the intrinsic pathway (Kinnally K 2011). Therefore, one would 
hypothesis that inactive BAD would lead to a reduction in MPTP opening and subsequently reduced 
cleavage of capsase-9. Experiments showed that indeed in the presence of HCQ there was a 
reduction in cleaved caspase-9, but not caspase-8 when cells were exposed to simulated I/R injury 
(chapter 4, figure 4.8). 
Further in vitro data suggests that HCQ treatment is required prior to simulated I/R injury in order 
for it to have a maximal protective effect as seen by a reduction in cleaved caspase-3 (chapter 4, 
figure 4.9a) and maximal enhancement of ERK phosphorylation (chapter 4, figure 4.9b). Protection 
with HCQ was only observed in cells treated with HCQ prior to simulated ischaemia and continued 
incubation throughout simulated ischaemia and reperfusion. In relation to translational relevance, a 
critical issue is that in humans HCQ takes a number of weeks to achieve steady state concentrations. 
However administering the standard dose (200 mg to 400 mg daily) as well as a loading dose, has 
been shown to speed this process up (Furst DE 1999) as well as HCQ being used in higher doses in 
cancer trials (1000 mg daily) (Goldberg S 2012).   
The cytoplasmic ubiqituin-like protein Atg8 (LC3) targets autophagosomes through binding to the 
autophagosome membrane and integrating into the lipid bilayer through undergoing lipidation to 
LC3-II via ATG7, ATG5-ATG12, and ATG16. LC3-II in turn recruits cargo adaptor proteins (also 
known as autophagy receptors), such as p62, Nbr1, or NIX which recruit cargo such as damaged 
organelles or ubiquinated aggregates from the cytoplasm and are delivered to the lysosome, broken 
down and then recycled. HCQ inhibits autophagy through inhibition of lysosomal function and this 
has recently been exploited as a target for cancer treatment (Yang Z 2011). Inhibition of lysosomal 
function therefore results in an accumulation of autophagosomes in the cytoplasm and hence LC3-II. 
Interestingly, recent evidence points towards LC3-II acting as a scaffold for the phosphorylation of 
ERK 1/2 (Martinez-Lopez N 2013). It could therefore be hypothesised that HCQ results in the 
accumulation of autophagosomes and LC3-II, which in turn serves to enhance phosphorylation of 
ERK 1/2 as observed. This hypothesis is supported by our observation that LC3-II is increased in 
cardiomyocytes incubated with HCQ (chapter 4, figure 4.10), however further experiments are 
required, as discussed in the future work section of this thesis. 
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In parallel, experiments were performed to identify potential mechanisms through which IgG from 
patients with aPL caused pathogenicity in simulated I/R injury. As previously mentioned, the MAPK 
family are a group of serine-threonine kinases involved in cell proliferation, survival and 
differentiation (Cobb 1999). Within I/R injury, it is thought that they play both a pro- and anti-
apoptotic role, in a kinase specific manner. For example, ERK 1/2 has been shown to induce pro-
survival mechanisms when activated in I/R injury but in contrast p38 MAPK and JNK have been 
implicated in enhancing apoptosis-induced cell death in I/R injury (Yue T 2000). It was observed 
that cells treated with IgG that was aPL positive, enhanced phosphorylation of p38 MAPK, whereas 
IgG without aPL had no such effect (chapter 4, figure 4.11). No differences were seen with other 
kinases such as ERK 1/2 and Akt (chapter 4, figure 4.12). This data complemented previous work in 
our lab and others, who have shown that aPL positive IgG leads to p38 MAPK activation in 
monocytes, which is believed to play a major role in inducing thrombotic events in APS patients 
(Vega-Ostertag ME 2007; Lambrianides A 2010). Activation of p38 MAPK is known to be mediated 
through TLR4, however preliminary experiments in this thesis suggested neonatal rat 
cardiomyocytes are not sensitive to LPS stimulation and therefore TLR4 activation. Previous studies 
have suggested that aPL mediated p38 MAPK activation in a variety of cell types could be through 
TLR4 activation (Poulton K 2011). However, within cardiac I/R injury it has been shown that p38 
MAPK activation can also occur in response to other signals such as oxidative stress (Su H 2013). 
Furthermore, studies have shown that in autoimmune prone mice, pathogenic IgM natural antibodies 
target specific neoepitopes to exert their pathogenic effects and activate signalling pathways during 
I/R injury (Zhang M 2004). Therefore, it can be hypothesized that aPL positive antibodies bind , 
unidentified neoepitopes which are exposed during cardiac I/R injury, leading to activation of p38 
MAPK. Further experiments are required to explore this theory and are discussed in the future work 
section of this thesis. 
Following on from the finding that aPL positive IgG enhanced p38 MAPK phosphorylation, a 
commercially available p38 MAPK inhibitor (SB203580) was purchased. Optimisation experiments 
were carried out to ensure successful inhibition of p38 MAPK could be achieved. As shown by 
previous studies, 10 µM SB203580 induced complete inhibition of p38 MAPK, when cells were 
incubated 1 hour prior to simulated I/R injury (chapter 4, figure 4.13). Protein lysates from this 
experiment were also used to confirm that the inhibitor was specific to p38 MAPK inhibition. Other 
MAPK family members including ERK 1/2 as well as the pro-survival kinase Akt detected no 
changes in phosphorylated levels in the presence of HCQ (chapter 4, figure 4.13). 
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Subsequent experiments were performed to identify if in the presence of the p38 MAPK inhibitor 
(SB23580) the pathogenic effects of aPL positive IgG were reversed. It was observed that in 
simulated I/R injury caspase-3 cleavage was induced and as shown previously in chapter 3, figure 
3.16 this was enhanced most significantly in cells pre-treated with aPL positive IgG. However, when 
cells were incubated with both IgG and the p38 MAPK inhibitor this increased caspase-3 cleavage 
was no longer observed (chapter 4, figure 4.14). Interestingly, levels of cleaved caspase-3 were 
reduced to that seen in aPL negative IgG treated cells. However, cleaved caspase-3 was still greater 
than that observed in the presence of healthy IgG suggesting that other mechanisms contributing to 
pathogenicity most likely exist. This experiment therefore suggests that IgG that is aPL positive is 
mediating its pathogenic effect, at least in part, through up-regulation of the pro-apoptotic kinase   
p38 MAPK. However, further experiments are required to identify additional mechanisms through 
which aPL positive and negative IgG accelerates injury in this in vitro cardiac I/R injury model.  
Another observation of chapter 3 was that IgG from patients with JSLE enhanced simulated I/R 
injury compared with healthy controls. However, it should be noted that healthy controls could not 
be age matched. Interestingly, these samples were all aPL negative but followed the trend of adult 
onset SLE/aPL +ve and APS samples. Their effect on p38 MAPK phosphorylation was explored and 
it was shown that JSLE IgG treated cells had the same enhanced phosphorylation as that observed in 
aPL positive IgG treated cells (chapter 4, figure 4.15). As previously mentioned in chapter 3, IgG 
purification yields a polyclonal population and therefore it is possible that an unidentified subset of 
IgG is present in both aPL positive adult onset SLE and JSLE patients, that is not present in the aPL 
negative group. However, it is also possible that another IgG population, yet to be identified in the 
purified JSLE IgG, targets the same antigen as aPL antibodies. The finding that JSLE IgG increases 
p38 MAPK phosphorylation suggests that JSLE IgG is targeting the same unidentified neoepitope as 
aPL positive IgG patients. However, the discovery that JSLE IgG also decreases the pro-survival 
kinase Akt suggests that JSLE IgG may regulate additional signalling pathways. It should be noted 
however that only 3 JSLE patient samples have been tested to date and therefore further validation is 
required.  
Finally, this chapter explored the effect of treating cells with both HCQ and IgG from SLE patients. 
Patient IgG was pooled from 5 SLE patients who had previously shown the most pathogenicity in 
this simulated I/R injury model (all aPL positive), with IgG also being pooled from 5 healthy age and 
gender matched controls. Results showed that in the presence of IgG from healthy controls, HCQ 
was able to still have a cardioprotective effect. However, interestingly, cells pre-treated with IgG 
from SLE patients prevented HCQ from being cardioprotective in this simulated I/R injury model. It 
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would be interesting to compare aPL positive and aPL negative patients and investigate what effects 
there is on ERK 1/2 and p38 MAPK phosphorylation. There is evidence that cardiovascular events 
are less frequent in SLE patients treated with HCQ, however no evidence to suggest less deaths. 
Nevertheless, it is possible to predict that in patients without SLE, that HCQ could be protective, and 
therefore this should be explored further as discussed in the future work section of this thesis. 
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Overview of Chapter V 
This final chapter aims to validate the in vitro data that has so far shown HCQ is cardioprotective in 
simulated I/R injury within an in vivo model of cardiac I/R injury. The first part is dedicated to 
optimisation of the correct dose of HCQ to rats in order to achieve a blood concentration of             
1-2 μg/mL. Additionally weight was monitored throughout dosing to ensure there was no toxicity 
with administration of HCQ.  
The second part of this chapter goes on to look at the effects of HCQ in this model of cardiac I/R 
injury, with infarct size quantified via histological analysis. Following on from this, further 
experiments were performed to look at ERK1/2 phosphorylation and the effect of the ERK 1/2 
inhibitor U0126 in the presence of HCQ within this model. 
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5.1 Optimisation for treatment of rats with HCQ in an in vivo cardiac I/R injury model 
5.1.1 Introduction 
Previous chapters have discussed the finding that in an in vitro simulated I/R injury model the drug 
HCQ inhibits apoptosis and overall cell death. Additionally, protection was shown to be through an 
ERK-dependent mechanism. The next step was to demonstrate that this protection in vitro translated 
to protection in vivo.  
An in vivo cardiac rat I/R injury model that has been established within UCL (The Centre for 
Biomedical Imaging (CABI)) was used. Notably, optimisation experiments were carried out for the 
administration method and dose of HCQ that should be given to the rats, with particular important 
emphasised on achieving a transnationally relevant concentration of HCQ in the rat blood (1-2 
µg/mL). To achieve this in a short term model would take high doses of HCQ, which had to be non-
toxic, therefore the weight of the rats and their drinking water consumption were monitored 
throughout optimisation studies. 
5.1.2 Optimisation 1. Rats dosed with HCQ via drinking water have both reduced water 
consumption and weight accumulation  
Rats were dosed with 20, 60 or 100 mg/kg HCQ for one week, via their drinking water. A reduction 
in their water intake and subsequent weight accumulation (figure 5.1a) was observed suggesting that 
the rats disliked the taste. Due to this reduced water intake, bottles containing drug were substituted 
for normal drinking water at various points to prevent dehydration. Dextrose was added to the water 
to try and mask the taste of the drug, however this did not alter the water intake and subsequent rat 
weights. Additionally, rat blood was taken to assess the concentration of HCQ using HPLC. Due to 
inconsistent intake of HCQ, blood concentrations were varied and the level of 1-2 µg/mL desired 
wasn’t achieved (figure 5.1b). 
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Figure 5.1 Optimisation 1. The weight of rats and their HCQ blood concentrations. Rats were 
dosed with varying concentrations of HCQ (0, 20, 60 and 100 mg/kg) in their drinking water for 
seven days and their weight (a) was recorded daily.  HPLC was used to detect levels of the two 
metabolites of HCQ (MDOH and desethly-hydroxychloroquine) a well as total HCQ (b).  
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5.1.3 Optimisation 2. Rats dosed with HCQ for three days via gavage accumulate weight 
normally 
Due to administering HCQ via drinking water being unsuccessful, dosing via gavage was explored. 
Rats were dosed with 100 mg/kg and 500 mg/kg for three days and their weight was monitored to 
ensure toxicity did not occur. Weight gain occurred in the rats in a normal manner for the 100 mg/kg 
dose, however 500 mg/kg appeared to reduce the amount of weight put on suggesting potential drug 
toxicity (figure 5.2a).   
After three days of treatment with HCQ (or water alone), rats were scarified and blood samples 
taken. Blood concentrations of HCQ were measured using HPLC to detect two metabolites MDOH 
(methylenedioxyhydroxyamphetamine) and desethyl-HCQ, as well as total HCQ. MDOH represents 
the active metabolite. This optimisation showed much more consistency in levels of total HCQ 
between rats within the same group. Rats dosed with 100 mg/kg HCQ achieved approximately    
600-700 ng/mL HCQ (figure 5.2b). We observed toxicity at 500 mg/kg and therefore excluded this 
as a potential dose, which was further confirmed by detection of HCQ over the desired threshold 
previously stated as 1-2 µg/mL (figure 5.2b). We therefore decided for subsequent experiments to 
use a dose of 200 mg/kg to achieve a desired HCQ blood concentration, which also does not prove 
toxic. 
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Figure 5.2 Optimisation 2: The weight of rats and their HCQ blood concentrations. Rats were 
dosed with varying concentrations of HCQ (0, 100 and 500 mg/kg) for three days, their weight was 
recorded daily (a) and when sacrificed, blood was collected.  HPLC was used to detect levels of the 
two metabolites of HCQ (MDOH and desethly-hydroxychloroquine) as well as total HCQ (b).  
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5.1.4 Optimisation 2. Rats dosed with HCQ for three days via gavage have detectable levels of 
HCQ in their organs 
Additionally in this optimisation experiment organ lysates were harvested and processed to detect 
HCQ levels. We felt it important to ensure accumulation of HCQ occurs in organs, specifically the 
target organ, the heart. Figure 5.3 confirms detection of HCQ in the heart and liver, with low levels 
in the brain. 
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Figure 5.3 Optimisation 2: The concentration of HCQ in rat organ lysates. Rats were dosed with 
varying concentrations of HCQ (0, 100 and 500 mg/kg) for three days and when sacrificed the heart 
(a), liver (b) and brain (c) were collected.  HPLC was used to detect levels of the two metabolites of 
HCQ (MDOH and desethly-hydroxychloroquine) as well as total HCQ.  
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5.2 HCQ significantly reduces the infarct size of rats in an in vivo cardiac I/R injury model 
5.2.1 Introduction 
Following optimisation experiments a protocol was established whereby HCQ was administered at a 
dose of 200 mg/kg daily for 3 days via gavage. The technicians administering the reagents, 
undertaking the injury and performing histological analysis were blind to the identity of the reagents 
that were given.  
5.2.2 HCQ was detected in the blood of rats dosed with HCQ 
Rats were treated with HCQ for three days via gavage in an in vivo cardiac I/R injury model and 
using HPLC levels of the two metabolites of HCQ (MDOH and desethly-hydroxychloroquine) as 
well as total HCQ were detected. A mean level of 1895 ng/mL (±SD436.9) (figure 5.4), therefore the 
desired level of HCQ in the blood of rats was achieved. 
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Figure 5.4 Detection of HCQ in the blood of rats dosed with HCQ Rats were dosed by gavage 
with 200mg/ml HCQ for three days (3 control and 3 HCQ treated). When sacrificed blood was taken 
and assessed using HPLC to detect levels of the two metabolites of HCQ (MDOH and desethly-
hydroxychloroquine) and total HCQ (as shown in this figure).  
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5.2.3 HCQ reduced infarct size in an in vivo rat cardiac I/R injury model 
In the group treated with HCQ the infarct size (IS) over the area at risk (AAR) (IS/AAR) were 
significantly reduced as compared to the water-only control group (figure 5.5a). The mean IS/AAR 
for control rats was 25.32% (± SD8.1 (n=10) which was reduced to a mean of 12.28% (± SD5.8 
(n=11)) in HCQ treated rats (figure 5.5a). This represents a significant reduction of 51.5% 
(p=0.0002) in IS/AAR. This is also seen when looking at infarct size alone where the mean IS for 
control rats was 13.15 (± SD5.65 (n=10)) which was reduced to a mean of 6.7% (± SD2.1 (n=6)) 
(figure 5.5b). Finally, figure 5.5c shows the size of AAR for each rat, which is a measure of 
occlusion consistency. There was no difference in AAR between rats in all groups, therefore 
highlighting the reproducibility of the results. 
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Figure 5.5 Infarct size relative to area at risk (IS/AAR) is reduced in rats pre-treated with 
HCQ and then subjected to cardiac I/R injury in vivo. Rats were dosed by gavage with 200mg/ml 
HCQ for three days prior to surgery (1 hour occlusion of LAD artery + 24 reperfusion) and when 
sacrificed hearts were stained with Evans blue and TTC to assess area of infarct size (IS) (b) and area 
at risk (AAR) (c). The data is presented as IS/AAR as shown in figure a. All graphs show mean 
±SEM of quantitative analysis from 10 control and 11 HCQ treated rats. Statistical analysis 
determined by unpaired t-test (*** p =0.0002)(a) and  (** p=0.0022)(b). 
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5.2.4 Rats dosed with HCQ for three days via gavage have significantly increased ERK 
phosphorylation level in an in vivo cardiac I/R injury model 
The hearts were collected from the sacrificed rats and processed to be used in western blotting. The 
level of ERK phosphorylation was detected, and as seen in vitro, HCQ increased phosphorylation of 
ERK, suggesting a potential mechanism of protection (figure 5.6). 
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Figure 5.6 ERK phosphorylation is increased in HCQ treated rats subjected to cardiac I/R 
injury. Rats were dosed by gavage with 200 mg/ml HCQ for three days prior to surgery (1 hour 
occlusion of LAD artery + 24 reperfusion). All graphs show mean ±SEM of quantitative analysis 
from 6 control and 8 HCQ treated rats. Statistical analysis determined by Mann Whitney U test (p42 
(p=0.0293) and p44 (p=0.02)). 
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5.3 The ERK inhibitor U0126 blocks protection by HCQ in an in vivo rat cardiac I/R injury 
model 
5.3.1 Introduction 
Due to previously discussed in vitro data showing that when ERK phosphorylation is prevented that 
HCQ no longer reduces apoptosis, it was decided that this inhibitor would be used in vivo to see if it 
had the same effect. As shown in chapter 5, figure 5.6, in HCQ treated rats ERK phosphorylation 
was enhanced which parallels the in vitro data presented in chapter 4. 
5.3.2 Optimisation of the ERK inhibitor U0126  
It was important to establish the correct dose of the inhibitor in order to inhibit ERK phosphorylation 
in the absence or presence of HCQ. Due to HCQ appearing to enhance ERK phosphorylation as 
shown in figure 5.6, inhibitor optimization experiments were performed in rats previously dosed with 
200 mg/kg for three days. Literature suggested that a single intraperitoneal (IP) injection of the 
inhibitor at a concentration of 1 mg 30 minutes prior to surgery would be sufficient to inhibit ERK 
phosphorylation and yield no toxicity (Alderliesten M 2007). Our experimental protocol allowed for 
three days of dosing following by IP injection of U0126 on day 4. The rats were then left for 4 hours 
or 24 hours as they would have if the surgery had been carried out before being sacrificed. Figure 
5.7 shows complete inhibition of ERK phosphorylation in rats treated with U0126.  
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Figure 5.7 ERK phosphorylation is inhibited by U0126. Rats were dosed by gavage with 200 
mg/ml HCQ for three days and then administered 1 mg U0126 via IP 30 minutes before surgery. 
Rats were sacrificed 24 hours later and hearts were collected for western blotting. All graphs show 
mean ±SEM of quantitative analysis from 3 control, 3 HCQ treated and 4 U0126 treated rats. 
Statistical analysis determined by one way ANOVA (* p<0.05, *** p<0.0005) 
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5.3.3 The ERK 1/2 inhibitor U0126 increases Akt phosphorylation in rats exposed to cardiac 
I/R injury 
To ensure that U0126 was specifically inhibiting ERK 1/2 activation other kinases were looked at in 
the heart lysates. A significant increase in Akt phosphorylation was observed in the heart lysates of 
rats treated with U0126 (figure 5.8a), however no difference in p38 MAPK phosphorylation was 
observed (figure 5.8b). 
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Figure 5.8 The ERK inhibitor U0126 enhances Akt phosphorylation in rats exposed to cardiac 
I/R injury. Rats were dosed by gavage with 200 mg/ml HCQ for three days and then administered 
U0126 via IP 30 minutes before surgery. Rats were sacrificed 24 hours later and hearts were 
collected for western blotting. All graphs show mean ±SEM of quantitative analysis from 3 control, 
3 HCQ treated and 4 U0126 treated rats. Statistical analysis determined by one way ANOVA (*** 
p<0.0005) 
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5.3.4 Infarct size is reduced in rats dosed with HCQ and then subjected to cardiac injury in 
vivo through an ERK 1/2 dependent manner 
Rats treated with HCQ cause a significant decrease in infarct size relative to area at risk (IS/AA) as 
shown in figure 5.9a. However, in the presence of HCQ and U0126, infarct size is no longer reduced 
and is restored back to that seen in control rats (figure 5.9a). Control rats have a mean IS/AAR of 
25.32% (± SD8.1 (n=10) which was reduced to a mean of 12.28 % (± SD5.8 (n=11)) in HCQ treated 
rats.  In the presence of the ERK inhibitor U0126 alone there is no significant difference in infarct 
size compared with control rats (mean IS/AAR of 22.31% (± SD12.3 (n=6))). However, in the 
presence of HCQ and U0126 the mean infarct size was 23.86% (± SD11.23 (n=5)), therefore 
blocking the protective mechanisms seen in rats treated with HCQ alone. 
Additionally when looking at infarct size alone, there is a significant difference between HCQ and 
HCQ with U0126 treated rats (figure 5.9b). The area at risk remains constant, again highlighting the 
consistency of the surgical technique (figure 5.9c). 
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Figure 5.9 Protection by HCQ is blocked by the ERK inhibitor U0126 in a rat in vivo cardiac 
I/R injury model. Rats were dosed by gavage with 200mg/ml HCQ for three days and administered 
U0126 via IP injection 30 minutes prior to surgery (1 hour occlusion of LAD artery + 24 
reperfusion). The data is presented as IS/AAR as shown in figure a. When sacrificed hearts were 
stained with Evans blue and TTC to assess area of infarct size (IS) (b) and area at risk (AAR) (c). 
Figure d represents tissue staining for all groups. All graphs show mean ±SEM of quantitative 
analysis from 10 control, 6 U0126 treated, 11 HCQ treated and 5 U0126 + HCQ treated rats. 
Statistical analysis determined by unpaired t-test (** p =0.0002, *** p=0.0077)(a) and (** p=0.0022, 
** p=0.0097)(b). 
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5.4 Discussion 
The purpose of this chapter was to demonstrate that the cardioprotection by HCQ in the in vitro model 
translated to protection in an in vivo cardiac I/R injury model. To test this, a collaboration with a core-
service, who have an in vivo I/R injury rat model, was set up at UCL and performed in line with standard 
protocols published previously (Stuckey D 2012). The administration of HCQ was first optimized with the 
goal of achieving 1-2 µg/mL blood concentration, which translates to levels achieved in patient blood. The 
first optimisation consisted of 3 doses of HCQ; 20, 60 and 100 mg/kg administered via drinking water over a 
period of 7 days. It was observed from the beginning that the rats disliked the taste of the drug, particularly at 
60 and 100 mg/kg and therefore had a reduced intake of water. This led to a reduction in weight gain 
(chapter 5, figure 5.1a) and low and inconsistent levels of HCQ detected in the rat blood (chapter 5, figure 
5.1b). Due to dosing rats via their drinking water yielding low and inconsistent levels of HCQ in their blood 
it was decided a new approach had to be taken. Optimisation 2 consisted of administering HCQ via gavage 
for three days at a concentration of 100 and 500 mg/kg, as suggested by previously published data (Pareek A 
2009). This time rats dosed with 100 mg/kg HCQ accumulated weight at a normal rate, with 500 mg/kg 
proving to be slightly toxic causing weight gain to plateau (chapter 5, figure 5.2a). Furthermore, blood levels 
of HCQ were much more consistent between rats in the same group, with 100 mg/kg achieving slightly under 
the desired concentration and 500 mg/kg yielding 5 times above (chapter 5, figure 5.2b). Additionally, 
concentrations of HCQ were measured in organ lysates to ensure that HCQ was accumulating in target 
organs i.e. heart (chapter 5, figure 3). From this optimisation it was concluded that administering HCQ via 
gavage was much more consistent, and a dose of 200 mg/kg was decided upon which yielded a blood 
concentration of 1895 ng/mL ±SD436.9 (chapter 5, figure 5.4).  
Rats were dosed with HCQ 200 mg/kg daily for 3 days via gavage (or water only as a control) and then 
exposed to I/R cardiac injury and sacrificed 24 hours post reperfusion. The technicians administering the 
reagents, undertaking the injury and performing histological analysis were blind to the identity of the regents 
that were given. In the group treated with HCQ the infarct size relative to the area at risk (AAR) was 
significantly reduced as compared to water only control group (chapter 5, figure 5.5a). Infarct size alone also 
showed a significant decrease (chapter 5, figure 5.5b), whereas the AAR size remained dependable, 
highlighting consistency in the protocol (chapter 5, figure 5.5c). Heart lysates were collected and when 
probed for ERK, the group of rats that received HCQ had significantly enhanced phosphorylation of ERK as 
compared to rats treated with water alone (chapter 5, figure 5.6). Hence the protection observed in vitro with 
HCQ in a simulated model of I/R injury is also observed with I/R cardiac injury in vivo in rats and HCQ and 
also enhances phosphorylation of the pro-survival kinase ERK in vivo in hearts. 
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In keeping with the in vitro data previously reported in this thesis the next step was to use the ERK inhibitor 
U0126 to see if this protective effect could be blocked. An optimisation experiment was performed whereby 
rats were dosed with HCQ for three days and then injected (intraperitoneal (IP)) with 1 mg of U0126 (or 
water only as a control) 30 minutes prior to surgery. This treatment with U0126 yielded complete abrogation 
of ERK phosphorylation as shown in figure 5.6. Other kinases were also probed for to ensure U0126 
specifically inhibited ERK 1/2 inhibition. There was no significant difference in p38 MAPK phosphorylation 
(chapter 5, figure 5.7a), however Akt phosphorylation was significantly increased in rats dosed with U0126 
(chapter 5, figure 5.8b). This may be due to mechanisms being activated to try and counteract the reduction 
in ERK phosphorylation, as previously reported (Hausenloy D 2004). It is thought that this feedback is either 
via p70s6k or BAD which are both known to interact with Akt and ERK. It would be expected that if a vital 
protective mechanism such as ERK phosphorylation was inhibited then infarct size would infact be enhanced 
in the presence of U0126. This increase in Akt phosphorylation therefore presents an explanation as to why 
there is no enhancement in infarct size relative to AAR when ERK phosphorylation is inhibited. 
Results showed that when rats are dosed with HCQ and then treated with U0126 infarct size over AAR is 
restored to that observed in control rats (chapter 5, figure 5.8). Infarct size alone is also significantly reduced 
in the presence of HCQ but restored in the presence of HCQ and U0126. As previously shown AAR remains 
consistent highlighting the reproducibility of the data. This data suggests that HCQ is exerting its protective 
effect through increased phosphorylation of ERK as previously reported in vitro.  
Limitations of this experiment include that the model used is short term and therefore the long term effects of 
HCQ on myocyte viability, cardiac function and cardiac remodelling haven’t been explored. Additionally due 
to evans blue and TTC staining being required to assess infarct size no post immunofluorescence could be 
performed or markers of apoptosis such as cleaved caspase-3 be measured. In future it would be ideal to use 
imaging techniques such as magnetic resonance imaging (MRI) to assess infarct size so that heart tissue can 
be used for alternative analysis. 
In summary, this chapter has confirmed previous in vitro data in a cardiac in vivo I/R injury model. Firstly, 
when HCQ is administered to rats to achieve a dose of 1-2 µg/mL in rat blood there is a significant decrease 
in infarct size relative to AAR. Additionally when the ERK 1/2 inhibitor U0126 is administered to rats this 
protection is blocked suggesting that protection is via enhanced ERK phosphorylation.  
This chapter concludes the data presented in this thesis, however chapter 6 will discuss the overall findings of 
this project as well as identify further work to be carried out in order to expand on this data further. 
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Overview of Chapter VI 
This chapter gives an overview of the main findings of this thesis. Firstly it will discuss the principal 
findings regarding the drug HCQ and its protective effects in cardiac I/R injury. The second part will 
discuss the role of pathogenic IgG autoantibodies from patients with SLE, JSLE and APS in this in 
vitro model of cardiac I/R injury. This chapter will then discuss the potential for future projects to 
take this work forward as well as identify potential new hypotheses. 
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6.1 Overall findings 
MI carries a significant burden of both mortality and morbidity post-infarct. Prompt diagnosis and 
treatment through thrombolysis or angioplasty remains the mainstay of treatment and long-term 
outcomes are determined by both the site and extent of the infarct. The infarct size is not just 
dependent on damage ensued during ischaemia. An important contributor to the size of the eventual 
infarct is injury that occurs to the myocardium during the reperfusion phase, which in animal studies 
has to been shown to account for up to 40-50% of the final infarct size (Yellon D 2007). The 
dominant mechanisms through which cardiomyocytes die during the ischaemic phase is necrosis. 
However, during the re-perfusion phase a complex interplay of multiple pathways and mechanisms 
are activated which ultimately culminate in cell death primarily through apoptosis (Eefting F 2004). 
These mechanisms have been studied extensively and revolve around dysregulation of mitochondrial 
function and eventual rupture of mitochondrial membrane releasing multiple pro-apoptotic mediators 
into the cytoplasm, generation of ROS, initiation of inflammatory response pathways further 
aggravating injury, complement, autophagy and TLR activation to name but a few (Verma S 2002). 
HCQ was originally an anti-malarial drug, however it is now used to treat autoimmune disorders 
such as SLE. It has been shown to reduce inflammation as well as have potential cardiovascular 
benefits in these patients (Wallace D 2012). This includes lowering atherogenic lipids such as 
cholesterol, triglycerides and LDL levels (Morris S 2011). Additionally, it has been shown to have 
anti-thrombotic effects, with the risk of suffering from an event reducing by 68% in patients with 
SLE (Jung H 2010). Despite cardiac morbidity and mortality being enhanced in patients with lupus 
(Esdaile JM 2001), the effect of HCQ on cardiomyocyte survival in relation to I/R injury prior to this 
thesis had yet to be explored. 
Work carried out in H9c2 rat cell line and neonatal rat cardiomyocytes identified a cardioprotective 
effect of HCQ in simulated I/R injury. Previous work has suggested a protective role for HCQ in 
renal and liver I/R injury (Fang H 2013; Todorovic Z 2014), however this was the first suggestion 
for a protective role in the heart. To validate the findings observed in vitro, an in vivo rat cardiac I/R 
injury model was utilised to see if the same protective effect with HCQ could be seen. After 
optimization of the model to ensure equivalent HCQ concentrations in vivo, a reduction of 51.5% in 
infarct size relative to area at risk was observed in HCQ treated rats compared with controls gavaged 
with water alone. Subsequent experiments explored specific mechanisms through which HCQ may 
be mediating its protective effect. Pro-survival kinases such as ERK 1/2  and Akt have been 
identified as being modulators of cardioprotection and constitute the RISK pathway (Haunsenloy 
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2007). The RISK pathway is up-regulated prior to I/R injury, therefore allowing maximal protection 
to be induced during the reperfusion stage (Davidson S 2006). Therefore, enhancing components of 
the protective RISK pathway through pre-conditioning offers an appealing therapeutic target to 
ameliorate I/R injury (Yang X 2010). Pharmacological pre-conditioning is an area of great 
therapeutic interest, and drugs such as sildenafil have been shown to be cardioprotective through 
enhancing ERK phosphorylation prior to simulated I/R injury (Das A 2009). Results in this thesis 
showed a significant increase in ERK 1/2 phosphorylation in HCQ treated cells in the in vitro 
neonatal rat cardiomyocyte I/R injury model as well as the in vivo cardiac I/R injury model. 
Furthermore, when the ERK 1/2 inhibitor U0126 was incubated with cells or administered to rats, 
protection was blocked in the presence of HCQ. The work from this thesis has the potential to 
underpin the rationale for future clinical studies, investigating a re-purposed role for HCQ as a 
protective agent for I/R injury as described below in section 6.2. 
The other focus of this project was the role of IgG purified from whole blood of patients with SLE in 
cardiac I/R injury. The possibility of cardiac I/R injury being enhanced in lupus is relevant, given 
that there is increased cardiovascular morbidity and mortality rates observed in lupus, yet possible 
explanations for this are yet to be explored. There is some evidence from a lupus mouse model 
within a mesenteric I/R injury model that lupus IgG are pathogenic (Fleming S 2004) but no study as 
yet has investigated human lupus IgG in a heart model. In humans, there is no large-scale study to 
our knowledge that has compared cardiac infarct sizes between patients with lupus and age and 
gender matched controls. Therefore the aim of this section of the project was to explore the effect of 
IgG in the in vitro neonatal rat cardiomyocytes model of simulated I/R injury. 
It was found that the pre-treatment of neonatal rat cardiomyocytes with IgG purified from patients 
with SLE enhanced caspase-3 cleavage and TUNEL positivity in cells exposed to simulated I/R 
injury. When this group of patients was sub-divided into those positive for aPL antibodies versus 
those that were negative, it was found that there was a significantly greater increase in cleaved 
caspase-3 for aPL positive patients compared to aPL negative. This suggested that aPL positive 
patients have a mechanism of action which differs to that in aPL negative patients for causing 
pathogenicity in this simulated I/R injury model. Furthermore primary APS patients who are by 
definition aPL positive (but do not have SLE) showed similar levels of increase caspase-3 cleavage 
as SLE/aPL positive. Another group of patients was included that consisted of patients with JSLE 
that were all aPL negative. Interestingly, they followed the trend of adult onset aPL positive patients, 
in that their caspase-3 cleavage was more significant than adult onset aPL negative. It should be 
noted that the purified IgG is a polyclonal population. Therefore, an explanation for this finding may 
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be that they share a common pathogenic subset of autoantibodies as aPL positive patients that is yet 
to be discovered. 
Due to the observation that aPL positive patients had enhanced pathogenicity, mechanisms of action 
were explored. Work previously published by members of the lab of my supervisor Dr. Ioannou and 
his collaborators suggested that IgG derived from aPL positive patients causes enhanced p38 MAPK 
phosphorylation in monocytes (Lambrianides A 2010) whereas this was not observed with IgG 
purified from patients with SLE without aPL nor healthy volunteer controls. p38 MAPK is known to 
play a pro-apoptotic role in cardiac I/R injury (Kumphune S 2012) and therefore one would 
hypothesise that aPL positive IgG could be exerting its pathogenic effect through up regulation of 
this kinase. A commercially available p38 MAPK inhibitor (SB23580) was used to show that the 
enhanced pathogenicity of aPL positive patients is p38 MAPK dependent. Results showed that when 
cells were treated with IgG from aPL positive patients in the presence of SB23580, there was a 
significant decrease in cleaved caspase-3, to levels similar to that observed in the presence of aPL 
negative patient IgG. To conclude, this data suggests an aPL positive, p38 MAPK dependent 
mechanism, for aPL mediated pathogenicity in cardiac I/R injury as observed in this simulated in 
vitro model; however an increase in patient numbers is required to confirm this. 
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Figure 6.1. A summary of the main findings for HCQ. The drug HCQ causes a reduction in apoptosis in H9c2 and neonatal rat 
cardiomyocytes. This cardioprotection is also observed in an in vivo rat model of cardiac I/R injury. A proposed mechanism of action 
is enhanced phosphorylation of ERK 1/2 and therefore the addition of the ERK inhibitor U0126 blocked protection both in vitro and 
in vivo. 
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6.2 Future work 
To take the findings of this thesis forward there a number of experiments that could be suggested. 
Due to the two distinct pathways of this work, future experimental suggestions will be split into two 
sections. 
This thesis has made the observation that HCQ is protective in cardiac injury and therefore future 
experiments could aim to explore the role in protection against cardiac injury in detail. This should 
include dissecting out potential mechanisms related to autophagy and assessing whether reducing 
infarct size translates to improved cardiac function in the longer term, in terms of the effects on 
cardiac remodelling. At present, the success rate of lead candidates targeting pathways relevant to I/R 
injury progressing through to market has been poor. The advantage of HCQ is that it has a well-
defined and favorable safety profile, having been in routine use within rheumatology (e.g. for SLE) 
for the last 50 years. This would greatly facilitate its development within clinical studies as a lead 
candidate for this indication as compared to a new chemical entity, which requires far greater 
regulatory hurdles to overcome. Additionally, studies such as exploring the effects of HCQ in long 
term models of cardiac I/R injury are essential. This would allow its effects on cardiac remodeling to 
be assessed. The use of MRI studies would allow the tracking of infarct size and function over time 
without having to sacrifice animal or stain tissue, allowing the assessment of effects on apoptosis and 
signalling pathways. If these extensive in vivo experiments support HCQ as a protective agent in 
cardiac I/R injury, with beneficial effects on cardiac function and remodeling over time, then this will 
provide the rationale for developing HCQ in human studies for ameliorating outcomes post MI. It 
should be noted that most likely HCQ would need to be given prophylactically. This is firstly due to 
data in this thesis suggesting that HCQ is most protective when cells are pre-treated chapter 4, figure 
4.16. It has also been shown in SLE patients that HCQ can take a number of weeks to reach 
therapeutic levels   (1-2 µg/mL) therefore complementing the in vitro data in the suggestion that 
HCQ would need to be administered prior to an MI, as is currently suggested for other 
cardioprotective drugs such as statins (Davignon 2004). However, it should be noted that it is 
possible to administer a loading dose of HCQ to achieve therapeutic blood levels quicker with no 
toxic effect, as shown in RA patients (Furst D 1999). 
As well as defining the relevance of HCQ as a protective agent it is also important to further dissect 
the mechanisms through which it is exerting a cardioprotective effect. This thesis has identified a 
central role of ERK 1/2 phosphorylation, however as yet has not identified how this enhanced     
ERK 1/2 phosphorylation is mediated. It is therefore proposed that subsequent experiments would be 
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performed to look at the role of autophagy. HCQ is known to inhibit autophagy through inhibition of 
the lysosome, resulting in accumulation of autophagosomes. These autophagosomes have scaffold 
proteins such as LC3 attached to their membrane, which integrate into the lipid bilayer by undergoing 
lipidation to LC3-II via ATG7, ATG5-ATG12, and ATG16. LC3-II in turn recruits cargo adaptor 
proteins (also known as autophagy receptors), such as p62, Nbr1, or NIX which recruit cargo such as 
damaged organelles or ubiquinated aggregates from the cytoplasm and are delivered to the lysosome, 
broken down and then recycled (Rabinowitz 2010). The ability of HCQ to inhibit autophagy through 
inhibition of lysosomal function has been exploited as a target for cancer treatment recently (yang Z 
2011). Inhibition of lysosomal function hence results in an accumulation of autophagosomes in the 
cytoplasm and hence LC3-II. Interestingly, recent evidence points towards LC3-II acting as a 
scaffold for the phosphorylation of ERK (Martinez-Lopez 2013). Hence, our hypothesis is that HCQ 
results in the accumulation of LC3-II on the accumulated autophagosomes, which in turn serves to 
enhance phosphorylation of ERK as observed. This hypothesis is supported by our observation that 
LC3-II is increased in cardiomyocytes incubated with HCQ. LC3-I lipidation to LC3-II is dependent 
on ATG5 and ATG7 and recycling of LC3 II to LC3-I via de-lipidation is dependent upon ATG4 
(Satoo K 2009). Hence, depletion of ATG5 or ATG7 results in reduced LC3-II and conversely 
depletion of ATG-4 hence results in an accumulation of LC3-II which in turn leads to enhanced ERK 
phosphorylation (Martinez-Lopez 2013).  Thus if this hypothesis is true, in the presence of HCQ, 
silenced ATG5 or ATG7 should inhibit the resultant accumulation of LC3-II which in turn should 
inhibit LC3-II mediated increase in ERK phosphorylation during simulated I/R injury and remove the 
protective effect of HCQ. Conversely, ATG4 silencing should result in LC3-II accumulation, 
enhanced ERK phosphorylation and mirror the protective effects seen with HCQ. 
For the work produced concerning the pathogenicity of IgG derived from patients who are SLE/aPL 
positive, there are many avenues through which this work could be progressed. In the first instance, 
it is important to acknowledge that number of patient samples tested in the presence of the p38 
inhibitor SB23580 should be expanded to make the data more robust. Anti-ß2GPI antibodies mediate 
their pro-thrombotic pathogenicity through targeting domain I (DI) of ß2GPI (Ioannou Y 2007; 
Ioannou Y 2010). The laboratory of my supervisor Dr Ioannou together with his collaborators have 
previously shown the IgG-APS mediated exacerbation of thrombosis in a validated in vivo model of 
APS may be inhibited by using recombinant DI (rDI) as a decoy peptide (Ioannou Y 2009). The lab 
is now developing this as a novel therapeutic for APS. Hence, it would be of interest to observe 
whether the pathogenic effects of IgG-APS in this simulated model of I/R injury is also dependent on 
binding DI of ß2GPI. 
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Human rDI is expressed and purified within an E.coli expression system, as described previously. 
This system is now optimised to produce around 35-40 mg/L culture of purified, untagged, 
conformationally correct rDI. Purified IgG could be pre-incubated with rDI for 1 hour at room 
temperature prior to adding to the cardiomyocytes. This set of experiments will determine if the 
pathogenic effects of IgG-APS that are anti-ß2GPI positive are dependent upon binding DI of ß2GPI. 
Once this pathogenic population of aPL is confirmed in vitro, these can be affinity purified and used 
within a passive transfer animal model to confirm pathogenicity in vivo. This can be confirmed in the 
in vivo rat cardiac I/R injury model previously descried in this thesis. 
The data produced in relation to the pathogenicity of JSLE IgG should be explored further. It would 
be of interest to identify the subset of pathogenic antibodies from this polyclonal population and/or 
the antigens that these antibodies are targeting to cause accelerated injury. Experiments whereby 
cells are incubated with IgG and exposed to simulated I/R injury should be performed. Cell lysates 
can then be used for pull-down experiments using dynabeads, to isolate specific IgG-protein 
interactions. This will allow identification of novel neoepitopes, which are being exposed during I/R 
injury, to be identified by mass spectrometry. 
Finally, a preliminary study in this thesis showed that co-incubating cardiomyocytes with HCQ and 
IgG from an aPL positive patient blocked protection by HCQ. Firstly this finding should be validated 
further by increasing patient samples numbers, however it would also be of interest to see the effect 
of HCQ in the presence of IgG from SLE/aPL negative, APS and JSLE patients. This would 
determine if the enhanced phosphorylation of the pro-survival kinase ERK seen in the presence of 
HCQ ‘overrides’ the pro-death effects of p38-MAPK phosphorylation observed with IgG-APS or 
not. This will give insight into whether HCQ can protect in the presence of antibodies from patients 
with APS and SLE and, if so, to what extent and in which groups. 
The outcome of this research may identify a new mechanism through which antibodies from patients 
with APS and lupus may cause cardiac damage following an MI. This research would then underpin 
future clinical studies to determine if patients with APS or lupus suffer larger heart attacks or strokes 
as compare to age and gender matched people without APS and lupus. Additionally it would also 
support animal in vivo studies of I/R injury to confirm and validate the findings. Ultimately, this may 
lead to identification of novel pathogenic roles for antibodies from patients with lupus / APS and 
investigation of potential new targets and therapeutics which hold the promise of improving 
outcomes for patients with these conditions and CVD. 
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